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Blood transfusion is a globally accepted medical intervention that can save life and improve
health but like many valuable therapies it also poses risk. From the patient perspective,
therefore, it should therefore be prescribed only when it is absolutely appropriate to do so.
Pressures on the blood supply also make it essential to promote the appropriate and
effective use of allogeneic blood so as to preserve supply. The way blood is used within a
given population needs to be carefully monitored and published evidence on blood use is
available for various populations and settings. However, there is an increasing need for
evidence about the patterns of use by clinical case group that can be used to identify areas
where change in transfusion and clinical practice may be needed. The Scottish Transfusion
Epidemiology Project (STEP) aimed to assess the feasibility of linking routine datasets of
transfusion data and clinical data for blood use analysis. This thesis reports on the study of
STEP data in order to describe blood component use by clinical case group and its
application in exploring transfusion practice.
Methods
This study employed computer-based methods to link the STEP data of transfusion day
records (Scottish National Blood Transfusion Service) and Scottish Morbidity Record
SMROl/cancer/death records (ISD Scotland). Clinically informed methods were devised to
attribute blood component use to purposely defined clinical case groups. The study dataset
was analysed to describe blood component use by age, gender and intensity of transfusion,
and for surgical procedure and haematological disease clinical case groups. The impact of
changes in transfusion practice and changes in population demographics on future blood




The study dataset comprises information on blood component use for a subset of Scottish
hospitals that received approximately 38% of the red blood cell units delivered by the
Scottish National Blood Transfusion Service in the year 2000. The dataset contains 41,431
transfusion day records of blood component use that represent 21,309 transfused patients
and the use of 60,130 red blood cell units, 4,795 platelet units, 9,446 fresh frozen plasma units,
and 1,759 cryoprecipitate units. For red blood cell, platelet and plasma use, although a small
proportion of patients were transfused intensively, they nevertheless accounted for a large
proportion of blood component units.
17,403 (29%) red blood cell units were attributed to surgical events defined by red cell using
procedures; 7,286 (12%) red blood cell units were attributed to 726 patients with a diagnosis
of pre-malignant or malignant haematological disease. The remaining 59% of red blood cell
units were not classified by clinical case groups in this study and represent areas for future
work.
Between 2000 and 2031 the Scottish population is projected to remain fairly stable in size but
to be proportionately older. Modelling the impact of this on the demand for blood indicates
that by 2031 there will be a requirement for 38% more red blood cell units. The impact of
applying best practice figures and potential savings using intra-operative cell salvage were
modelled and identified potential savings in blood use.
Conclusion
The study linked available routine data and employed specific, novel methods to enable
analysis of blood component transfusion, and specifically, blood component use by clinical
case groups. The potential for employing the data in modelling analyses of blood
component use and related applications was also demonstrated. Recommendations for
future approaches to studying the clinical use of blood are made. The findings of the study
can be used for future planning purposes and to inform guidelines and policy, with the aim




Table i. Definitions and abbreviations
Abbreviation Terminology Definition
Assigned [blood component] A blood component unit that has been
compatibility labelled for a patient and for
which a blood bank transfusion record has
been generated in the blood bank computer
system.
ATICS Audit of Transfusion in
Intensive Care in Scotland
A prospective benchmarking study of
transfusion practice in Scottish intensive care
units.
BBTP Better Blood Transfusion
Programme
A Scottish Executive initiative which, in
partnership with Donor Services Directorate
and Blood Express Project, undertakes a
range of initiatives that cover the transfusion
process from donor to patient.
Blood bank transfusion record Record generated when a patients' blood
sample was received for "Group and Save" (for
blood grouping and detection of red cell
antibodies, with sample saved for a maximum
of 3 days in blood bank), or for the assignment
of one or more blood component units to a
patient.
BC Blood component Component of whole blood (Refer to Table 2.1
for details of individual components)
BDC Broad Diagnostic Category Clinical coding classification system for
medical diagnostic information.
CABG Coronary Artery Bypass Graft A surgical procedure used to treat coronary
artery disease using a blood vessel graft,
usually from the leg, to bypass a narrowed or
blocked coronary artery, thereby improving
blood flow to the heart and reducing the
chance of a heart attack.
CE Consultant episode
CIPS Continuous inpatient stay
The period of inpatient care under a specific
consultant and/or in a particular ward between
the dates of admission and discharge. The
medical information pertaining to the
consultant episode is written in the discharge
letter and used in Standard Morbidity Records.
A specific pattern of inpatient stays defining




CRAG Clinical Resource and Audit
Group
Lead body within the Scottish Executive Health
Department providing advice and promoting
clinical effectiveness in Scotland. In 2003
CRAG became part of NHS Quality
Improvement Scotland.
CRYO Cryoprecipitate A blood component prepared from fresh frozen
plasma, which is rich in fibrinogen, factor VIII,




A blood component unit that is no longer linked
to a patient such as when blood is returned
unused to the blood bank. The deassingnment
is recorded in the blood bank transfusion
record in which the initial assignment was
recorded.
DRG Diagnosis-Related Groups Clinical coding classification system for
medical information based on International
Classification of Disease (ICD) diagnoses,
procedures, age, sex, and the presence of
complications or comorbidities.
EMAN East Manufacturing SNBTS blood component manufacturing site
for Eastern Scotland.
EUB Effective Use of Blood A Scottish National Blood Transfusion Service
research group. The main objective of the EUB
group is to work with hospitals in Scotland in
order to improve transfusion practice by means
of a clinical effectiveness programme using
audit, education and clinical research.
EUOBUP EU Optimal Blood Use Project A three year collaborative project to develop a
pan-European standard for optimal blood use.
Co-funded by the European Commission.
FFP Fresh frozen plasma A blood component prepared from plasma that
is frozen within a specific period of time
following collection.
g/dL grams per decilitre Unit of measurement of blood haemoglobin
levels.
HDC Health Department Circular Memorandum issued by the Department of
Health for England.
HIV Human Immunodeficiency Virus A retrovirus that can lead to Acquired
Immunodeficiency Syndrome (AIDS), a
condition in humans in which the immune
system begins to fail, leading to life-threatening
opportunistic infections.
ICD International Classification of Clinical coding classification system for
Disease diagnostic information that defines the medical
condition managed or investigated during an
inpatient stay. These codes were used in the
PhD study to define diagnostic case groups to















Intensive Care Unit The branch of medicine concerned with the
provision of life support or organ support
systems in patients who are critically ill and
require intensive monitoring.
Intra-operative cell salvage Medical procedure in which blood lost during
surgery is recovered, and re-infused into the
same patient following filter or wash cycles.
International Study of Peri¬
operative Transfusion
Research group investigating the use of new




Part of the NHS National Services Scotland,
the national organisation for the management
of health, information, statistics and
information technology.
The Joint United Kingdom
Blood Transfusion Services
(UKBTS) and National Institute
for Biological Standards and
Control (NIBSC) Professional
Advisory Committee
The professional body in the United Kingdom
for advising on, and publishing guidelines for,
transfusion and tissue transplantation.




Government agency responsible for ensuring
that medicines and medical devices work and
are acceptably safe.
Maximum Surgical Blood Order
Schedule
Guidelines for the maximum number of red
blood cell units that can be cross-matched pre-
operatively for a range of common elective,
surgical procedures, based on and developed
for specific, local clinical practices.
Month A calendar month.
National AIDS Control
Organisation
Government agency in India responsible for
control, surveillance, reporting and education
issues relating to HIV/AIDS.
National Health Service
(Scotland)
The National Health Service in Scotland.
Office of Population Censuses
and Surveys
Clinical coding classification system for
surgical operations and procedures that define
the therapeutic or surgical intervention
performed during the consultant episode.
OPCS codes are arranged in pairs, where A
details the main procedure code and B allows
for the recording of supplementary codes for
approach, technique, site or laterality. OPCS-
4 codes were used in the PhD study to define




PLT Platelets A blood component comprising blood cells that
are responsible for blood coagulation and
repair of damaged blood vessels.
RBC Red blood cells A blood component comprising blood cells that
carry haemoglobin and help remove waste
from tissues throughout the body.
SANGUIS Safe and Good Use of Blood in
Surgery
European-wide, multi-country, multi-centre
study of blood component and product use in
surgery.
sccc Scottish Clinical Coding Centre Publishes guidelines and training manuals of
clinical coding conventions for Scottish
Morbidity Records for the Information and
Statistics Division data schemes.
SD Standard deviation Statistical measure of variation.
SEHD Scottish Executive Health
Department
Health Department of the devolved Scottish
parliament.
SHOT Serious Hazards of Transfusion Organisation which aims to build an evidence
base of transfusion hazards and to promote
national and international haemovigilance and
to make recommendations for improvements in
transfusion practice and patient safety.
SMR Standard Morbidity Record Record of hospital activity (consultant episode)
generated from inpatient medical information
recorded in discharge letters, and held by
Information and Statistics Division (NHSS).
Used in this study are SMR01 (Inpatients and
day cases) and SMR06 (Cancer registration).
SMR01-CD SMR01/cancer/death record Linked SMR01/cancer(SMR06)/death(GRO)
records used in this study
SNBTS Scottish National Blood
Transfusion Service
The specialist provider of transfusion medicine
in Scotland that supplies blood, tissues,
products and related services, and facilitates
the safe and effective supply and use of blood.
SPSS SPSS Software package for statistical analyses
(Versions 13.0 to 15.0 used in this study)
STED Scottish Transfusion
Epidemiology Database
The BBTP blood data management system
that provides a population wide view of how
transfusions are used in Scotland with the aim
of identifying variation in practice, encouraging
clinical review of blood use and contributing to
the goal of reducing avoidable transfusions.
STEP Scottish Transfusion
Epidemiology Project
The Scottish National Blood Transfusion
Service feasibility study that aimed to establish
a link between SNBTS blood bank records and
ISD SMR01/SMR06/GRO records in order to
provide population based data on the use of
blood components by NHS (Scotland) Trusts.
xxi
Definitions and Abbreviations
Study period The 1 year period from 1 January 2000 to 31
December 2000 inclusive, for which data was
extracted for STEP (subsequently the study
period of this study).
Tx Transfusion The process of transferring whole blood or
blood components from a donor to a recipient
by infusion.
yr Year A calendar year.
Transfusion event A general term for the use of blood due to
transfusion.
TDR Transfusion day record The specific term for a blood bank transfusion
record of units assigned extracted from the
SNBTS Progesa blood bank computer system
and compacted to comprise all transfusion
events in a 24 hour period for one patient.
Transfused patient/recipient A patient with at least one transfusion day
record in which the number of units assigned
was more than the number deassigned.
Used
[blood component]
A blood component unit deduced to have been
infused into a patient. Calculated from units
assigned minus units deassigned as recorded
in a patient's blood bank transfusion record in
a blood bank computer system.
vCJD variant Creutzfeldt-Jakob
Disease
An infectious agent of the group Transmissible
Spongiform Encephalopathies (TSE), which
causes a rare and fatal human neuro¬
degenerative condition and which can
potentially be transmitted via blood transfusion.
UK United Kingdom
UKBTS United Kingdom Blood
Transfusion Service
A member group of JPAC
WMAN West Manufacturing SNBTS blood component manufacturing site
for Western Scotland.
WHO World Health Organisation United Nations authority responsible for health
by providing leadership and technical support,
monitoring and assessing trends, and setting







Transfusion medicine is under increasing pressures on a number of fronts. Blood is now
safer from infection than ever before but the increasing requirement for safety measures
makes blood an ever more expensive commodity. Serious hazards of transfusion such as
incompatible transfusion and adverse reactions to allogeneic blood continue to pose a risk to
transfusion recipients. Evidence for variant Creutzfeldt-Jakob disease (vCJD) transmission
via blood transfusion is the latest concern to affect the use of blood and further, has
impacted negatively on the supply of blood by limiting the potential donor pool. This and
other pressures affecting donor eligibility and the availability of supply make more effective
use of blood ever more necessary. Therefore, blood conservation strategies are being
developed to reduce or replace allogeneic transfusions that, along with improved blood
stock management and haemovigilance, are now essential considerations integral to
transfusion practice to ensure the safe and appropriate use of blood. Another essential
aspect of blood conservation is to monitor blood component use so that practice changes can
be implemented in a targeted and evidence-based approach to ensure the effective use of
blood.
Previous evidence focuses on-audits or studies of blood use for populations that were
restricted in time, setting or patient case mix. Few comprehensive, descriptive studies have
been reported for the clinical use of blood for a whole population or well-defined,
representative sample of a population for which an attempt was made to link transfusions to
clinical information that represents the patient's underlying reason for transfusion. Reports
that are available suggest that there is a decreasing trend in surgical blood use and a marked
increase in blood use for medical conditions, to be anticipated particularly where there is an
ageing population, but together they highlight methodological issues that represent areas
requiring consideration and development by future studies.
1
1. Introduction
The Scottish Transfusion Epidemiology Project (STEP) was a multi-centre, retrospective and
epidemiological pilot study initiated by the Scottish National Blood Transfusion Service that
was designed to assess the feasibility of data collection, linkage and analysis of routine
datasets of transfusion and clinical data in order to inform the development of a continuous,
automated blood use reporting system for the whole of Scotland.
The present study was an attempt to create a dataset and to devise methods to enable clinical
blood use to be described for the Scottish population using routinely available and
computerised sources of transfusion and clinical data. In this study the data that had
previously been extracted for STEP was utilised. Data extraction and internal record linkage
by patient identifier was performed by the Information and Statistics Division prior to the
present study, but all subsequent data management, file restructuring and file merging
processes formed part of this study. Relevant clinical methods were devised and
epidemiological and statistical analysis of the data was performed. The computer software




The aim of the study was two-fold. The first aim was to link available routine datasets of
blood transfusion records and inpatient medical care records in order to construct a study
dataset suitable for analysis. The second aim was to devise methods of analysis to describe
the epidemiology of blood component transfusion in Scottish hospitals, specifically by
clinical reason for transfusion, to help describe the population's need for blood.
In Chapter 2 a background to blood transfusion medicine, pressures on the supply of blood,
and blood conservation strategies is provided. Chapter 3 provides a review of the range of
published literature describing blood use, and in particular a review of comprehensive
studies of blood use by clinical reason for transfusion as well as reflections on the
methodology employed by previous studies.
Chapters 4 and 5 describe the materials, in particular the source data of blood transfusion
records and inpatient medical care records, and the methods devised to link the source data
in order to create a study dataset for subsequent analyses of blood component use.
In Chapter 6 the study dataset is described and in Chapter 7 the use of red blood cells,
platelets, fresh frozen plasma and cryoprecipitate is reported, particularly for age
distributions of blood component recipients and distributions of intensity of transfusion.
The use of red blood cells by purposely defined case groups for specific surgical procedures
and for specific haematological conditions is reported in Chapters 8 and 9, respectively.
Further, in Chapter 10 other questions about blood component use that can be explored
using the study dataset are described, including analysis of donor exposure and, specifically,
modelling the impact of the following factors on the use of blood:
■ Changes in transfusion practice, for example the use of best practice indicators,
■ The use of alternative interventions, for example intra-operative cell salvage,
• Changes in population demographics.
3
1. Introduction
In Chapter 11 a discussion is presented that addresses the findings of the present study, in
the context of previous reports, and of the strengths and weaknesses of the data and






The science of blood transfusion dates to the first decade of the 19th century though the first
early attempts to transfuse animal blood were recorded as far back as the 15th century at a
time blood was regarded as having mystical healing properties. The 19th century saw the
discovery of distinct blood types, the first human-to-human transfusions, and the first use of
blood transfusion to treat haemophilia (Thomas, 2005). The first reported use of transfusion
in a military setting was the use of non-human albumin to replace lost circulating blood
volume1. Since that time war has been a stimulus for developments in many aspects of
blood collection, storage, transport and transfusion, as well as donor recruitment and blood
services organisation. In the first half of the twentieth century the discovery of refrigeration
and anticoagulants enabled blood to be stored and thereby facilitated routine, indirect
transfusions in place of direct vein-to-vein transfusions. The discovery coincided with the
First World War and led to the establishment of the first British Army blood depot. During
the Spanish Civil War (1936-1939), a mobile field transfusion unit was set up, followed by a
large-scale organisation of blood transfusion centres (Pinkerton, 2002; Coni, 2002). This
development subsequently led to the establishment of the first blood banks such as in the
Soviet Union where a system of national, large and subsidiary blood banks were set up. By
World War Two an Army Blood Transfusion Service was set up in the UK to enable central
recruitment of blood donors and efficient collection of blood, so as to increase the supply of
blood to the military as it was required. By the end of the war more than half a million
volunteer donors were registered and a donor service, much like the present day UK
National Blood Services, was established. Within a few years the United States had followed
suit (Thomas, 2005).
During the mid to late twentieth century a number of significant discoveries enabled notable
advances in transfusion medicine. Whole blood was separated into red blood cells and
1
Renwick, W. (1854) Transfusions in a case of cholera. Dublin Medical Press. 31:258-9 (Thomas, 2005)
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plasma thereby improving the length of time blood could be stored for and meaning that
separate blood components were available for use in different clinical situations (Table 2.1).
The discovery of Rhesus antigens led to understanding of incompatibility transfusion
reactions. Together, the production of plastic bags that replaced glass bottles and the
development of new anticoagulant preservatives enabled safer and easier blood collection,
storage and preparation. Fractionated blood products derived from the plasma component
of blood were pioneered by Edwin Cohn (in 1940), opening up new treatments for a wide
range of medical conditions, including diseases of the immune system, haemophilia and
major blood loss reflected in medical practices today (Thomas, 2005).
Table 2.1 Blood components
Blood component Description Abnormalities
Red blood cells The most common cells in blood. Consist
(Erythrocytes) mainly of haemoglobin that carries oxygen
from lungs to tissues of the body and
carries waste product carbon dioxide away
from tissues.
Low levels/abnormality causes
anaemias, for example sickle cell,
thalassemia; high levels/surplus causes
erythrocytoses, for example
polycythaemia vera.
White blood cells Several different types with varying
(Leukocytes) morphology and function. All help to
defend the body against foreign materials
and infectious disease by various immune
processes.
Low levels predispose to infection in
conditions such as leukaemia; high
levels in some bone marrow disorders.
Platelets Activated by damage to blood vessels,
(Thrombocytes) adhere to the ruptured site and release
various coagulation factors that are
involved formation of blood clots.
Low levels predispose to bleeding in
leukaemia and some immune disorders;
high levels in some bone marrow
disorders.
Plasma The fluid in which other components are
suspended: 92% water, 8% plasma
proteins, and trace amounts of other
components (e.g. hormones, antibodies,
clotting factors). Cryoprecipitate is formed
when normal blood plasma is cooled and
is rich in Factor VIII.
Low levels of specific plasma proteins
in haemophilia (Factor VIII deficiency
causes bleeding), primary immune
deficiency (Immunoglobulin deficiency
predisposes to infections); high levels in




2.1.1. Blood conservation strategies
Blood transfusion is now globally accepted as a major medical intervention that can save life
and improve health (WHO, 2004; McClelland, 2007). Donated blood is a precious gift: the
collection and use of voluntary, non-remunerated blood donations is promoted by the World
Health Organisation. The appropriate and effective use of the donor gift is paramount and
the importance of blood transfusion today is undisputed but, as will be discussed in full in
the following section (section 2.2), it is a practice that is placed under increasing pressures
from many directions. Here, a range of approaches considered for reducing or replacing the
need for allogeneic blood transfusion are discussed. The key elements are to conserve blood
loss and to make safe and effective replacement where the need is considered to be absolute.
Better control of blood loss can be achieved by thorough pre-operative planning and patient
management such as clinical assessments and blood testing; more difficult is rescheduling
elective surgery for patients with specific contraindications for transfusion given the
extensive planning issues relating to theatre and staffing logistics. However, during surgery,
assessment of oxygen deprivation, monitoring of blood loss and judicious surgical and
anaesthetic techniques can be used to reduce blood loss and make well-informed and
appropriate decisions to transfuse. Post-operative monitoring and blood tests can be utilised
to address post-operative bleeding and to provide detailed pathophysiological information
about the patient which may negate the use or any further use of transfusion. These factors
are concerned with conserving blood by improving patient management through careful
monitoring and good clinical technique, related to which are other factors of organisational,
educational and financial review (Provan, 1999; Lemos & Healy, 1996; Tinmouth et al, 2005;
Madjdpour & Spahn, 2005).
The safe and effective replacement of blood implicates several techniques. Aside from
autologous blood pre-donation and acute normovolaemic haemodilution (the replacement
of donated autologous blood with volume expanders) that are not currently recommended
for clinical practice in the UK (UKBTS, online), intra-operative and post-operative cell
salvage are recommended ways of reinfusing a patient's own blood (washed or filtered) to
effectively reduce or completely negate the need for allogeneic transfusion, particularly in
cardiac and orthopaedic surgery (Carless et al, 2006). No safe blood substitutes have thus far
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been developed (Lemos & Healy, 1996). Available transfusion alternatives are
pharmacological agents including anti-fibrinolytics such as aprotinin and tranexamic acid,
which promote blood clot formation, and recombinant erythropoietin, which stimulates red
blood cell production (Madjdpour & Spahn, 2005; McClelland, 2007). Comprehensive
evidence for the use of crystalloid and colloid plasma volume expanders is still needed and
alternative oxygen carriers are still being developed. New and effective transfusion
techniques and blood alternatives must be continually researched and assessed so that
transfusion protocols and guidelines reflect the appropriate evidence base. Ultimately the




2.2. Pressures afffecting blood transfusionmedicine
Increasingly blood transfusion is affected by a wide range of pressures and issues of
controversy. This section describes these pressures that affect the supply of and the demand
for blood as well as some general issues that have implications for the cost and resources
associated with transfusion practice (Table 2.2).
Table 2.2 Summary of pressures affecting blood transfusion medicine
Diminishing supply Increasing demand Other pressures
(section 2.2.1-2) (section 2.2.3) (section 2.2.4-5)
• New infection risks e.g. vCJD » Ageing population ■ Economics
■ Additional tests for donated blood ■ Changing epidemiology of ■ Evidence-based guidelines
■ Leucodepletion filtering diseases of the elderly « Clinical governance
■ Population movements ■ Transfusion used in wider range • New legislation and
■ Difficulties recruiting and retaining of treatment programmes enforcement
young donors ■ More complex/chronic disease ■ Public awareness
2.2.1. Supply: blood safety and risk reduction
While blood transfusion is safer now than ever before in countries with well developed
health systems, it is not a practice without risk and current guidelines advise that it only be
used when it is considered to be absolutely necessary, that is when the risk of not receiving
blood outweighs the risk of transfusion (McClelland, 2007).
Since the 1970s a range of tests has been introduced to identify blood donations that are
infected with transmissible viruses so that they can be removed from the supply chain and
thereby reducing the potential risk of transmission of viral infection to the transfusion
recipient. In the UK every donation must be tested for Human Immunodeficiency Virus
(HIV, type 1 and 2), Hepatitis C (HCV), Hepatitis B (HBV), Human T-cell Lymphotropic
virus I and II (HTLV-I and HTLV-II), and syphilis, and in America, due to differences in the
epidemiology of infectious agents, West Nile virus and Trypanosoma cruzi (Chagas parasite)
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are also tested for. Screening blood donations in this way has resulted in a substantial
decrease in transfusion-transmitted infections and related deaths (Thomas, 2005).
Also posing a threat to blood recipients is bacterial contamination of blood components.
This can cause immediate severe and sometimes fatal adverse reactions in the transfusion
recipient. Contamination originates from an existing bloodstream infection in the donor or
may occur at the time of blood collection from sources such as donor skin and collection
equipment. Preventing transmission of bacterial infection relies on the use of sterile, single
use equipment for blood collection and transfusion, screening at the point of donation by
questioning the donor, and good collection techniques, including adequate skin preparation
and the practice of diverting the initial blood flow to a separate collection pouch (Brecher &
Hay, 2005). In some countries blood components, especially platelets, are cultured to detect
bacteria before the blood is released for transfusion.
A majority of immediate adverse reactions related to transfusion are caused by blood group
incompatibility (ABO incompatibility), that is the administration of blood of the wrong ABO
blood group, such as giving donor group A, B or AB red blood cells to a group O patient.
Medical errors of this type have serious consequences for the recipient, reportedly causing
complications in one out of every 38,000 units of red blood cells transfused and causing
twelve to thirteen deaths a year in the US (Dzik et al, 2003). Further, it is believed that
transfusion errors, including ABO incompatibility as well as inappropriate transfusion and
wrong dosing, are often underreported. Rates of wrong blood transfusion of between 16%
and 30% have been reported in Australia (French et al, 2002).
The safety measures required to reduce the risk of administrative transfusion errors focus on
the role of education of all staff involved in the process. The implementation of hospital
transfusion committees and transfusion safety officers in some countries has begun to
address the issue of education and has put patient safety first thereby improving the practice
of blood administration (Dzik et al, 2003; Torella et al, 2002). However, even when blood is
free of viral and bacterial contamination and is administered correctly, recipients are not free
from transfusion-related risk of serious adverse reactions such as transfusion-related acute
lung injury and transfusion-mediated immuno-modulation which can cause clinical
complications, morbidity and even result in mortality (Goodnough et al, 1999).
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Currently in the UK, the greatest concern regarding blood transfusion safety is the
emergence of the infectious agent variant Creutzfeldt-Jakob disease (vCJD). vCJD is a
Transmissible Spongiform Encephalopathy (TSE) that was first described in March 1996 and
is known to cause fatal neurodegeneration in humans. CJD was previously known to exist
in three forms: sporadic (unknown cause), familial (genetic mutation), and iatrogenic
(accidental transmission by surgery or transplant). This fourth, new form affects younger
patients and has a longer illness phase. A link has been established between vCJD and
exposure to Bovine Spongiform Encephalopathy (BSE), most likely through infected meat in
the food chain. The link between vCJD and BSE is based on epidemiological,
pathophysiologic and molecular features of the agents and resultant infection (WHO, online).
There is no evidence for the transmission of sporadic or familial CJD through the transfusion
of blood or blood products but it is now accepted that the potential exists for vCJD to be
transmitted by blood. To date there have been 165 confirmed and probable cases of vCJD in
the United Kingdom (JPAC, 2007). Of the confirmed cases of vCJD, eighteen patients
previously donated blood that was used by 66 recipients, of whom 24 are still alive. To date,
four recipients of blood from donors who subsequently developed vCJD have been
confirmed as being infected with the agent: one recipient was diagnosed with vCJD in 2003,
one recipient died of unrelated causes in 2004 and two recipients have developed symptoms
of clinical vCJD disease in recent years (2006 and 2007). It is likely that a proportion of
people currently incubating the infection will never progress to clinical disease. Recent
surveillance reports suggest that the trend in vCJD mortality has been falling since a peak in
2000 but the Joint United Kingdom Blood Transfusion Services (UKBTS) and National
Institute for Biological Standards and Control (NIBSC) Professional Advisory Committee
(JPAC) report of 2007 warns that further cases may arise due to secondary transmission via
surgical instruments (JPAC, 2007).
The screening process that is currently available for vCJD is not completely reliable,
potentially reporting false positives, and thus it is not routinely used. However, a recent
announcement by researchers in Edinburgh suggests that a new test that currently identifies
low levels of vCJD prion proteins in brain tissue could be developed further to test for prions
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in blood and be introduced for routine use in testing donations by 2009. This announcement
has prompted concerns about a loss of donors who do not wish to know if they are infected
with vCJD. Professor Ian Franklin (National Medical and Scientific Director, SNBTS) has
suggested that the number of donors could fall by as much as 20% even although it is
expected that few people will actually test positive for vCJD (Moss, 2007).
In the meantime, current safety measures introduced so far in the UK include leucodepletion
of all donated blood units, sourcing plasma for fractionation from outwith the UK, and
withdrawal of blood components or tissues previously donated by individuals who are later
diagnosed with vCJD. Further, exclusions prohibit whole blood and live bone donation by
anyone who has received a blood transfusion in the UK since January 1980, and any donor
whose blood was transfused to a recipient who later developed vCJD (JPAC, 2007). Other
countries including America, Canada, Australia and France, have banned the donation of
blood by people who have lived in the UK at any time since 1980 (WHO, online(b)).
Haemovigilance
Haemovigilance, the surveillance of serious adverse events (unintended occurrences
associated with the transfusion process) and serious adverse reactions (unintended response
of donor or recipient) that result in clinical complications, morbidity and mortality is now
essential to improving transfusion practice. In 1996 the Serious Hazards of Transfusion
(SHOT) reporting procedure was implemented in NHS and private hospitals in the UK and
Ireland. The aim of the report is to collect data on actual and near-miss serious adverse
events and reactions related to blood component transfusion in order to improve safety and
standards, and to inform policy and guidelines for transfusion practice. Although voluntary,
participation in SHOT is high and results indicate that the number of adverse events and
near-misses related to blood transfusion has decreased since reporting began. Indeed, the
risk of transfusion-transmitted infection has never been lower (Murphy, 2005). Further,
since 2005 all blood banks and related establishments in the UK are required to notify
adverse events and reactions to the Medicines and Healthcare products Regulatory Agency
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(MHRA)2 through a system called SABRE (Serious Adverse Blood Reactions & Events)
(MHRA, online).
In the UK, in the seven years between 1996 and 2003, 23 million blood component units were
supplied. The incidence of death from serious adverse reactions was 0.2 per 100,000 units of
blood supplied and the incidence of serious morbidity from serious adverse reactions was
1.1 per 100,000 units of blood supplied. The risk of viral transmission per 100,000 units of
blood supplied was estimated to be 0.014 for HIV, 0.024 for hepatitis C and 0.176 for
hepatitis B. The figures indicate that the risk of transmission of viral infection via blood
transfusion is low and major morbidity is more likely to be due to bacterial contamination.
However, the risk of wrong blood transfusion was estimated to be slightly greater at 6 per
100,000, of which ABO incompatibility poses a risk of 1 per 100,000 (McClelland & Contreras,
2005a & 2005b). This data from the UK suggests that the overall risk of infection, morbidity
and mortality from receiving blood transfusion is small. However, the risk does exist,
particularly if a patient's lifetime exposure or recipients exposed to multiple transfusions for
treatment of chronic conditions are considered. This issue reinforces the philosophy that
transfusions should only be given when deemed clinically to be absolutely necessary.
2.2.2. Supply: influences on donor pool
An adequate blood supply that meets the needs of the population is essential. However,
with changes to clinical and transfusion practice, developments in areas of new and
alternative interventions and blood conservation strategies, and changes in demography and
to the progression and patterns of disease, it is extremely challenging to define how much
blood a population actually needs.
National blood transfusion services work constantly to ensure that adequate blood stocks are
collected from healthy, adult volunteers. In countries with well-structured health care
systems and blood transfusion services an adequate supply of blood is generally provided
2
Medicines and Healthcare products Regulatory Agency (MHRA) is the UK government agency responsible for
ensuring that medicines and medical devices work and are safe, and to whom serious adverse events or reactions
related to the transfusion of blood and blood components should be reported.
13
2. Background
and often taken for granted. However, in countries with disparate urban and rural health
care provision or general poor health care provision across the whole country, a safe and
reliable supply is more difficult to achieve (WHO, 2004; Goodnough et al, 1999; Enosolease,
Imarengiaye & Awodu, 2004).
The donor pool is adversely affected by the increasing number of restrictions on donor
criteria that are imposed in an attempt to increase the safety of blood (Cobain, 2004). To
protect the donor, those with bleeding disorders, anaemia, diabetes mellitus and epilepsy
are precluded from giving blood, and changes in the number of people with these conditions
(and other conditions that may be implicated in the future) are likely to affect the number of
potential donors (Donaldson, 2003). To protect the recipient from the risk of transmission of
infection in donor blood, persons who have been exposed to malaria, HIV, hepatitis, syphilis
and West Nile virus, as well as those who have had recent body piercing or tattoos, are
requested not to give blood (SNBTS, online). The emergence of variant Creutzfeldt - Jakob
disease (previously described in section 2.2.1) is the latest infectious agent to impact on the
donor pool. The rise in the popularity and ease of international travel can promote the
spread of infection by exposing a growing proportion of the world population to infections
they wouldn't normally encounter. It is also becoming more difficult to engage the younger
population in donating blood for reasons of travel and time constraints but also because of
changing public awareness and attitudes to blood transfusion. Nevertheless, despite the
impact on the donor supply, precautions are clearly essential for ensuring the greatest safety
of donated blood product for the recipient as well as the safety of the donor.
Due to the pressures described, the recruitment and retention of donors is now a critical part
of national blood services' programmes. It is particularly difficult for developing countries
to maintain a stable and adequate donor pool. Repeat donors are reliable and are known to
provide safe blood, thus conserving collection resources and reducing wastage (Thomson et
al, 1998). It has been demonstrated that repeat donors who give blood for more than five
years are less likely to test positive for viral infection than first time donors (Schreiber et al,
2001). In the UK and many other countries blood donors are volunteers and are not
remunerated for their gift of blood. However, this is not the case in all countries. Where
donors are paid there is concern about the reliability of responses to screening questions and
hence about the safety and quality of donated blood (Donaldson, 2003).
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2.2.3. Demand: demography and clinical epidemiology
The demand for blood is determined by a population's demography and medical needs,
combined with clinical intervention and decision making processes that are influenced by
healthcare provision, clinical practice and transfusion guidelines and strategies.
It is well documented in studies of blood use that a majority of transfusion recipients are
elderly patients: for example, 53.3% (Vamvakas & Taswell, 1994) and 57.0% (Mathoulin-
Pelissier et al, 2000) of red blood cells were reported to be transfused to patients aged over 65
years. The elderly suffer a higher incidence of concurrent medical conditions than younger
people and are less likely to be able to tolerate being anaemic, hence their greater
requirement for blood transfusion (Wells, 2004). With population expansion expected in the
older age groups over future years the resulting increase in the demand for blood will put
pressure on the supply chain.
Along with a change in population demographics, a change in clinical disease trends and
treatments will also affect the demand for blood. Transfusion was traditionally used to
counter blood loss due to surgery, trauma and obstetric complications but there is an
increasing requirement for blood as a supporting intervention in the treatment of a whole
range of clinical conditions as advances in medicine, for example cancer treatments, and
surgery, for example organ transplant, are made (Pitocco & Sexton, 2005). In conditions
such as leukaemia effective treatment with chemotherapy, irradiation, and transplantation of
bone marrow can only be effectively undertaken if transfusion of red blood cells and
platelets is available to support the patient during periods of bone marrow suppression.
Improved survival rates, increased rates of comorbidity and complex or chronic disease,
wider use of transfusion in the treatment of medical conditions and the ageing population all
contribute to an increased demand on the blood supply.
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2.2.4. Resource and regulatory pressures
The economic cost of blood reflects the cost of collection, processing and testing of blood
components as well as the supply of blood to the end-user, the transfusion recipient. Costs
associated with the testing and production of blood suitable for transfusion are escalating as
new measures are introduced to improve the safety and quality of blood. Extensive
developments include viral infection testing, and testing to detect abnormal prion protein in
donated blood in tandem with prion removal filtration. Specifically, in the UK since 1995,
the cost of blood has risen substantially because of the measures introduced to reduce the
risk of vCJD transmission through blood transfusion (Lin, 2004). Prion removal filtration of
blood components to reduce the risk of Transmissible Spongiform Encephalopathy
infectivity such as vCJD is likely to add an estimated £100 million to the cost of blood
provision by the NHS (Murphy, 2005; Burnouf & Padilla, 2006). Costs associated with
implementing measures to improve safety and efficiency of hospital blood transfusion
practices such as hospital transfusion committees and transfusion safety officers, research
initiatives and reporting systems add to the total cost of providing a transfusion.
The infrastructure of blood services vary by country and depending on need. In Denmark
blood collection is decentralised and based in hospitals. In the USA several large
organisations, including the American Red Cross, Americas Blood Centres, compete for
blood collection activities. Some countries, for example Hong Kong, have found that
outsourcing aspects such as product delivery saves money and frees up resources in other
areas of the blood service and supply chain. Economic and resource constraints on the
infrastructure of blood services have prompted some developed countries, including the UK,
France, Canada and Australia to centralise their services thus enabling them to reduce the
number of testing and production sites whilst increasing levels of accountability and quality.
Developing countries however can find it difficult to centralise services due to a lack of
resources and investment; it should be regarded as the responsibility of international
organisations to help them to establish suitable infrastructures that can deliver appropriate
and sustainable services (Lin, 2004).
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It is a complex issue for the blood services to deliver a sustainable service not least because it
is difficult to predict the influence of factors such as large scale infection outbreaks (for
example Severe Acute Respiratory Syndrome (SARS) in 2002/3, or a winter influenza
epidemic), emergency incidents including terrorist attacks, natural disasters and seasonal
variations (Lin, 2004; Donaldson, 2003). As part of stock management, hospitals should
make contingency plans to deal with potential blood shortages.
The variations in temporal and logistical factors related to providing an adequate blood
supply means shortages can not always be predicted although advances are being made in
automated, time-series forecasting programmes (Pareira, 2004). Well-developed blood
transfusion services use production planning models to try to predict demand in order to
keep adequate supplies whilst minimising wastage (Lin, 2004). The UK Blood Stock
Management System is a database of blood unit issues, stock inventory, wastage and shelf
life operated as a partnership between the National Blood Service of England and North
Wales and hospitals with participation on a voluntary basis. The Blood Stock Management
System enables analysis of the entire supply chain, provides real-time monitoring of stock
management, is used for benchmarking of transfusion practices, and can be used to drive
improvements such as reducing inventory levels (Chapman & Hick, 2003; Donaldson, 2003).
In America, National Blood Data Resource Centre (NBDRC) surveys of the blood supply
highlighted concerns that according to projected trends up to the year 2000, demand would
start outstripping supply and so a government sponsored programme to monitor supply
and predict shortages was implemented (Nightingale et al, 2003). With this sort of resource
available, stock management systems can have practical and beneficial impact on the blood
supply thus helping to reduce the effect of growing pressures. However, more information
is needed on the clinical use of blood and patient outcome following transfusion in order to
better inform such models of supply and demand.
For transfusion practice, resource requirements go beyond the practical issues of finance and
infrastructure. In addition, blood transfusion practice relies on social factors such as local
clinical practice, public understanding and expectations of clinical treatment and blood
transfusion, as well as a knowledgeable donor community to provide an adequate and
sustainable blood service (Lin, 2004).
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Further, resource provision and utilisation is increasingly influenced by regulatory pressures.
Legislation increasingly enforces standards on prescribing, ordering, collecting, storing and
administering practices involved in the provision of blood components for transfusion such
as the 2005 UK Blood Safety and Quality Regulations (Cobain, 2004). However,
comprehensive evidence-based guidelines on the appropriate use of blood for all clinical
contexts are not available. The Handbook of Transfusion Medicine sums up the concern:
"Correctly used, blood and blood products can save lives and provide clinical
benefit to many patients. However, aspects of blood transfusion practice have not
been rigorously proved by clinical trials so it is impossible to give a completely
evidence-based account." (McClelland, 2007)
It is generally accepted that transfusion practice should be based on national guidelines that
are informed by evidence-based medicine but where evidence is lacking, compliance with
guidelines and appropriateness of transfusion can be hard to measure (Wallis, Stainsby &
McClelland, 2002). Where appropriately conducted, audits and monitoring programmes can
be used to identify areas for practice intervention and assess the effect of change on
transfusion practice in the hope of improving the appropriate use of blood (Kanter, 1998;
Goodnough et al, 1999). A full review of studies relating to transfusion medicine practise is
reported in Chapter 3. The policy responses of the United Kingdom that aim to improve the
safe and effective use of blood are considered next (section 2.3).
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2.3. UK policy and Scotland specific research in response to improving blood
transfusion medicine
In this section an overview of the policy response of the United Kingdom with respect to
transfusion medicine is presented. The actions required to improve the safety and efficacy of
blood use are described in a series of Health Department Circulars (HDC) (England) and
Management Executive Letters (MEL) (Scotland). The recommendations provide the context
in which developments in monitoring and analysis of the use of blood components in
transfusion, such as the present study, were prompted.
In the summer of 1998 the UK Chief Medical Officers held a symposium entitled "Evidence-
based blood transfusion" that focused on improving transfusion practice throughout the
National Health Service (NHS). It brought together a range of transfusion specialists,
clinicians and managers from NHS trusts to discuss requirements to ensure the safe and
effective use of blood in light of increasing demands for use, decreasing donations, rising
costs, emerging risks associated with vCJD, implications of clinical governance, SHOT
reporting, the waiting list initiative and changing perceptions of clinicians and the public.
The symposium focused on variations in blood use, the evidence base for best practice and
the need for monitoring to improve understanding of patterns of blood use. It concluded
that improvements could be made by all stakeholders to ensure safe, effective and
appropriate use of blood for the future. The recommendations formed the "Better Blood
Transfusion" Health Service Circular, HSC 1998/224 (Department of Health, England, 1998)
and Management Executive Letter, MEL (1999)9 (Scottish Executive Health Department
(SEHD), 1999a). The minimum recommendations are summarised in Table 2.3a. Further
recommendations considered to need additional consultation at that time are given in Table
2.3b.
A follow-up symposium held in 2001 was jointly organised by the National Audit Office, the
National Blood Service and the Department of Health, and was attended by the UK Chief
Medical Officers. It was agreed by those in attendance that progress had been made since
1998 with the formation of Hospital Transfusion Committees and satisfactory engagement in
the SHOT reporting system. The 2001 symposium focused on further promoting integrated
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and collaborative approaches to improving transfusion practice. The recommendations and
updated action plan were published in Health Service Circular, HSC 2002/009, "Better Blood
Transfusion - Appropriate use of blood" (Department of Health, England, 2002) and NHS
HDL (2003)19 (SEHD, 2003).
Table 2.3a Minimum recommendations of HSC 1998/224 to be implemented in all
NHS Trusts where blood is transfused
Time scale Action
From March 1999 ■ Ensure Hospital Transfusion Committees in place to oversee all aspects of transfusion.
■ Participate in annual SHOT enquiry.
By March 2000 ■ Agree and disseminate local transfusion protocols based on guidelines and best
practice.
■ Support local transfusion protocols with training.
■ Explore feasibility of autologous blood transfusion and ensure patients aware of option
where appropriate.
■ Consider introduction of peri-operative cell salvage
Table 2.3b HSC 1998/224 recommendations requiring further discussion
Action
■ Extend accreditation of haematology laboratories to include whole of transfusion service (i.e. including
hospitals).
■ Integrate national advice systems for blood and tissue safety and consider the development of a web site for
the exchange of good practice.
■ Carry out systematic review and research into clinical and cost effectiveness of blood component therapy and
variations in transfusion practice.
■ Consider potential role of a specific Blood Transfusion Medicine academic department.
■ Consider potential application of new technologies to improve transfusion.
■ Carry out comparative audit in blood transfusion practice.
■ Review the regional and national organisational structure of blood user groups and patient representation.
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The themes laid out in the recommendations are the foci of a range of projects in the United
Kingdom. The significant projects and studies carried out in Scotland over more than a
decade share the common aims of increasing understanding of how and why blood is
transfused and striving to optimise the use of blood, setting the context in which the STEP
feasibility study was initiated (Table 2.4). The projects represent collaborative efforts that
have made, and are continuing to make, advances in promoting the safe and effective use of
blood.
Table 2.4 Blood use projects in Scotland (1991 to present day)
Project title Aim
Participation in SANGUIS project European-wide, multi-country, multi-centre study of blood component and
(Data collected 1991, Published 1994) product use in surgery.
Optimal Use of Donor Blood Report Clinical effectiveness project funded by Clinical Resources and Audit
(1995) Group (CRAG), Scottish Executive Health Department (SEHD).
Formation of SNBTS Effective Use of An SNBTS research group whose main objective is to work with hospitals
Blood group (1999) in Scotland in order to improve transfusion practice by means of a clinical
effectiveness programme using audit, education and clinical research.
Project Manager: Sandra Gray (SNBTS)
Participation in International Study of Research group investigating the use of new technologies to minimise
Peri-operative Transfusion (ISPOT) peri-operative (elective surgery), allogeneic blood transfusion.
(1999-2004)
Scottish Transfusion Epidemiology SNBTS pilot project to assess the feasibility of collecting and linking
Project (STEP) (2000) routine transfusion and clinical data for use in analysis of clinical use of
blood. Current PhD study developed from this.
Safe and Effective Transfusion in CRAG/SEHD funded study investigating the role of the Nurse Transfusion
Scottish Hospitals study Specialist, in clinical quality assurance and improvement following MEL
(2000-2003) 1999(9) "Better Blood Transfusion". Project lead: Sandra Gray (SNBTS)
Better Blood Transfusion Programme In partnership with Donor Services Directorate and Blood Express Project,
(BBTP) (2004) undertakes a range of initiatives that cover the transfusion process from
donor to patient.
Scottish Epidemiological Database The BBTP blood data management system that provides a population
(STED) (2005) wide view of how and why transfusions are used in Scotland with the aim
of identifying variation in practice, encouraging clinical review of blood use
and contributing to the goal of reducing avoidable transfusions.
EU Optimal Blood Use Project A three year collaborative project to develop a pan-European standard for





Current pressures affecting transfusion practise include the risk posed by the emergence of
vCJD, rising costs associated with blood safety initiatives and regulatory requirements,
public perceptions of risk, the ageing population and a change in the epidemiology and
treatment of disease (section 2.2). In this changing environment patterns of blood use must
be monitored in order to provide information for the way blood is used by a given
population. The information can be subsequently used to inform guidelines, policy and
strategies that promote practice change in order to achieve appropriate transfusion in all
settings and to relieve the practice of the pressures it is under.
Audits and descriptive analyses of blood component use for specific groups of patients,
typically those that are relatively straightforward to categorise, such as patients undergoing
major surgical operations, are frequently reported. However, rather fewer studies report on
the use of all blood component types across the full spectrum of patients who have
conditions, or who undergo treatments, that may require transfusion. The evidence that
does exist highlights the range of difficulties with this type of research.
Examples of audits, outcome studies and descriptive studies that have contributed to
informing the evidence base about the use of blood for transfusion are described here
(sections 3.2-3.4). Finally a review of quantitative descriptive studies of red blood cell use
related to clinical case group is reported and the methodological factors that must be




Audit of transfusion practice is the systematic, independent and documented assessment
against defined criteria to obtain evidence to determine whether transfusion practice
conforms to planned guidelines, and whether these guidelines are implemented effectively
and are suitable to achieve the policy and objectives of appropriate transfusion (Last, 2000).
Given an awareness of practice variability and inappropriate use in the field of blood
transfusion, audits are required to record current practice for means of information,
education and benchmarking for the future (Wallis, Stainsby & McClelland, 2002). Audits
often report on blood use and pre- and post-operative and pre- and post-transfusion
haemoglobin levels with respect to guidelines in order to assess the appropriateness of
transfusion. They provide an evidence base which can be used to inform policy revision as
well as identifying areas of transfusion practice that require further input from education
and guidelines. Ultimately, audits aim to contribute to improving safety and
appropriateness of blood use, which is of great importance given the pressures affecting the
supply of blood.
A marked change in transfusion practice has been the move away from whole blood
transfusion to the use of blood component therapy as developments in blood component
production and understanding physiological need have been made. A survey of clinicians'
requests for whole blood was carried out in the UK in 2001 to assess the extent to which, and
reasons for which, whole blood was still being used (MacLennan & Murphy, 2001). Whole
blood was primarily used for neonatal exchange and paediatric surgery, and in adults, for
major bleeding and in particular for post-operative bleeding following cardiac surgery that
was unresponsive to component therapy generally recommended for emergency
haemorrhage (MacLennan & Murphy, 2001). More than 90% of responding hospitals (58%
response rate) had made no request for whole blood, though the true extent of the issue may
be underestimated because users of whole blood were less likely to provide data and risk
facing criticism over their practice.
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The audits of red blood cell use described next represent a range of audit cycles: single audit
(Bray et al, 2003), audit and re-audit following guideline development and implementation
(Mallett et al, 2000), three audit cycle involving guideline development and practice
reminders (Spencer et al, 2005), and an extensive cycle of four audits over ten years during
which the study period and outcome measurements were expanded (James et al, 2001).
Further, three audits of fresh frozen plasma use (FFP) are described. The appropriate use of
FFP is of increasing interest given the impact of precautions against vCJD on the supply of
fresh frozen plasma, the rise in the use of blood component types other than red blood cells
and emerging evidence that casts doubt on the efficacy of treatment using FFP transfusion
(Stanworth et al, 2004).
The only audit of red blood cell use in all clinical settings, rather than surgical settings
described here is a study of a representative sample of transfused adults in India when a
National Blood Policy, that encompassed strategies to encourage the appropriate use of
blood, had just been introduced (Bray et al, 2003). The audit compared the reason for
transfusion with national transfusion guidelines (NACO)3 to assess the appropriateness of
blood use. The audit did not extend to paediatric and neonate transfusions because of the
difference in transfusion guidelines from adult transfusions. 74% of adult transfusions were
assessed as being inappropriate; inappropriate transfusion was most commonly identified as
being for unnecessary treatment of iron-deficiency anaemia and volume replacement. 92%
of transfusions to patients with a haemoglobin level of at least 7g/dL were assessed as being
inappropriate (Bray et al, 2003). The audit over-represents young males, and, because
young people are less likely to be inappropriately transfused, the audit is likely to under¬
estimate the true extent of inappropriate transfusion. The report concludes that
inappropriate transfusion is a significant issue in India.
Haemoglobin levels are commonly cited as a measure used to asses appropriateness of
transfusion. Pre-operative haemoglobin levels and haemoglobin levels at the time of
transfusion were measured in an audit of red blood cell use in elective surgery patients
(Mallett et al, 2000). The results were used to develop departmental guidelines and the audit
was repeated eighteen months after the guidelines were implemented. The results of the
3 NACO: National AIDS Control Organisation, 1996, Transfusion Guidelines. The National AIDS Control




second audit showed that a decrease in the total number of peri-operative transfusions by
43% mostly attributable to the reduction in two-unit transfusions as the level of blood loss
associated with triggering a two-unit transfusion was increased during the study period
(Mallett et al, 2000). A significant change in departmental peri-operative transfusion
practice was observed in comparable audits following guideline implementation, however,
post-operative transfusion practice was largely unaffected by the guidelines although there
were indications that the practice of top up transfusions had decreased.
Another prospective audit cycle of blood use in elective surgery, in this instance, specifically
hip and knee replacement surgery, was carried out using three audits over a period of two
years (Spencer et al, 2005). The study aims were to determine the proportion of patients
transfused post-operatively following joint replacement surgery and again to develop
guidelines for transfusion practice. Transfusion rates from the first audit were compared
with regional figures in order to inform local guidelines. The new guidelines required the
indication for transfusion to be recorded. This recommendation illustrates the increasing
awareness of the importance of reporting the clinical reason for transfusion. Transfusion
practice was audited a second time, and a third time following the issue of guideline
reminders. The overall rates of transfusion for hip and knee replacements fell from 71% to
37% after the second audit and were maintained at around 40% a year later (after the third
audit and guideline reminder) indicating that the reinforcement of guidelines can contribute
to reducing unnecessary peri- and post-operative transfusion (Spencer et al, 2005).
Four audits of red blood cell use related to surgery were carried out at a large district
hospital over the period of ten years: outcomes were reported for 1990, 1994, 1996, and 1999
(James et al, 2001). Initially, the number of units transfused and the cross-match to
transfusion ratio for each surgical procedure were reviewed by the hospital transfusion
committee and used to revise a maximum surgical blood order schedule (MSBOS) that
contains guidelines for the number of units required for transfusion of specific surgical
procedures (1990). In the third and fourth audits blood use by consultant was included, and
the study period of the fourth audit was extended from three months to one year to address
seasonal variation (1999). Overall the report demonstrates a sustained reduction in the
amount of wasted blood, that is, blood which is requested but not used, from 1990 to 1996
but an increase in subsequent years. This trend is thought to reflect the lag phase between
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changes in transfusion practice, such as ordering habits or updated MSBOS changes, and
improvements in surgical techniques that reduce the need for blood. The report also
identifies the lack of communication about cancelled operations between clinical teams and
laboratory staff as an area to target in order to further reduce blood wastage. Thus,
communication, collaboration and self-regulation are strongly implicated in improving the
efficacy of transfusion practice.
Further to red blood cell audit, the study of blood component use must encompass the other
blood component types in order that a complete view of transfusion practice and targets for
practice change can be made. Particularly, there is compelling evidence for the need to audit
fresh frozen plasma use. A recent report suggests that there are very few clinical conditions
for which treatment with fresh frozen plasma has been shown to be effective (Stanworth et al,
2004). Further, new regulations on the supply of plasma in the UK due to the emergence of
vCJD add to concerns over its use as it is a more scarce and expensive resource than years
gone by. Concerns such as these prompted the study of appropriate use of FFP by clinical
indication in three separate prospective audits (Chaudhary et al, 2005; Plui, Williams & Davis,
2005; Palo et al, 2006a). The audits assessed all FFP issues during the study period (one of
two two-month periods, one of thirty days, and one of two years). Appropriate transfusion
of FFP was reported for 29.5% of patients (Chaudhary et al, 2005) and 72% of units (Hui,
Williams & Davis, 2005) and was considered as inappropriate where no medical indication
was recorded at the point of use, where no follow up coagulation tests were done, or where
dosage differed from national guidelines (Palo et al, 2006a). The major indications for which
FFP units were appropriately issued were chronic liver disease, coagulopathy and
prolonged bleeding (Chaudhary et al, 2005), and anti-thrombotic warfarin effect and massive
transfusion with bleeding and abnormal coagulation (Ffui, Williams & Davis, 2005).
Inappropriate transfusion was highlighted in areas of post-cardiac surgery bleeding and
bleeding associated with normal coagulation (Chaudhary et al, 2005), and in haematology
and cardiothoracic surgery departments (Hui, Williams & Davis, 2005). The results indicate
that both studies were able to determine appropriate clinical indications for FFP transfusion,
which, in accordance with national guidelines, may represent areas for targeted intervention
to improve practice in the future. The main diagnostic indications for FFP use reported by
Palo et al (2006a) were circulatory diseases and the main procedures were digestive, cardiac
and thoracic surgeries. Further, a major factor discussed in that report was the
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methodological issues associated with the study sample in which there was a high
representation of severely ill patients and the lack of information on patient indicators such
as blood loss, anticoagulant use, and previous and subsequent morbidity (Palo et al, 2006a).
A report by the same authors in the same year describes new methodology that incorporates
electronic national registers of data and computer processes to effectively monitor and
compare population-based transfusion practice for all blood components (section 3.6) (Palo
et al, 2006b).
The audits of red blood cell and FFP use that were described here are evidence that
continual assessment of blood use is recognised to be important especially given variations
in transfusion thresholds and clinical indications which point to inefficiency in use.
However, a critical appraisal of blood transfusion audits suggested that the influence of
confounding factors on audit results are not always properly considered (Kanter, 2005).
Further, the report found no significant efficacy of audit of transfusion as an intervention in
itself on changing appropriate use of blood in any hospital-wide transfusion audit studied
during the course of the critical appraisal. To fully address this issue, an appropriately
designed study of the effects of audit versus non-audit intervention on the use of blood is
required. In summary, blood use audits should be rigorous and frequent, and the study
design and data interpretation must be carefully considered. They should be used to revise
guidelines and policy and the outcomes continually reinforced to maximise effect (Joshi &




Descriptive studies that report outcome measures of blood use and transfusion practice such
as the demographics of transfused and non-transfused patients, transfusion rates, intensity
of transfusion, trends in use, and post-transfusion survival can provide useful data for
planning and research proposes. Of interest are measures of cross-matched,
irradiated/leucodepleted and wasted/discarded units as well as units used for all blood
component types. Further, given the rising economic implications, cost-effectiveness
analyses associated with transfusion are required.
Described here are two different types of outcome study: survival studies and studies of
transfusion protocols. These were chosen because each evaluates the effects of the
intervention of transfusion; the specific outcome measures are patient related with respect to
survival and practice related with respect to transfusion protocol. Reports on post¬
transfusion survival generally provide a descriptive analysis of patient survival for
particular groups of transfusion recipients or compare survival of patients who are and are
not transfused. Reports on the effect of transfusion protocol on blood use can evaluate the
effect of variations in transfusion practice and new treatment plans such as the use of
restrictive versus liberal transfusion of blood.
3.3.1. Survival studies
There are two main types of survival study: one, observational studies of survival of
transfusion recipients, and two, the study of the influence of transfusion on survival where a
causative relationship is implied. Studies of survival rates of transfusion recipients provide
baseline data for the quantity of blood transfused as well as analysis of patient variables,
notably morbidity and mortality. Survival studies contribute to the evidence base regarding
transfusion safety, efficacy and cost-effectiveness are used to inform the decision to transfuse
based on benefit versus risk analysis (Kleinman et al, 2004).
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Many patient and practice variables have been implicated in predicting post-transfusion
survival: age, sex, volume of blood transfused, length of hospital stay, specialty of treating
physician, severity of injury or illness, physiological/biochemical test results and clinical
category. However, studies of transfusion and survival are intrinsically confounded due to
the effects of the underlying nature or severity of the clinical condition. The severity of
disease influences treatment with blood transfusion and is likely to be the dominating
influence on survival regardless of transfusion status. Due to such confounding as well as
bias in case selection previous studies have found it difficult to identify variables that
successfully predict post-transfusion survival. For example, in a seven-year review of
trauma patients who received massive transfusion, shorter post-transfusion survival was
shown to be related to higher injury severity, and shorter intensive care unit and hospital
length of stay, and not transfusion related variables such as the volume of blood transfused
(Criddle, Eldredge & Walker, 2005).
Diagnostic case group has been hypothesised to affect post-transfusion survival: a regional,
population-based study of one- and seven-year post-transfusion survival for a case mix of
primary diagnoses and surgical procedures was devised to address this (Tynell et al, 2005).
The study reported that between 1993 and 2000, one-year survival rates increased from 68%
to 74%, and that post-transfusion survival was longer for surgical patients (versus medical
patients) and for young, female patients, a finding comparable to the one year post¬
transfusion survival rate of 69% reported for a large study of post-transfusion survival in
mid-western and southern America (Kleinman et al, 2004). Further, the report attributes
variation in post-transfusion survival to variation in population demographics, clinical
practice and transfusion policy which may be indicative to some extent of areas of
inappropriate transfusion (Tynell et al, 2005).
Currently the issue of post-transfusion survival is particularly pertinent in the United
Kingdom given concerns regarding the potential risk of vCJD transmission through blood
transfusion. The first study of long-term survival following transfusion in the UK was
carried out in northern England to quantify the number of transfusion recipients surviving
long enough to be at risk of transfusion-acquired vCJD, though not to assess the effects of
transfusion on survival per se (Wallis et al, 2004). The median survival per red blood cell
unit transfused was 31 months, and was less for FFP and platelets (19 and 6 months
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respectively). Patients who were older, male, transfused with more red blood cells, and who
were transfused with FFP or platelets had shorter survival, as did patients in medical
specialties. The overall survival rate was 68% after one year and 47% after five years, rates
that are in accord with post-transfusion rates reported by Tynell et al (2005) and Kleinman et
al (2004). Post-transfusion survival was shorter than previously reported for other countries,
a difference that was attributed to population and clinical practice changes. The report
concludes that unless many recipients subsequently have a high rate of donor exposure and
the infectivity of vCJD is high, it is unlikely that transfusion recipients are at a significant
risk of infection from transfused blood (Wallis et al, 2004). Studies such as this are essential
in monitoring post-transfusion survival in the context of infection risks, and particularly
given concerns regarding vCJD, in order to provide evidence that can be used to inform the
decision to transfusion based on the balance of risk versus benefit.
3.3.2. Studies of transfusion protocols
Medical protocols are concerned with the rules or guidelines for the use of a medical
treatment or intervention. Described in this section are studies of transfusion protocols for
the use of blood component transfusion. Evidence-based and revised transfusion guidelines
are essential for uniformly directing the safe and effective use of blood.
A central, determining factor in the decision to transfuse is the level of haemoglobin in the
blood: specific haemoglobin levels below which transfusion is prompted are referred to as
transfusion thresholds or triggers. General guidelines for transfusion quote figures for
transfusion thresholds but these guidelines can vary by country, clinical context and author
and are not always based on compelling or current evidence. Compliance too varies
between clinicians and hospitals (Clark & Mintz, 2001). Transfusion triggers are a principal
factor in studies of appropriate transfusion in compliance with protocols. In previous years
a transfusion trigger of lOg/dL was accepted but there is growing evidence for a restrictive
trigger of 6-7g/dL (McClelland, 2007; Clark & Mintz, 2001). The decision to transfuse at a
particular threshold must take into consideration the levels of oxygen deprivation and
specific clinical needs of the individual patient, for example, anaemia and oxygen
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deprivation are less well tolerated in critical care and trauma patients and the elderly. As for
all transfusion events the balance of risk versus benefit of transfusion to the patient must be
considered (Hill et al, 2002; Carson et al, 2002). Guidelines now recognise the safety and
efficacy of restrictive transfusion thresholds where the haemoglobin level at which
transfusion is triggered is lower than previously endorsed.
Furthermore, transfusion practice has historically been dominated by the practice of two-
unit transfusions, deemed to be the volume necessary to make any significant improvement
to anaemic patients. However, the need to conserve blood and protect patients from
exposure to risks associated with allogeneic transfusion is more predominant now than ever
before and has prompted a move away from unnecessary, though apparently standard two-
unit transfusions and a move toward reductions in allogeneic blood use in general. Studies
of the impact of transfusion protocols, such as single-unit transfusions (Ma et al, 2005) and
restrictive transfusion thresholds (Hebert et al, 1999a), aim to save blood and reduce
recipient exposure to transfusion-related risks and are essential to informing the evidence for
future transfusion practices.
Blood use in critically ill patients presents particular challenges given the complexity and
clinical instability of these patients. The impact of restrictive transfusion protocols on the
conservation of blood and patient outcome was assessed in a randomised control trial of red
blood cell transfusion in critical care (Hebert et al, 1999a). In this trial all-cause mortality
rates and severity of organ dysfunction associated with restrictive versus liberal transfusion
protocols in the critical care setting was examined. With the restrictive protocol the
transfusion threshold was a haemoglobin level of 7g/dL and with the liberal protocol the
transfusion threshold was lOg/dL. 30-day mortality rates were significantly lower in less
acutely ill patients and patients less than 55 years old who received transfusion according to
the restrictive protocol. The report concludes that the restrictive protocol was at least as
effective if not more so, than a liberal transfusion protocol, except in cases of acute cardiac
disease. This conclusion may indicate that the side effects of transfusion counter any added
benefit from the oxygen carrying capacity of the additional blood transfused in liberal
protocols. In a report on the ten best randomised controlled trials in the area of transfusion
practice in terms of relevance to or impact on transfusion practice and policy this study was
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considered to be that with the biggest potential to make a significant impact on changing
transfusion practice (Blajchman, 2005).
The Hebert et al (1999a) study was also included in a Cochrane review of transfusion
thresholds and other strategies for guiding allogeneic blood transfusion (Hill et al, 2000).
The review identified a total of ten trials relating to transfusion thresholds in which
restrictive and liberal transfusion protocols were compared, and concluded that the use of
restrictive transfusion thresholds was supported by the data reported for the studies
included in that review. Using restrictive thresholds, reductions were made in the risk of
receiving an allogeneic transfusion and the volume of red blood cells transfused without
affecting mortality, morbidity, cardiac events and length of stay in hospital. The exception
was for patients with notable cardiac disease (Hill et al, 2000).
The first published report to assess single-unit transfusion in terms of reducing blood use
and maintaining acceptable haemoglobin levels was of a retrospective study by Ma et al
(2005). To achieve a 7g/dL transfusion threshold single-unit transfusions would have been
sufficient in 98% of cases (42% of cases to achieve a 9g/dL transfusion threshold), and could
represent a saving of 0.82 units per patient (0.21 units per patient if a 9g/dL transfusion
threshold was required). The actual haemoglobin increase for single-unit transfusions was
not assessed, rather was calculated assuming that it would be half that of the increase
achieved by two-unit transfusions. Nevertheless, the report concludes that, except in cases
of acute haemorrhage and anaemia, a single-unit transfusion protocol could significantly
improve blood use and reduce recipient exposure to allogeneic blood (Ma et al, 2005).
The conclusions reported by Hebert et al (1999) and Ma et al (2005) are supported by a study
of the impact of a restrictive protocol for red blood cell use in intensive care in which
restrictive transfusion was associated with reduced mortality and one third of transfusions
were single-unit transfusions (Farrar et al, 2004), and by an Australian study of appropriate
red blood cell use in haematology, cardiothoracics and orthopaedics that reported areas of
inappropriate transfusion with reference to haemoglobin levels and concluded that one-unit
transfusions were not common (Grey et al, 2006).
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The reports described here demonstrate the impact of liberal versus restrictive transfusion
protocols and one-unit versus two-unit transfusion protocols on allogeneic blood transfusion.
Further, an algorithm designed to direct transfusion protocol in a novel way is described
here: compliance with a transfusion algorithm for red blood cell transfusion in primary
elective total knee replacement surgery has been prospectively assessed (Boralessa et al,
2001). Given that there was no evidence for a specific haemoglobin level at which
transfusion would improve outcome, and with the knowledge that outcome is affected by
blood loss, age of patient and comorbidities, as well as wide variation in practice amongst
clinicians and institutions, the available transfusion guidelines were considered to be
inadequate by the researchers. The transfusion algorithm incorporated the variables pre¬
operative haemoglobin level, volume of blood lost and crystalloid and colloid treatment, and
was based on a restrictive post-operative haemoglobin level of 7g/dL. Compliance with the
algorithm for transfusions on the day of surgery and for subsequent transfusions was 62%
and 89% respectively. Further, the results were compared with those from a retrospective
survey by the same authors. The two study populations were described as being similar but
there was a significant difference in mean post-operative blood loss between transfused and
non-transfused patients in the prospective study, which was not the case in the retrospective
study suggesting that the decision to transfuse in the prospective study was influenced by
post-operative blood loss (and hence, haemoglobin level). The transfusion rates for the
retrospective study without the algorithm and for the prospective study employing the
algorithm were 64% and 30% respectively. The report concludes that the algorithm can be
used to reduce inappropriate transfusions, and advocates continuous audit of practices and
education of staff (Boralessa et al, 2001).
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3.4. Comprehensive, descriptive studies of blood use
Here the term comprehensive, descriptive study of blood use refers to a study of blood
component use that encompasses a specific group of patients, typically those that are
relatively straightforward to categorise. For example, described here are studies of patients
undergoing major surgical operations, trauma and critical care patients, and elderly patients.
Studies and routinely published reports that quantify national blood use data are also
described.
3.4.1. Elective Surgery
Early studies of clinical blood use primarily addressed transfusion practice in surgical
settings. A study bias towards a small range of high blood using surgical specialties and
specific operations and procedures arose because these were perceived to be clinical areas of
importance and relevance and because the study populations were relatively easy to define.
(Stanworth et al, 2002). The use of packed red blood cells in surgery at a single teaching
hospital was assessed not just by type of procedure but also by consultant performing the
procedure and the time of transfusion in relation to surgery (Pinkerton, Seigel & Coovadia,
1993). No significant variation in blood use between surgeons at the same hospital was
found, and as a result local utilisation guidelines were produced based on the transfusion
practice reported by that study. However, the report did acknowledge that a wider
population study would be useful for further development of guidelines, particularly given
the concurrent increase in regulatory pressures at the time that were pushing for better audit
of comparative blood use data.
In contrast, red blood cell use in surgery in an Australian tertiary care hospital was studied
in a setting where blood component use was already being monitored and blood
conservation strategies were already employed (Maxwell et al, 2002). The surgical events
were classified using the Commonwealth Medical Benefits Schedule, a clinical classification
system developed to calculate benefit payments for medical conditions, which was used as a
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proxy for defining clinical case groups. Blood use and transfusion incidence for the
frequently performed (>10 times in a year) surgical procedures were reported but the
findings did not detail procedures that had a high transfusion rate but were not frequently
performed. Further, not all surgical specialties were represented at the study hospital (for
example paediatrics, obstetrics and gynaecology specialties were absent). The report
acknowledges that the findings relate only to a single institution but suggests that data such
as this is useful for benchmarking and resource planning if considered in conjunction with
national surgical statistics relating to the number of procedures performed. Moreover, the
report provides evidence of methodological approaches that could be utilised by others in
future blood use studies and reveals that the issue of blood use by clinical case group is of
interest and importance.
Further, a specific study of autologous blood use in elective surgery was carried out by the
same group in Australia, where at the time the utilisation of autologous transfusion was still
on the increase (Savoia et al, 2002). The findings demonstrate that patients transfused with
pre-operative autologous blood donations are more likely to be transfused than other
recipients: the more liberal transfusion policy and increased likelihood of anaemia due to
pre-operative donation can explain this to some extent. The effect of other confounding
variables such as severity and complications relating to the procedure was not assessed in
this study (Savoia et al, 2002). Also, a 28% wastage figure for blood that was donated but not
transfused is reported. While highlighting important issues regarding autologous blood
donation specifically, overall the report is illustrative of the need to study blood use in
various settings in order to answer a range of questions surrounding the appropriateness
and effectiveness of transfusion practise as a whole.
The studies by Pinkerton, Seigel & Coovadia (1993), Maxwell et al (2002) and Savoia et al
(2002) described here were single-institution studies of blood use in surgery. By contrast, the
Belgium BIOMED study was a multi-centre study (63 hospitals) of all blood components
(allogeneic and autologous) used in four common surgical procedures (Baele et al, 1998).
These were two joint-related and two colectomy-related procedures defined by the Belgian
classification system for medical benefits, INAMI'/RIZIV. As in Maxwell et al (2002) and
Savoia et al (2002), this clinical classification system is related to economic medical benefits
4 INAMI: National institute for sickness and invalidity insurance (Institut national d'assurance maladie-invalidite)
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nomenclature which may be a poor proxy for clinical classification in the context of
measurements in clinical practice given the different purpose for which it was devised. The
BIOMED study provided valuable data on countrywide, inter-hospital variation in
transfusion practice and attributed this variation to differences in transfusion practice rather
than differences in the patient populations (Baele et al, 1998). Also, the multi-centre
approach encompassed both teaching and non-teaching hospitals: the data contradicts
previous thoughts that teaching hospitals transfuse more due to the inexperience of junior
trainees by reporting that transfusion practices in teaching hospitals actually benefit from
the current teaching and awareness of factors relating to the transfusion practice of junior
doctors. This aspect echoes the findings of other audits and studies that adherence to
guidelines can be improved and inappropriate transfusion reduced by continual education
and the reinforcement of transfusion related policy.
The example of the BIOMED study introduces joint surgery as a notable area of blood use.
Blood loss associated with total hip and knee replacement surgery can be substantial
meaning that the patient may require blood transfusion as well as the use of alternative non-
blood interventions (Bierbaum et al, 1999; Churchill et al, 1998; Boralessa et al, 2000). In some
settings, pre-operative donation of autologous blood was a commonly used strategy
although it has logistical, administrative and cost implications as well as clinical implications
for the patient by exposing them to a risk of pre-operative and post-operative anaemia.
However, a study of pre-operative and discharge haemoglobin levels and blood loss of
transfused and non-transfused patients undergoing primary total hip replacement surgery
concluded that more than 90% of post-operative transfusions had been routinely given
without consideration for the clinical need of the patient (Boralessa et al, 2000). The
indication for transfusion was not recorded but these findings and the lack of a transfusion
protocol suggest that a significant number of transfusions may have been unnecessary.
Further, following from a lack of evidence for autologous transfusion criteria for a broad
spectrum of procedures, The Collaborative Hospital Transfusion Study embarked on a
multi-hospital study (5 university hospitals in the USA) of autologous red cell transfusion
for primary hip and knee surgery (Churchill et al, 1998). The procedures were defined by the
medical classification system Diagnosis-Related Groups (all coded in section DRG 209). For
both knee and hip replacement procedures the study reports a significant difference between
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hospitals in the number of patients pre-operatively donating blood, in the number of
patients and units transfused, and the number of unused autologous units but no significant
difference in number of patients who pre-operatively donated blood but subsequently
required allogeneic blood in addition to autologous transfusion (Churchill et al, 1998). The
findings echoed those of a similar study of allogeneic red cell use in total hip and knee
replacement reported seven years previously in which practice variation between hospitals
was described for the number of patients, but not units, transfused (Surgenor et al, 1991).
The reports provided further evidence of the effect of practice variation on transfusion
practice.
Another large-scale study of autologous and allogeneic blood use of patients undergoing
total hip and knee replacement reported that overall 46% of patients were transfused (of
which 66% of patients received autologous blood, 34% received allogeneic blood) (Bierbaum
et al, 1999). 45% of pre-operatively donated autologous blood units were not transfused and
9% of patients who pre-operatively donated autologous blood also required allogeneic blood
transfusion. Notably, the report highlighted that complex logistics and high costs, as well as
the risk of anaemia and need for supplementary allogeneic transfusion, were associated with
pre-operative autologous blood donation, and called for further research into alternative
strategies to reduce or replace allogeneic transfusion, other than pre-operative autologous
blood donation.
Like joint surgery, coronary artery bypass graft (CABG) surgery has also proved to be a
focus for analysis of transfusion practices. The studies referred to here describe the
determinants of blood use for CABG surgery and demonstrate comparative variation in
transfusion practices. Blood use data for two studies carried out in two different years has
been compared: the first study in 1998 included six hospitals, the second in 2000 included 32
hospitals (Boralessa et al, 2002). The data revealed a decrease in blood use for CABG surgery
between 1998 and 2000 but also indicated wide variation in the number of patients per
hospital who were transfused: in the 1998 study the number of patients transfused varied
between 58% and 91% (mean 89%) and in 2000 the number of patients transfused varied
between 6% and 90% (mean 53%). The decrease in blood use in 2000 reflected the
introduction of blood conservation strategies (71% of hospitals had implemented a more
restrictive transfusion threshold) and it is reported that blood use was improved if three or
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more blood conservation strategies were in place (Boralessa et al, 2002). A multi-centre
retrospective analysis of blood use for one medical condition and three surgical procedures
included analysis of red blood cell use for CABG surgery (Hasley et al, 1995). The mean
percentage of CABG patients transfused was 81% but variation in transfusion practice was
again highlighted as the number of units transfused and the percentage of CABG patients
transfused varied between hospitals. Whilst variation in blood use for the medical condition
(ulcer disease) was attributable to demographic and patient variables, the variation in blood
use for the surgical procedures was attributed to transfusion practices (Hasley et al, 1995).
Further, a relatively early, prospective study of red blood cell use and the determinants of
transfusion for CABG surgery at two institutions reported overall transfusion rates of 73% (5
units per patient) at one hospital and 52% (2.9 units per patient) at the other (Goodnough et
al, 1989). Transfusion rates and determinants varied between the hospitals studied
prompting recommendations for further multi-institution audit of transfusion practice in
cardiac surgery. The research group subsequently carried out a similar study of transfusion
practice for CABG surgery in eighteen institutions and again variability in blood use and
determinants of transfusion were reported. When the effects of patient and surgical practice
variables were controlled for factors related to transfusion practice accounted for the
variation in blood use (Goodnough et al, 1991).
The Collaborative Hospital Study group, which was described above for a study of blood
use in total hip and knee replacement surgery in which comparative analysis revealed
variation in transfusion practices (Surgenor et al, 1998), has also studied the use of blood for
coronary artery bypass graft surgery (Surgenor et al, 1996). The study was not a comparative
analysis of blood use; rather the report reveals that transfusion requirements in CABG
surgery were associated with patient characteristics and the type of procedure (primary or
revision, and type of conduit used for revascularisation). Further analysis of practice
variation in this study population would provide useful comparative data.
What can perhaps be considered as the cornerstone of comparative analysis of transfusion
practices for surgery was a study by The Safe and Good Use of Blood in Surgery (SANGUIS)
group (Sirchia et al, 1994). Initiated by the European Commission, the SANGUIS study
brought together interested parties from ten European countries, representing forty-three
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different hospitals, to assess blood use for six commonly performed elective surgical
procedures over a period of two and a half years. The group gathered data for the number
of patients and units of each blood component transfused, use of albumin and artificial
colloids, ratio of units requested to units transfused, reasons for transfusion and transfusion-
related complications. Overall, the study represented 7,195 patients of whom 34% were
transfused with 11,464 units of allogeneic red blood cells. Two of the six procedures studied
were CABG and total hip replacement: for which 87.7% and 80.8%, respectively, of operated
patients were transfused, mostly peri-operatively, with autologous and allogeneic red blood
cell units (37.6% and 56.8% with allogeneic units only). Like other studies discussed
previously, wide inter-hospital variation in blood use among hospitals of the same country
as well as between countries was identified by the SANGUIS study. For example, in CABG
and total hip replacement surgeries the percentage of operated patients transfused with red
blood cells ranged from 17% to 100% and from 29% to 100%, respectively (Sirchia et al, 1994).
This report attributes the variability not with biological factors but rather professionals'
attitudes towards and consequently their practice of blood transfusion. Further, the reason
for red blood cell transfusion (low haemoglobin, bleeding and volume replacement) was
reported but for just 23% of transfused patients. In conclusion, the report sets out the
priorities of optimising the appropriate use of blood through data analysis, guideline
development and the modification of transfusion practitioners' behaviour (Sirchia et al, 1994).
The comprehensive, descriptive studies discussed here are examples of studies of surgical
blood use that have provided insight into the use of blood in areas of particular interest such
as joint and cardiac surgery and that have addressed pertinent issues such as pre-operative
autologous donation and practice variation.
3.4.2. Trauma and critical care
Although elective surgery was a focus for early studies of blood use by clinical indication,
interest in better understanding transfusion practices in other high-user settings such as
intensive care is growing. A multi-centre study of inter-hospital variation in the number of
patients transfused, the mean number of units transfused per patient, and in mean
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haemoglobin levels for the critical care setting was discussed previously with respect to
restrictive transfusion protocols (section 3.3.2) (Hebert et al, 1999a). Other studies of blood
use in intensive care and trauma are discussed here.
Given that critically ill patients are adversely affected by anaemia but evidence exists to
suggest that restrictive transfusion strategies have no negative effect on these patients,
analysis of blood use in comparison with practice guidelines was needed to inform the
evidence base for an appropriate transfusion strategy specifically for use in the critical care
setting. This aim was addressed by the Audit of Transfusion in Intensive Care in Scotland
(ATICS) study of blood transfusion for a sample of patients admitted to hospital intensive
care units (ICU) (Walsh et al, 2001 and 2004). The study likely underestimated total red
blood cell use by critical care patients as it did not include additional transfusions that these
patients may have received in other wards once discharged from ICU. However, the
findings revealed that 26% of ICU admissions, and almost 50% of red blood cell units
transfused in the study were given when the patient had a low haemoglobin level without
evidence of bleeding. Overall, Scottish ICU patients were estimated to use 7% of the total
Scottish red blood cell supply supporting the belief that ICU patients are an important group
of transfusion recipients.
Inter-hospital variation in surgery has been well-described, as illustrated by reports
discussed here; furthermore, variation is also evident in the critical care setting. A study that
reports the practice of red blood cell transfusion for critical care patients in Canada (TRICC:
Transfusion requirements in critical care) reveals notable practice variation between
hospitals even after adjustment for patient age, diagnosis and disease severity (Hebert et al,
1999b; Walsh & McClelland, 2003). The study also investigated the clinical indication for
transfusion in these patients but only report for "acute bleeding" (35% units transfused) and
"augmentation of oxygen delivery" (25% units transfused), a reflection of the advances
required in the classification and analysis of blood use by clinical reason. The report
concludes that the findings support a call for further research into transfusion of critically ill




Evidence for variation in transfusion practice and the determinants of transfusion is largely
indicative of the need for appropriate analysis, guideline development and targeted
approaches to reducing inappropriate transfusion. Corwin, Parsonnet & Gettinger (2005)
reported on red blood cell use in a critical care centre in which, at the time of the study, there
was no specific transfusion protocol in place. The reason for transfusion was classified
according to the National Institutes of Health Consensus Conference transfusion criteria that
relate to physiological and biochemical factors such as haemoglobin level, cardiac output
and oxygen transport rather than specific clinical conditions. In addition, two clinical case
groups are listed: a broad, procedure-based group, "surgery/bleeding" and a specific
medical condition, "myocardial ischaemia". Also available as reasons for transfusion are
"none" and "other": 29% of transfusion events could not be attributed to an indication
suggesting that the decision to transfuse was based on an arbitrary haemoglobin level rather
than a physiological need for blood (Corwin, Parsonnet & Gettinger, 2005). The findings
prompted a call for the development of and adherence to new guidelines.
Further to reversing anaemia in critically ill patients, transfusion is an integral part of
resuscitation support for trauma patients and as such this area of clinical care makes a
significant demand on the blood supply. Two studies of blood use in the related field of
trauma quantified blood use and trends in transfusion of trauma patients in order to assess
practice change and further, to use the data to inform guidelines for this clinical setting
(Coovadia, Pinkerton & Sharkey, 1992; Farion, McLellan & Boulanger, 2007). Patients in a
regional trauma unit were studied to assess the impact of a trauma specific target
programme aimed at reducing blood use (Coovadia, Pinkerton & Sharkey, 1992). The data
described trauma patient blood use and indicated the potential for implementing practice
change. A few years later trends in blood use by trauma patients demonstrated that
reductions in both the number of patients transfused and the total number of units
transfused were indicative of the implementation of recommended changes in clinical and
transfusion practices in this setting (Farion, McLellan & Boulanger, 2007).
The evidence describes notable variations in transfusion practice and a need for appropriate
transfusion protocols in critical care and trauma settings where patients are especially
vulnerable to oxygen deprivation, anaemia and haemorrhage. The appropriate transfusion
threshold for critically ill and anaemic patients depends on a range of patient variables and
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must always consider the balance of benefit versus risk. Further evidence of good quality is
needed for different patient groups in order that practice concerns can be addressed,
particularly for transfusion thresholds in the borderline range of lOg/dL to 7g/dL, in order to
help direct the decision making process for the transfusion of critically ill patients (Walsh &
McClelland, 2003).
3.4.3. Elderly population
One of the pressures on the blood supply discussed in section 2.2 was the growing ageing
population in countries such as the United Kingdom and the United States. Here a study of
blood use by an elderly population is described to illustrate the importance of the demand
for blood in this specific patient group. A recently published report on blood use data for
the inpatient population aged 65 years and older in the United States in 2001 is claimed to be
the first systematic, population-based study of blood use in the elderly inpatient population
(Anderson et al, 2007). In total six percent of the 635,700 inpatient hospital stays analysed
were associated with blood transfusion. The highest users were aged between 70 and 84
years old, after which age blood use declined because the number of patients over this age
was small and transfusion rates decrease because very elderly patients are considered less
likely to benefit from the intervention. More blood was used by patients who underwent
more procedures: the top procedures by mean blood use are reported to be surgeries related
to cardiac, gastrointestinal and orthopaedic specialties. The top diagnoses by mean blood
use are reported to be cardiac and gastrointestinal conditions. Overall, only small variations
in blood use by age, sex, and ethnicity were reported. Despite complications in the way
blood transfusions were recorded in the data, a methodological point acknowledged in the
report, the study represents a valuable contribution to understanding clinical blood use for
an elderly population with considerable significance for the future given the ageing
population in America and elsewhere.
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3.4.4. National studies and statistics
Studies that are restricted to specific clinical settings or patient groups, defined by ward,
medical specialty or surgical procedure for example have been discussed (section 3.4.1-3.4.3).
Studies that observe a whole population or an epidemiologically defined sample of a whole
hospital, regional or national population are described in this section. These studies
encompass a broad case mix of patients and can provide valuable quantitative data that can
be used to assess the population's need for blood as a whole.
Official and often routine national statistics are good examples of population-based studies.
For example, the Blood Utilisation Survey by the National Blood Strategy Implementation
Group in the Republic of Ireland to the Minister for Health and Children reports data for
allogeneic and autologous red blood cell use and other blood components for the whole of
Ireland. In the year 2001 the transfusion practice of 69 hospitals was surveyed. The data
represented 558,844 inpatients, and reported an estimated national red blood cell use of 3.75
units per patient transfused (O'Reilly, 2004). The survey also highlighted interventions that
were employed at that time to address the safety and efficiency of transfusion: 73.8% of
hospitals surveyed had a maximum surgical blood ordering schedule, 78.7% had a hospital
transfusion committee, and 80.3% had formal transfusion guidelines for red blood cell use
(O'Reilly, 2004). This study also reported a high level classification of blood use by clinical
specialty revealing that 42% of red blood cell units were transfused to surgical patients, 22%
to general medical patients and 16% to haematology/oncology patients. Although the
clinical categories lacked specific details of procedures and conditions the report made some
attempt to describe blood use by clinical case group. The importance of studying blood use
by clinical case group is discussed in full in section 3.5.
A marked contribution to population blood use statistics has been made by a research team
in the United States which has undertaken a series of national surveys of blood collection
and transfusion activities for a large study sample that is representative of the whole country
(Wallace et al, 1993, 1995 &1998; Sullivan et al, 2002 & 2007; Sullivan & Wallace, 2005;
Surgenor et al, 1998). Prospective surveys for years 1980-1985 ,1989, 1992 ,1994,1997,1999
and 2001 reported data for measures of units (of initially whole blood and red blood cells
but later all blood components) collected, discarded/outdated, leucodepleted/irradiated,
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wasted and transfused. In 2001 the survey was extended to include data for cellular therapy
product use in haematopoietic transplantation, reflecting growth in the range of medical
conditions that can be treated with blood component transfusion (Sullivan et al, 2007).
The data from each year was compared with previous studies in the series, thereby enabling
analysis of trends. In addition, the 1980-1985 study compared rates of transfusion between
four hospitals (Surgenor et al, 1998). Overall the studies report an increase in transfusion
rate between 1980 and 1982, followed by a levelling and constant rate between 1982 and 1985
(Surgenor et al, 1998), in parallel with an increase in the country's total blood supply to 1989
(Wallace et al, 1993); a decrease (by 3.1%, 3.3% and 5.5%) in blood supply in years 1992,1994
and 1997 (Wallace et al, 1993; Sullivan et al, 2002); a constant average red cell units used per
1,000 population (approximately 42.8) over years 1994 and 1997 (Wallace et al, 1998; Sullivan
et al, 2002); and an increase in total blood supply (10.1% to 10.4%) as well as an increase in
average red cell units used per 1,000 population (5.8% to 9.9%) over latter years 1999 and
2001 (Sullivan & Wallace, 2005). Together the data provide comprehensive, quantitative
data on the supply and demand of blood in the United States over a period of many years.
A weakness perhaps of these studies is that no attempt was made over the years to include
clinical data in light of growing awareness of the importance of understanding the clinical
reasons for which blood is transfused. In the most recent of the series, the authors do refer
to a need to address physician preferences regarding transfusion practices and they
recognise the effect of general heightened awareness about safety issues on the supply of
and demand for allogeneic blood transfusion (Surgenor et al, 1998).
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3.5. Comprehensive, descriptive studies relating blood use to clincal data
Large and comprehensive, descriptive studies that relate blood use to the clinical reason for
transfusion are required to provide a complete view of the clinical conditions that together
constitute the total use of blood in a population, and to determine the proportion of
individuals in a population who are transfused. In this way the need for blood for the whole
population's clinical case mix of patients can be assessed. Like the audits and surveys
described previously, the ultimate aim is to inform the evidence base for blood use in order
to identify variation in transfusion practices, inform policy and optimise appropriate use for
the future.
Factors in the assessment of a population's need for blood should include the prevalence of
specific stages and severity of disease, patients' pathophysiology and mechanisms and
frequency of treatment. Suitable data sources containing valid parameters, appropriate
study period and representative study population have been cited as being required in order
to provide a clinically relevant framework within which to study the patients who have the
greatest need and who will gain the most benefit from receiving transfusion.
As has been described in previous sections, the relevant evidence base typically reports for
specific patient groups or biased case mix groups, for single or few institutions that are
representative of local demand for and use of resources, and that are not representative of a
whole country or sample population. Here the noteworthy population based reports of
blood component use for the full spectrum of patients who have conditions or undergo
treatments that may require transfusion described by clinical categories that represent
patients' underlying reasons for transfusion requirement are discussed. A thorough, albeit
non-systematic review of published reports was carried out to identify studies of the
transfusion of red blood cell units in relation to clinical information pertaining to the
transfused individual. The methods used to identify studies fall short of the required
standards of Cochrane systematic reviews (Figure 3.1) (Higgins & Green, 2006). However,
the process did employ search and refinement methods, forward citation searches, and
literature recommended by experts in the field, to develop a specific search strategy with
assistance from specialists at SNBTS and university libraries (Table 3.1). The inclusion
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criteria for this review were studies of red blood cell use for a well defined population or
appropriately selected and described sampled of a population in which an attempt had been
made to relate transfusion data to clinical information. A specific review of the methodology
of these quantitative, population based studies of blood component use with specific
reference to well-defined clinical categories was undertaken (sections 3.5 and 3.6).
Figure 3.1 Literature citation selections
Table 3.1 Study selection search criteria
Search * Search term (number of citations)
1 Blood transfusion/sn, ut (1,550)
2 Blood component transfusion/sn, ut (141)
3 Erythrocyte transfusion/sn, ut (254)
4 "Blood banks/sn, ut (81)
5 Surgical procedures, operative/ (43,456)
6 Hospitals/ (81,598)
7 (or/1-3) and (or/4-6) (208)
* Ovid Medline, 1966 to February Week 2 2006 (10th February 2006)
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Fourteen studies were identified for inclusion in the review (Tables 3.2a&b). These studies
were carried out in France, Germany, Denmark, Finland, United States, United Kingdom
and Korea, the earliest of which was published in 1979 (Friedman, Burns & Schork, 1979).
Studies reflect changes in transfusion practice in response to emerging pressures on blood
services over the intervening years. The study by Friedman, Burns & Schork (1979) proved
to be a pinnacle paper of its time and in its area of research, and prompted many questions
about future research requirements in order that studies provide sound evidence on the
clinical use of blood for transfusion. In 1991 the results of the first regional study of blood
use by clinical case group in the United States were published (Cook & Epps, 1991). Those
findings supported Friedman et al's suggestion that a sizable proportion of transfused blood
could be linked with patients diagnosed with malignant neoplasms and added evidence for
the high use of blood for surgical interventions. Over the years a number of studies have
contributed to the evidence for high blood use in the areas of malignant and haematological
disease (Titlestad et al, 2001 & 2002; Syrjala et al, 2001; Chiavetta et al, 1996; Mathoulin-
Pelissier et al, 2000; Zimmerman et al, 1997 & 1998; Lim et al, 2004; Wallis, Wells & Chapman,
2006) and increasingly findings suggest that surgical interventions now use less blood (as a
proportion of total blood use) (Wells et al, 2002; Vamvakas & Taswell, 1994; Mathoulin-
Pelissier et al, 2000; Stanworth et al, 2002; Zimmerman et al, 1997; Wallis, Wells & Chapman,
2006). Where blood use for surgical events is described the clinical areas frequently reported
are gastroenterology, cardiology/cardiothoracics, orthopaedics and general surgery (Wells et
al, 2002; Chiavetta et al, 1996; Stanworth et al, 2002; Titlestad et al, 2001; Wallis, Wells &
Chapman, 2006).
Many of the studies identified here were the first in their region or country to carry out this
type of research on a large or population based scale. The study by Zimmerman et al (1998)
was the first to analyse data of this nature for a population of children and adolescents, and
not just for red blood cells but also for fresh frozen plasma and platelets. Blood use by age is
also described for studies that identified increasing use in the elderly population, although
definitions of age bands varied between studies (Wells et al, 2002; Vamvakas & Taswell, 1994;
Mathoulin-Pelissier et al, 2000; Wallis, Wells & Chapman, 2006). Studies have benefited from
developments in information technology by employing computerised registers of data and
record linkage to considerably ease the handling of large volumes of routinely collected data
(Titlestad et al, 2001 & 2002; Syrjala et al, 2001; Zimmerman et al, 19997 & 1998; Lim et al, 2004;
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Stanworth et al, 2002). One study specifically addressed the use of computerised registers
and developed processes for the automated generation of reports of blood use by clinical
category (Titlestad et al, 2002).
In the following sections three important aspects of study methodology are reviewed. These
areas are the study setting and population, clinical data and classification systems, and
source data and record linkage processes (Table 3.3). Findings quoted in the following
sections are included in Tables 3.2a and 3.2b that summarise the relevant information about
the studies reviewed. Aspects of methodology affect the interpretation and comparability of
reported data and reveal areas where further development of methods is required in order
to provide useful and meaningful data in the future.
Table 3.3 Information extracted for review: aspects of study methodology
Study Setting and Population
(Section 3.5.1)
Clinical Data and Classifications
(Section 3.5.2)
Source Data and Record Linkage
(Section 3.5.3)
■ Study setting (i.e. hospital, ward) ■ Surgical/procedural system ■ Source records
■ Geographical catchment ■ Medical system ■ Source of clinical indication
■ Population denominator ■ Categories reported ■ Method of attribution of
■ Age restriction ■ Level of detail of categorisation transfusion event to clinical
■ Study period ■ Percentage of total units not category
■ Blood component type(s) categorised or reported • Timeframe of attribution
■ Total number of units reported ■ Units used by clinical category ■ Timeframe for clinical relevance
3.5.1. Study setting and population
The studies included in this review encompassed a broad range of hospital settings
including teaching, non-teaching, tertiary care, State/Federal, district/general and university
hospitals, and included between one and 300 hospitals per study. Blood use in teaching
hospitals was thought to be higher than in non-teaching hospitals because of the relatively
inefficient prescribing practices of inexperienced, trainee doctors; conversely however
teaching hospitals may in fact transfuse less blood because of the raised awareness of newly
trained doctors, educated in current guidelines and available alternatives and blood
conservation strategies. The geographical catchment areas of study settings were hospital,
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city, county/regional, country-wide and in some cases was not-stated. One study in a
paediatric hospital had a maximum inclusion age of 18 years (Zimmerman et al, 1998), one
study included adults over the age of 18 years only (Lim et al, 2004), and the other studies
reported no age criteria. The study period ranged from 14 days to six years with the most
commonly reported period being one year. Five studies reported red blood cell use alone
(Chiavetta et al, 1996; Mathoulin-Pelissier et al, 2000; Wells et al, 2002; Stanworth et al, 2002;
Wallis, Wells & Chapman, 2006), eight reported data for red blood cells, platelets and fresh
frozen plasma (Titlestad et al, 2001 & 2002; Vamvakas & Taswell, 1994; Syrjala et al, 2001;
Zimmerman et al, 1997 & 1998; Lim et al, 2004; Cook & Epps, 1991), and one reported on
whole blood and red blood cell units (Friedman, Burns & Schork, 1979). The number of red
blood cell units studied and reported as used ranged from 6,831 (Mathoulin-Pelissier et al,
2000) to 594,810 (Stanworth et al, 2002); 2,869 used red cell units were studied for the
paediatric population reported by Zimmerman et al (1998).
For all but three studies the study population comprised all patients transfused within the
specified study period and setting, be that at a hospital, regional, or national level; the
remaining three studies collected data from a sample of the study population's transfusion
records (Friedman, Burns & Schork, 1979; Mathoulin-Pelissier et al, 2000; Cook & Epps, 1991).
Across reports study populations were expressed in terms of patients (Titlestad et al, 2002;
Chiavetta et al, 1996; Mathoulin-Pelissier et al, 2000; Zimmerman et al, 1997 & 1998; Lim et al,
2004; Friedman, Burns & Schork, 1979), records (Syrjala et al, 2001; Titlestad et al, 2002, Cook
& Epps, 1991) or units (Titlestad et al, 2001; Wells et al, 2002; Stanworth et al, 2002; Wallis,
Wells & Chapman, 2006), although the definitions for transfused patients, transfusion events,
and records or episodes of clinical care varied between studies. In all reports there was a
lack of comprehensive description of the denominator population from which the study
population was obtained. The variations in study settings and composition of study
population contribute to the explanation for why there was variation between institutions in
the distribution of blood use to clinical case groups (Tables 3.4a-c). How far these studies are
representative of their wider populations and therefore appropriate for directing national
guidelines on blood resource planning should be questioned, in particular for the four
studies based in a single institution where potentially the reported blood use data is not
representative of all transfusion and clinical events for the population served by the blood
services in that area (Syrjala et al, 2001; Lim et al, 2004; Zimmerman et al, 1997 & 1998).
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3.5.2. Clinical data and classification systems
The previous section highlighted the importance of well-defined study populations and
denominator information for full and useful interpretation of blood use data. This section
focuses on aspects of the clinical data, namely the classification systems used to record it and
the clinical case groups for which blood use was reported. The findings reveal disparate
distributions of used blood component units between clinical case groups, variation which
may in part be a reflection of the differing methods employed.
The data recorded in clinical records represents a range of clinical classification systems for
coding medical conditions and surgical procedures. In summary the classification systems
used to record medical conditions were the International Classification of Disease (ICD)-9
and/or ICD-10 (individual codes and Broad-Diagnostic Categories (BDC)) (Zimmerman et al,
1997 & 1998; Lim et al, 2004; Chiavetta et al, 1996; Mathoulin-Pelissier et al, 2000; Titlestad et
al, 2002), and variations of Diagnosis-Related Groups (DRG) (Syrjala et al, 2001; Friedman,
Burns & Schork, 1979; Cook & Epps, 1991). One study described automatic classification by
a process called "NordDRG grouper" which uses DRG classifications that map diagnostic
data to ICD-10 and surgical data to the Finnish NCSP5 classification (Syrjala et al, 2001; CIHI,
2004). Only one other study reported the classification system used to define and report
surgical operations and procedures: the Canadian Classification of Diagnostic, Therapeutic
and Surgical Procedures (CCP) (Chiavetta et al, 1996). Four studies relate clinical case group
definitions to medical specialties specifically (Titlestad et al, 2001 & 2002; Wells et al, 2002;
Wallis, Wells & Chapman, 2006), and a further study classifies blood use by clinical
specialty/directorate (Stanworth et al, 2002). In some cases the process of classification to
categories is unclear, and in these instances it is assumed that the decision on how to classify
clinical information was determined by the researchers on an ad hoc basis.
Studies also vary in the level at which clinical codes or case groups were grouped and in the
types of categorisation reported and because of this the reported blood use data was difficult
to compare (Table 3.4a-c). Three studies reported a specific surgical or medical classification
of red blood cell use: transfusion events attributed to the surgical case group accounted for
41-51% of total red blood cell units used during the study period (Titlestad et al, 2002; Wells
5 NCSP: NOMESCO Classification of Surgical Procedures
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et al, 2002; Stanworth et al, 2002). However, in only one of these studies was 100% of used
red blood cell units classified (Titlestad, 2002) with unclassifiable or unreported data, or
units attributed to "other" categories equalling 8% and 14% for the other two studies. In two
reports transfusion events that were attributed to the medical case group accounted for a
higher percentage of total red blood cell units used during the study period than surgical
blood use did: 52% (Wells et al, 2002) and 53% (Titlestad et al, 2002) versus 36% (Stanworth et
al, 2002) (Table 3.4a). The higher percentage of medical blood use may be explained by
methodology that biases the classification of blood use towards the medical case group. In
the study by Wells et al (2002) all gastrointestinal conditions were categorised into the
medical case group whereas gastrointestinal conditions in other studies are included in both
the surgical and medical case groups. Titlestad et al (2001 & 2002) link blood use with
clinical data in the admissions episode subsequent to the admission during which the
transfusion took place and hence blood use at the time of a surgical procedure may be
misclassified as a subsequent medical indication. Some studies further described red blood
cell use by sub-classification of medical and surgical case groups but not all sub-
classifications were reported (2% to 74% of relevant blood use was omitted from medical
classifications (Titlestad et al, 2002; Wells et al, 2002; Vamvakas & Taswell, 1994; Chiavetta et
al, 1996; Lim et al, 2004; Zimmerman et al, 1997; Cook & Epps, 1991), and 36% to 62% from
surgical classifications (Titlestad et al, 2002; 6, Friedman, Burns & Schork, 1979; Cook & Epps,
1991). Incomplete reporting further impaired the ability to compare and contrast results
between studies.
Table 3.4a Percentage of total blood use reported as surgical/medical classification
_. . RBC units Surgical Medical Other
' transfused classification classification classificationt
Titlestad, 2002 59,235 47.0 53.0 0
Wells, 2002 9,774 40.7 51.6 7.7*
Stanworth, 2002 594,810 51.2 36.0 12.8"
Note: Study is referenced by first author and year of publication, t Other classification: units not
accounted for under major surgical/medical classifications. *6.3% of reported units transfused
for obstetric or gynaecological indications and no clinical data available for 1.4%. "12.8%
described as being transfused for "combined" directorates or specialities.
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3.5.3. Source data requirements and record linkage
The previous section describes aspects of the clinical data, the classification systems used to
record it and the clinical case groups for which blood use is reported, concluding that
apparent practice variation may be in part due to the variation in study methodology
employed. This section explores further the methods used to link transfusion events to
patients' clinical information and further, describes the challenges related to this particular
and crucial aspect of methodology.
In the studies identified here, the piece of clinical data that was inferred to be the underlying
reason for the transfusion event was either directly interpretable from the source records
(transfusion and clinical registers, or survey form) or had to be deduced by linking data
sources. In five studies the former was the case: the clinical case group to which blood use
was attributed could be directly ascertained from the single source record (Mathoulin-
Pelissier et al, 2000; Cook & Epps, 1991; Wells et al, 2002; Stanworth et al, 2002; Lim et al, 2004),
though in only one report did the methods explicitly state that the clinical case group or
particular reason was reported in the source record (Mathoulin-Pelissier et al, 2000). In nine
reports the process of data linkage and attribution of transfusion event to clinical case group
was carried out automatically by computerised procedures (Titlestad et al, 2001 & 2002;
Vamvakas & Taswell, 1994; Syrjala et al, 2001; Chiavetta et al, 1996; Zimmerman et al, 1997 &
1998; Lim et al, 2004; Friedman, Burns & Schork, 1979). For some of the studies that
employed computers the methods used to infer a relationship between a transfusion event
and clinical data were explained to some degree (Titlestad et al, 2002; Vamvakas & Taswell,
1994; Zimmerman et al, 1997 & 1998; Friedman, Burns & Schork, 1979); however, in the
remainder the method was unclear, was described in insufficient detail or was not disclosed,
and therefore reports did not convey accurately the decision making process (Titlestad et al,
2001 & 2002; Syrjala et al, 2001; Chiavetta et al, 1996; Lim et al, 2004).
As well as varying in study period, studies reviewed here vary in their approach to defining
the time frame of association of clinical data with transfusion events. One study collected
data for the initial 24 hours after the first record of transfusion (Mathoulin-Pelissier et al,
2000). Another linked transfusion events to the hospital admission episode subsequent to
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transfusion (though the method used if patients had only one admission was not specified)
on the presumption that the clinical reason for transfusion was related to the medical
circumstance necessitating readmission (Titlestad et al, 2002).
3.5.4. Overview of review of published literature for comprehensive, large-scale,
descriptive studies of blood use by clinical case group
In conclusion, studies of blood use by clinical reason typically vary in study size,
methodology, comparability and bias, but where available, large-scale studies with common
methodology and those that embrace collaborative and multi-centre approaches make a
most useful contribution to the evidence base.
Studies that report blood use data for specific patient groups or settings are restricted in
their ability to inform the transfusion needs of the wider, general population case mix.,
whereas large-scale or population based studies have the potential to provide
comprehensive and representative data for a broad case mix of patients. The latter provide a
national picture of supply and demand, reveal areas of practice variation, allow for analyses
of trends in population demographics and clinical and transfusion practice), and provide
data about the transfusion needs of a whole population. Consequently the data can be used
to inform future resource planning by blood services. Even considering variations in
methodology the review of studies described here demonstrates apparent variation in
transfusion practice, echoing findings reported by other descriptive studies of blood use
(section 3.4) and by routine, national data that demonstrates that large variations in use exist
not just between countries of differing socioeconomic development status but also between
and within comparable populations (WHO, 2004). In order to optimise appropriate blood
use, improvements to prescribing behaviour, policy and audit, and ultimately, in study
design and interpretation of blood use data are required.
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3.6. Reflections onmethodology of comprehensive descriptive studies relating
blood USE to clinical information
The reports of red blood cell use by clinical case group that are described in section 3.5
suggest variations in blood use by setting for a range of clinical indications. Some of the
studies described here were considered in the first world-wide, comparative view of studies
reporting clinical use of blood (Cobain, 2007). That review examined the demographics of
transfused populations and the clinical indications for which patients were transfused,
concluding that there were notable similarities between countries for transfusion by age and
gender; differences in the types of blood components available, prevalence of disease and
treatment protocols meant that the clinical indications for which patients were transfused
varied (Cobain, 2007). The methodology of individual studies was also cited as a
contributory factor to the differences identified.
Together, the studies discussed previously illustrate particular methodological issues that
are central to appropriate analysis of blood use by clinical case group. These are: definition
of study population, coding of clinical data and classification of clinical case groups, and the
methods used to link blood use to clinical case groups. Variability in the methods of these
studies prevents useful aggregation, comparison or interpretation of results. The challenges
of denominator and study populations, the variations in diagnostic and surgical
classification systems and clinical categories reported, the problems regarding linkage of
transfusion events to clinical data, as well as, crucially, the variation in terminology and
definitions, suggest important areas for development of improved epidemiological methods
for blood use research. This section highlights the developments needed in research
methods to ensure studies are conducted appropriately and effectively in the future.
Accurate and meaningful reporting of clinical data in patient records is essential as it affects
the identification and extraction of relevant clinical data to which blood use can be attributed.
The type of clinical data available may also affect the researchers' decision regarding how to
classify it into clinical case groups, and subsequently which clinical case groups to report.
There are numerous coding conventions and classification systems available, many of which
are illustrated by the range of studies described in section 3.5. For example, the International
Classification of Disease (ICD) system is a recognised, standardised tool that enables
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meaningful, comparative analysis of diagnostic information across time and setting. Some
studies reviewed here used a variation of the ICD system called Diagnostic-Related Groups,
originally an American adaptation now used by other countries that clusters ICD codes
(along with patient age, sex and discharge data) into patient categories that are similar
clinically as well as in terms of resource use (ISD, online; CIHI, 2004). This type of
classification system was originally developed for, and used widely to determine the cost of
a patient's care for medical billing, but its usefulness has been extended to encompass the
classification and reporting of clinical data in other contexts. The results of studies that use
ICD codes or DRG classifications are considered to be comparable because of the similarity
in structure between the two classification systems (CIHI, 2004). Classification systems that
are economic coding systems currently used by insurance companies and in the assessment
of medical benefits (rather than having been developed further such as ICD or DRG have
been) may provide readily available and accessible clinical data but could be a poor proxy
for clinical classification when used in the context of measurements of clinical practice.
Universal and clinically sound coding systems that enable comparability of coded data are
the ideal and future studies should strive to achieve this wherever possible.
The source of data is a particular issue because it affects the method used to attribute blood
use to the appropriate clinical indication that explains transfusion. There is marked
variability in data sources utilised by the studies reviewed here in that data was sourced
from one or a combination of the following: blood bank records, hospital transfusion records,
clinical registers, patient case notes, and specific survey forms. In general, existing, routinely
collected health services registers provide large amounts of structured, comparable data for
analysis and, where effectively governed by quality management, are likely to do so
accurately. These are a useful source of data for healthcare research which more studies
might consider for future analysis. The role of electronic data registers and use of computer
methods for data extraction, linkage and analysis is emerging as a major requirement for
progress in timely and reliable research of clinical blood use (Palo et al, 2006b; Grey et al,
2006).
Routine data on the clinical condition that necessitates the use of blood is rarely recorded
adequately, if indeed at all, in blood bank records or patient case notes. Consequently,
attempts must be made to infer this information from data recorded in clinical registers, or
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be prospectively collected by survey specifically developed for the study. In the former case
each transfusion event must be linked to the relevant piece of information in the clinical
register representative of the correct period of clinical care during which the patient was
transfused. This process however is particularly difficult, complicated by the large amount
of data contained in multiple, potentially relevant transfusion and clinical records, and
because of the complexities of interaction between surgical and diagnostic data contained in
clinical records.
The method used to link a transfusion event to a clinical case group should ideally reflect 1)
the nature of the surgical and diagnostic data in recipients' clinical records, 2) the potential
for the transfusion event to be linked to multiple records of clinical data, and 3) the time
frame that links the transfusion event with clinical data pertaining to a relevant period of
clinical care.
In the literature reviewed, little reference was made to the time frame used to link a
transfusion event with the relevant period of clinical care thereby making it difficult to
understand the period of study observation relative to patients' clinical history. Within the
study period of most studies identified here, recipients of all ages, stages of disease, and
complexity of surgical intervention were observed. Most studies examined blood use for a
fixed window of time on a record by record basis rather than on a multiple record basis or at
the patient level, and there was never reference to whether historical clinical data was
considered as a requirement or was even available. In future, studies might consider
studying blood use for a single episode of care (for example appropriate for elective surgical
intervention) or for a significant fixed time period such as one year, but which incorporates
as much data as possible that is relevant to each patient. For patients with chronic or
recurring conditions it may be more appropriate to study blood use for the patients' lifetime
or for the period from first inpatient admission to time of death, implicating survival and
quality of life analyses.
The variations in methods described here and in section 3.5 reflect the complex nature of
research in this area of transfusion practice. Careful consideration and clear definitions are
needed as to what constitutes a transfusion event or record of clinical care and what the
appropriate clinical categories are. Also, the time frame used in the study to link transfusion
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events with clinical data, the relevant period of clinical care, and their effect on data
interpretation, should be defined and reported. Taken together, the challenges of variation
in classification and reporting of clinical case groups, the relevance of study population and
study period, and the issues related to linking transfusion events to clinical data suggest






The study utilises data collected for the Scottish Transfusion Epidemiology Project feasibility
study. The data comprises routinely collected blood bank transfusion records and clinical
data for patients treated during the year 2000 in all Scottish hospitals that were served by a
blood bank operated by the Scottish National Blood Transfusion Service (SNBTS) which
utilises the Progesa blood bank computer system (Progesa, MAK-Systems, Paris) (Figure 4.1).
The denominator population for clinical data was all SMR01-CD records in the year 2000 for
hospitals in the study population.
Figure 4.1 Hospitals that have Progesa blood bank transfusion day records (SNBTS)
and are included in the study dataset




4.2.1. Transfusion record data
Blood banks store records of information about tests performed on patients' blood samples
as well as records of the assignment of blood component units created when blood
component units are allocated to a patient. Table 4.1 describes the actions performed by
blood banks and the related data that is available, and indicates which data is included in
the records extracted for STEP and subsequently used in this PhD study. Patient specific
blood bank transfusion records for the year 2000, from 1st January 2000 to 31st December 2000,
inclusive, were extracted from the Scottish National Blood Transfusion Service blood banks
that use the Progesa blood bank computer system (SNBTS/Progesa blood bank).
Table 4.1 Hospital blood bank actions: pre-transfusion testing and blood
component assignments
Blood bank actions Patient group Status in study
Group and screen
■ Patients' red cell types (Rh and ABO) determined
■ Patients' plasma tested for clinically significant
antibodies to red cell antigens
Transfusion request
submitted in advance of
planned surgery
Not selected for inclusion
in initial data extraction
Crossmatch - As above plus:
■ Patients' sample tested for compatibility with one
or more red cell units
■ One or more red cell units assigned to patient
Transfusion request
submitted when need for
blood is anticipated
Selected in initial data
extraction
Assignment - As above plus:
■ One or more of the assigned red cell units is not
deassigned and is therefore assumed to be "used"
Transfusion request Selected from extracted
fulfilled when blood needed data for inclusion in study
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For the study, records of assigned units were extracted along with relevant patient details
from the blood bank computer system. These records were compacted by 24-hour period,
using patient identifier number and transfusion event date to facilitate record linkage by
date variables at a later stage of dataset development. Compacted transfusion records are
referred to as transfusion day records (TDR). Thus the transfusion data available for the
study included all transfusion day records that contain units of any blood component (red
blood cells, platelets, fresh frozen plasma, and cryoprecipitate) assigned to a patient during
the study period.
Transfusion day records contain data for the number of units of blood component that are
assigned to individual patients and the number of units that were subsequently deassigned
(and so known not to have been transfused). Transfusion day records do not contain a
reliable record of the actual infusion of each unit of blood. This has two important
consequences for the study. Firstly, an estimate of the actual number of units assumed to be
transfused into a patient, referred to as "units used", had to be calculated, and equals the
number of units assigned minus the number of units deassigned. A previous validation of
this assumption has been carried out by SNBTS by comparing blood bank transfusion
records with specific audit data (Palmer, personal communication). Secondly, the date of
blood component assignment must be used as a proxy for the date of use of blood units.
Transfusion day records that contained data for one or more blood component units used
were selected for inclusion in the final study dataset.
Some transfusion day records lacked complete patient identifying information. This can
occur when the allocation of patient details is urgent or when full names are for any reason
unavailable at the time of blood component issue. In these cases standard operating
procedures permit the use of proxy forename and/or surname data in the blood bank
transfusion record, for example "unknown/male", "flying/squad", "accident/emergency",
"baby/X", together with an emergency blood order number that is allocated by the admitting
hospital department. For medical legal reasons the SNBTS policy has been to preserve the
identifying data submitted to the blood bank with each transfusion request without
subsequent alteration. Therefore, so called "emergency" identifiers are retained in the blood
bank computer system with the potential to appear in the transfusion records extracted for
the study. Only where appropriate identifying information was available could a unique
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patient number be generated by which all records would be identified as belonging to an
individual patient: this is termed the patient identifier (PID) (the process is described more
fully in section 4.3).
Transfusion day records contain the age and sex of the recipient, the date and hospital of
transfusion, and the number of units of each component assigned and deassigned, and are
listed in order of unique patient identifier (Table 4.2).




















Number of red cell units issued per transfusion record
Number of red cell units returned per transfusion record
Number of adult dose equivalent units of platelets issued per transfusion record
Number of adult dose equivalent units of platelets returned per transfusion record
Number of fresh frozen plasma units issued per transfusion record
Number of fresh frozen plasma units returned per transfusion record
Number of cryoprecipitate units issued per transfusion record
Number of cryoprecipitate units returned per transfusion record
Age in years at first appearance in study SMR data
Age in months at first appearance in study SMR data
4.2.2. SNBTS delivery data
Data was available for the year 2000 for the total number of units of each blood component
supplied by SNBTS to blood banks relevant to the study. A total red blood cell supply figure
for all Scotland was also available (Stack, personal communication). This information was
used to calculate the proportion of blood component units supplied across all of Scotland
that was supplied to hospitals included in the study. Further, the red blood cell supply data
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was used in calculations to estimate the standardised age and sex specific rates of blood
component use for the study data (Chapter 7).
In order that the study population can be understood in the proper context the SNBTS blood
distribution model is outlined here (Figure 4.2). Blood components are delivered by the
SNBTS East Manufacturing (EMAN) unit in Edinburgh to hospital blood banks in the east of
Scotland: namely Edinburgh, Dundee and Aberdeen. The SNBTS West Manufacturing
(WMAN) unit in Glasgow delivers blood components to hospitals in the west of Scotland
and also to the Inverness blood bank. The main hospitals served by Edinburgh, Dundee,
Aberdeen and Inverness blood banks, and for which data was available for the study, are
listed in Figure 4.2 (full details of all hospitals in study are reported in Appendix A.l). The
other hospitals in Scotland receive their supply of blood directly from SNTBS, and not via a
regional blood bank.
Figure 4.2 SNBTS blood component distribution model for Scotland
* Hospitals in bold are the main hospitals represented by study data (Full explanation for all hospitals: Appendix A.1)
66
4. Materials
Within the hospital setting blood component units are assigned to an individual patient:
blood may subsequently be used by the patient or returned to the blood bank and
deassigned. Blood which is not used may be discarded to waste or quality assurance, or
distributed to another hospital site. Returned blood may be assigned to a second individual.
The transfer of blood components between hospitals may occur when a patient is transferred,
along with blood components already assigned to them, to another site or when a special
request is made by one site for blood components of a particular or rare type that are held
elsewhere. However, SNBTS advice is that the occurrence of transferred units is minimal
and does not affect the interpretation of results of blood component use where transfusions
can still be linked to the relevant patient's clinical data.
4.2.3. Scottish Morbidity Records
The source of clinical data used in the study was the Information and Statistics Division (ISD)
data scheme of Scottish Morbidity Records (SMR), specifically SMR01 records. SMR01
comprises general inpatient and day case data for all acute specialties excluding obstetrics,
psychiatry and geriatrics. The data recorded in SMR01 records includes variables for patient
characteristics, clinical data and episode management which can be used to build a picture
of the patient journey through hospital care (Table 4.3) (described further in SMR coding
conventions, below).
Guidelines require the data to be submitted by hospitals to ISD within six weeks of date of
discharge (to be reduced to four weeks by the end of 2007). These time frames are not
generally met by hospitals but by the time the data was extracted for the study (in 2004) all
SMR01 records for the year 2000 had been submitted. SMR01 records have been collected
nationally since the 1960s and have been routinely linked using probability matching of
patient details by ISD to the Cancer Register (SMR06) and General Register Office for
Scotland (GRO) death records since 1981. Linked SMROl/cancer/death (SMR01-CD) records
were used in this study. Maternity (SMR02) and neonatal (SMR11) datasets exist in the SMR
data scheme but for technical reasons could not be linked to SMR01 at the time the data was
extracted for this study.
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An SMR01 record is generated when a patient is discharged upon the completion of an
episode of inpatient or day case care spent under the charge of a consultant within a specific
facility and specialty in a hospital setting (a consultant episode). Upon discharge patients
may return home (Figure 4.3a) or be transferred to another ward or hospital (Figure 4.3b).
Discharge may also follow as a result of the death of the patient (Figure 4.3b). Continuous
inpatient stays (CIPS) are specific inpatient admission patterns comprised of more than one
contiguous episode during which the patient may be moved between clinicians, wards and
specialties, and where a new SMR01 record is generated for each (Figure 4.3c).
Table 4.3 Data variables in linked SMROl/cancer/death records
Variable Description
ISD number ISD unique patient identifying number
Sex Sex of patient
Age 2 (years) Age in years at time of SMR record
Age 2 (months) Age in months at time of SMR record
Hospital Hospital of inpatient admission
Date of admission Date of admission
Date of discharge Date of discharge
Specialty Clinician specialty
GMC main Clinician identification number
Date of operation 1, 2 ...4 Date of operation coded in Op1a, 2a ... 4a
GMC operation 1,2 ...4 ID number of clinician in charge of operation coded in Op1a, 2a ... 4a
Operation 1a, 2a ...4a Operation (OPCS-4) coded in Op1a, 2a ... 4a
Operation 1b, 2b . . .4b Operation (OPCS-4) coded in Op1b, 2b ... 4b
Diagnosis Main diagnosis (ICD-10)
Diagnosis 1, 2 ... 6 Diagnosis (ICD-10) coded in Diagl, 2 ... 6
Discharge type Type of discharge
Discharge to Location to which patient is discharged
Date of death Date of death (General Records Office death record)
Cause Cause of death (General Records Office death record)
Cancer Flag of record in cancer register (SMR06)
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Figure 4.3 Representation of examples of different inpatient stay patterns as
determined from data recorded in Scottish Morbidity Records
a. Single episodic admission: one SMR01 episode containing an operation
Episode 1




b. Multiple episodic admissions: multiple SMR01 episodes interspersed throughout study period with
periods of no inpatient hospital interaction, followed by death
Episode 1 Episode 2
o A
Admission Discharge Admission Discharge Death
c. Continuous inpatient stay: multiple, contiguous SMR01 episodes of movement between wards
before discharge
Episode 1 Episode 2 Episode 3 Episode 4
a o-
Admission Move ward Move ward Move ward Discharge
SMR coding conventions
Following a patient's discharge the clinician responsible for the episode of care writes up a
discharge letter. The information in the discharge letter (and sometimes information in the
original patient notes) is coded by hospital-based encoders to form a standard information
set that is sent to ISD and used to generate SMR records. Guidelines and training manuals
for clinical coding are published by the Scottish Clinical Coding Centre (SCCC): these are
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based on guidelines from the World Health Organisation but reflect Scottish specific rules
which must always be used when coding clinical data in the Scottish context (ISD, online).
Surgical operations and procedures are coded using the Office of Population Censuses and
Surveys' Classification of Surgical Operations 4th revision (OPCS-4). There are four variables
available (Opla-4a) in each SMR01 for the coding of OPCS-4 data: a primary procedure
variable (Opla) and three others. In addition, there are a further four fields (Oplb-4b) for
supplementary OPCS-4 codes that add details such as left or right side of body. The primary
procedure and the order in which the other procedures are to be coded should be specified
in the discharge letter by the clinician responsible for the episode of care. The clinician
should be consulted personally if more than four procedures were carried out during the
single episode or where queries regarding the information in the discharge letter arise. In all
instances the guidelines require that for OPCS-4 codes the recording of therapeutic
procedures takes priority over diagnostic procedures (ISD, online).
Table 4.4 Example of hierarchical coding structure for OPCS-4 codes
Level Code Description
Chapter W Other bones and joints
Sub-chapter W37-W92 Joints
Section W37-W39 Total hip replacement
Sub-section W37 Primary hip replacement
Specific procedure W370 Conversion from previous cemented total prosthetic replacement of hip joint
W371 Primary total prosthetic replacement of hip joint using cement
W372 Conversion to total prosthetic replacement of hip joint using cement
W373 Revision of total prosthetic replacement of hip joint using cement
W378 Other specified total prosthetic replacement of hip joint using cement
W379 Unspecified total prosthetic replacement of hip joint using cement
Diagnostic data is coded using the International Classification of Diseases and Related
Health Problems 10th revision (ICD-10). The International Classification of Diseases is
published by the World Health Organization and uses terminology that is internationally
accepted. This facilitates comparability in the classification and interpretation of clinical
data (WHO, online). SMR01 records contain six variables (Diagl-6) in which ICD-10 codes
can be recorded. The first diagnostic variables (Diagl) should contain the ICD-10 code for
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the main medical condition that was investigated during the patient's episode of care. If
more than one condition is reported in the discharge letter, that which required the most
clinical resource input should be recorded; if no specific condition is reported by the
clinician then the main symptom or abnormality should be recorded. The remaining
diagnostic variables are used to record other existing or developing comorbidities but
should not be used to record conditions related to previous episodes of care unless their
presence is persistent at the current time (ISD, online).
Table 4.5 Example of hierarchical coding structure for ICD-10 codes
Level Code Description
Chapter ll(C00-D48) Neoplasms
Sub-chapter C81-C96 Malignant neoplasms, stated or presumed to be primary, of lymphoid,
haematopoietic and related tissue
Section C81 Hodgkin's Disease




OPCS-4 and ICD-10 classification systems are organised according to internationally
recognised, logical and anatomical hierarchies. The standard format for OPCS-4 and ICD-10
is four character (4-digit) alphanumeric codes: these are hierarchical from left to right, where
the first character (letter) defines the broad chapter; the second character (numeral) defines
the sub-chapter and so on, with each subsequent character providing more specific and
detailed information about the surgical procedure or clinical diagnosis. Examples of the
hierarchical coding structures illustrate the large amount of clinical data and the complexity
involved in coding (Table 4.4 and 4.5). The specificity and detail of the clinical coding
systems employed enable a wide variety of operations and procedures (OPCS-4), and




The completeness of data collection, coding and timeliness of submission to the SMR data
scheme is the responsibility of the hospital that is providing the data. The process is
overseen by ISD which undertakes rigorous and frequent validation at each stage of data
cleaning, storage and publication. When SMR01 records (and other SMR data schemes) are
created from submitted information, automatic checks are made by ISD to ensure that
recorded procedure and diagnostic codes are valid relative to the respective classification
system, record type, date and patient variables, and other codes recorded during the same
episode of care (ISD, online; Harley & Jones, 1996).
A report by the Data Quality Assurance team on the quality of SMR01 data is outlined here
as evidence of the quality assurance process (ISD, 2004). An assessment of the quality of
SMR01 data items recorded by hospitals that represent 95.8% of Scottish NHS acute
discharges was begun in the year 2000 and completed in 2002. A 4% sample of three
months' data was extracted, of which half just was assessed (5,724 SMR01 records). Data in
these records was compared to information recorded in patient case notes and all observed
differences were documented. The target at this time was an accuracy of coding of 90% at
the 3-digit level: the overall rates of accuracy identified by this audit were 88% for main
diagnosis and 91% for main procedure. At the 4-digit level clinical data items were recorded
with overall rates of accuracy 81% for main diagnosis and 86% for main procedure. The
accuracy rate for coding procedures was affected by the recording of non-operative
procedures such as scans, transfusions and injections: excluding these reveals higher
accuracy rates of 95% (3-digit) and 89% (4-digit). These rates represent an overall drop in
accuracy since the previous audit in 1996/1997, though rates for individual hospitals varied.
The report also identified that comorbidity conditions other than the main condition were
both misreported and underreported in SMR01 records, and thus the complexity of the
patient case mix was portrayed inaccurately. Importantly, the quality assessment included
analysis to identify areas where coder accuracy was affected by limited quality of source
information versus a lack of access to full medical case notes. The report concludes that
routine quality assurance assessments of SMR01 coding accuracy are desirable: routine
assessments subsequently began in 2004 (ISD, 2004).
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4.3. Information and Statistics Division preparatory work on source data:
Probabilitymatching & Internal record linkage
Probability matching is a statistical method developed to address the fact that there may be
multiple records for each individual with minor differences in identifiers such as spelling
errors, spelling variations or missing data points. The process allocates a unique patient
identifier number to all records belonging to an individual patient based on forename,
surname and date of birth by considering the available data and accounting for variant or
incomplete patient details. ISD employ an algorithm that has been developed so as to
perform this function with 98% accuracy (Kendrick & Clarke, 1993; Kendrick, 1997).
Transfusion day records with emergency identifiers (described for transfusion records in
section 4.2.1) were removed prior to undergoing probability matching by ISD as it would not
be possible to identify other records with which these could be appropriately linked and
they could not be matched further to SMR01-CD records.
A second record linkage process required for this study was internal record linkage to match
patients with transfusion day records with patients with SMR01 records that appear in the
Scottish Morbidity Record (SMR) data scheme in the year 2000 in order to select the relevant
clinical data for the study population. Some transfusion day records were rejected by ISD at
this stage of record linkage because they failed to be linked with a patient identity in the
SMR01 data scheme (Figure 4.4).
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4.4. Transfer of datasets
The source data comprising transfusion day records and SMR01-CD records were provided
by ISD as separate SPSS data files with all specific patient identifying information removed
and unique patient identifiers attached to all records. Figure 4.4 summarises the steps
involved in the data extraction, manipulation, and linkage processes to this point.
Figure 4.4 Record linkages of source data prior to study




5.1. Initial investigation of source data
The initial investigations carried out on the source data of transfusion day records and
linked SMROl/cancer/death records were to examine the data for errors and coding issues
and to gain insight into the content and nature of the available data.
The number of blood component units used per patient, and by hospital, for all transfusion
day records was checked for erroneous values by eyeballing the available figures. The data
was also checked against Scottish National Blood Transfusion Service supply data to make
sure that no hospital had a greater number of units used than were originally supplied. The
transfusion day records and SMR01-CD records source data were both checked for entry
errors in age variables such as minus signs, large values) and the sex variable was checked at
the patient level to identify patients with both male and female entries (due, for example, to
entry error or sexual reorientation). Descriptive statistics were performed in SPSS (Version
13.0-15.0) to describe the source data.
Transfusion day records were examined at the individual record and the patient level to
check data for errors, and to provide summary measures of transfusion such as the number
of transfusion records per patient and blood component units assigned, deassigned and used
per patient or record, which enabled small or high users of blood to be identified. For
patients with multiple transfusion day records the temporal relationship between
transfusion events was explored. SMR01-CD records were also examined at an individual
record and patient level to gain an understanding of the relationships among procedure
codes in variables Opl-4, among diagnostic codes in variables Diagl-6, and between
procedures and diagnostic codes (SMR01 coding conventions, section 4.2.2). Coding
practices were investigated by examining frequencies of codes recorded in the primary
procedures variable Opl in comparison with all instances coded in variables Opl-4 and
similarly for primary diagnoses versus all instances coded in variables Diagl-6.
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Relationships between dates of admission, operation and discharge for SMR01 records were
also explored and analyses of patient profiles, and in particular of continuous inpatient stay
profiles, were attempted. By examining SMR01 records and transfusion day records
separately initially and then in relation to each other, a standard approach to describing the
patient journey during inpatient hospital care was developed (described further in section
5.2). Understanding gained from the data about patients' clinical and transfusion histories
subsequently informed the methods that were employed to relate SMR01-CD records to
transfusion day records in order to attribute a clinical reason to transfusion events.
The variables that were in the source transfusion day records and SMR01-CD records have
been described in sections 4.2. During the process of initial, exploratory investigations of the
data, additional variables were created for both transfusion day records and SMR01-CD
records (Table 5.1 and 5.2). Specifically, additional variables were computed for SMR01-CD
records to make it easier to understand, manipulate, summarise and report the data given
the large amount of clinical information available. The variables relate in the main to the
data coded by OPCS-4 codes in operations and procedures variables Opla-Op4a, and by
ICD-10 codes in diagnostic variables Diagl-Diag6 and were the first step in defining red cell
using procedures and diagnoses for later stages of the study. Individual OPCS-4 and ICD-10
codes, as well as small clusters of these codes, were used to define the initial red cell using
procedures and diagnoses considered for this study (section 5.4). These codes became the
basis of the clinical case groups to which blood use was attributed in subsequent analyses
(Chapters 6-9).
Table 5.1 Additional data variables generated for Transfusion Day Records
Variable Description Computation
Red used Number of red blood cell units used RBC assigned minus RBC deassigned
Platelets used Number of adult dose equivalent
platelet units used
PLT assigned minus PLT deassigned
FFP used Number of plasma units used FFP assigned minus FFP deassigned
Cryoprecipitate used Number of cryoprecipitate units used CRY assigned minus CRY deassigned
Total units Number of all units used Total assigned minus total deassigned
Hospital Health Board Hospital Health Board code First character of hospital code
Age group Age group at time of record creation Age variable grouped by decade
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Table 5.2 Additional data variables generated for SMR01-CD records
Variable Description
Procedure chapter 1 (1 digit) * 1 digit OPCS-4 chapter code for procedure coded in Op1a [A]
Procedure 1, 2, 3, 4 (2 digit) * 2 digit OPCS-4 code of procedure coded in Op1a - 4a [An]
Procedure 1, 2, 3, 4 (3 digit) * 3 digit OPCS-4 code of procedure coded in Op1a - 4a [Ann]
Diagnosis 1,2,3, 4, 5, 6 (3 digit) * 3 digit ICD-10 code of diagnosis coded in Diagl - 6 [Ann]
Blood procedure 1, 2, 3, 4 Procedure in Op1a - 4a if red cell using procedure [Ann]
Main blood procedure First red cell using procedure in SMR01 record [Ann]
Blood diagnosis 1,2,3, 4, 5, 6 Diagnosis in Diagl - 6 if red cell using diagnosis [Ann]
Main blood diagnosis First red cell using diagnosis in SMR01 record [Ann]
Supplementary 1, 2, 3, 4 Supplementary procedure in Op1a - 4a [Ann]
* OPCS-4 procedure and ICD-10 diagnosis codes are 4 digit alphanumeric codes with hierarchical
structure. Shortening from the end of the code to 1, 2 or 3 digits reduces the detail of the condition but
retains the hierarchical grouping (See materials section). [An]: denotes the alphanumeric code format




Following from initial investigations of the source data a model was devised to illustrate the
relationship between patients' transfusion and clinical data (Figure 5.1). The example
illustrated here shows a patient who has two transfusion day records during the year 2000
that can be linked via a patient identifier to five SMR01-CD records comprising multiple
episodic admissions and a continuous inpatient stay (CIPS): the CIPS profile is comprised of
SMR01 episodes 3, 4 and 5, where the patient enters hospital on the date of admission of
episode 3 and leaves on the date of discharge of episode 5. The specific example illustrates a
patient transfused with a total of six red blood cell units in the year and who is diagnosed
with malignant neoplasm of the kidney, undergoes a kidney transplant and who is
subsequently diagnosed with leukaemia.












Transfusion Day Record SMR01-CD record
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The model illustrates the potential for patients to have multiple transfusion day records and
multiple clinical records thereby instantly generating complexity with regards to the number
of potential relationships between records. Viewing the data in this way facilitated
understanding of the available data and so the impact of multiple records was identified
early in the creation of the study dataset as a large factor in the methodological approaches
employed in the study. To fully define all possible relationships between transfusion and
clinical each transfusion day record had to be linked with every SMR01-CD records on a
patient by patient basis in order that the relevance of the relationships could be assessed.
The SPSS restructure function enables a set of records to be restructured so that all records
belonging to a patient can be aggregated into a single, complex record. Patient records in
this form can subsequently be linked to other datasets via a common variable, in this case
the patient identifier number. The decision making process as to which dataset (transfusion
or clinical) to restructure involved a series of test examples. By restructuring transfusion day
records and linking with original source SMR01-CD records the numbers of blood
component units were duplicated: if left unresolved this duplication of data would have
posed an inherent complication in all future analyses. Further, because the study aimed to
quantify the reasons for blood use, and thereby account for all transfusion day records, it
was logical for the transfusion day records to be the key record set to which additional
information was linked. Therefore, the restructuring of SMR01-CD records and subsequent
merging with relevant transfusion day records was favoured.
Thus, SMR01-CD records were aggregated by patient number and restructured so that all
records for each individual patient were combined into a single, complex record that
represents the patient's available SMR01-CD information for the year 2000 (Figures 5.2a&b).
The unique patient identifier was used to link corresponding SMR01-CD records to
transfusion day records for each transfusion recipient. SMR01-CD records could not be
linked to a transfusion day record of blood component units used if the patient had no such
transfusion day record or if ISD had been unable to assign a patient number to the patient's
transfusion day record(s). The majority of SMR01-CD records that could not be linked to a
transfusion day record of units used represent the hospital activity of inpatients who were
not transfused but who had units assigned and who therefore may be considered to have
been at risk of transfusion due to some aspect of the nature of their hospital admission.
Unlinked SMR01-CD records were kept separately in case required for future analysis.
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Where a patient had more than one transfusion day record the restructured SMR01-CD
record was duplicated against each transfusion day record (Figure 5.2c). The resultant file of
transfusion day records (units used only) linked to the relevant, available clinical history for
the year 2000, that is, the restructured SMR01-CD records, provided a dataset that could be
used to consider all potential relationships between blood use and clinical data. Additional
variables were computed so that the relationships could be explored further (Table 5.3).
Figure 5.2 Processes to restructure SMR01-CD records and to merge with transfusion
day records to form the study dataset.
a. Representation of original file formats for source data records: example for two patients






A SMR episode 1
A SMR episode 2
B SMR episode 1
b. Restructure SMR01-CD records (transfusion day records not shown)
Patient SMR01 -CD record SMR01-CD record
A SMR episode 1 SMR episode 2
B SMR episode 1
c. Merge restructured SMR01-CD records with transfusion day records
Patient Transfusion Day Record SMR01-CD record SMR01-CD record
A Transfusion 1 SMR episode 1 SMR episode 2
A Transfusion 2 SMR episode 1 SMR episode 2
B Transfusion 1 SMR episode 1
B Transfusion 2 SMR episode 1
B Transfusion 3 SMR episode 1
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Table 5.3 Computed data variables for linked study dataset
Variable Description
Date linked Date link between SMR01-CD record and transfusion day record
Number of SMR01-CD records date-linked with transfusion day record
Code of red cell using procedure in SMR01-CD record linked to units used
Total date linked
Red cell using procedure
Total red cell using procedures Number of red cell using procedures related to use of red blood cell units
Red blood cells used (procedure) Number of red blood cell units attributed to a red cell using procedure
The transfusion day records of units used linked to the restructured SMR01-CD records are
herein referred to as the study dataset. The analyses used to describe the source transfusion
day records and SMR01-CD records, the linked study dataset, the populations of transfused
and non-transfused patients, and subsequent analysis of blood use by clinical case group
were carried out using the statistical package SPSS. Thus the next stage was to define the
methods with which to attribute clinical case groups to transfusion events. The clinical case
groups defined for use in this study and the full methods of attribution are described in the
following section (section 5.3).
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5.3. Attributing a transfusion event to a clinical case group
This section describes the definition and validation of methods to determine the relationship
between data in transfusion day records and data in SMR01-CD records. The aim was to
identify all appropriate pieces of clinical data that could be used to infer the reason for
transfusion.
The study dataset represents a population of patients that are diverse in terms of the surgical
interventions and medical conditions recorded in their clinical records. Using the
knowledge gained from approaches adopted by previous studies in combination with
essential clinical input specific to this study, separate methods for analysing different patient
groups were employed in this study. Therefore a range of clinical case groups considered
likely to represent particular populations of transfusion recipients were defined. These
formed two main categories: a surgical perspective of procedural events (section 5.3.1) and a
diagnostic perspective of chronic pre-malignant and malignant haematological conditions
(section 5.3.2).
The rules used to attribute blood use to clinical case group were defined using clinical
rationale that addressed the timing of the relationship and identified appropriate clinical
information. It is acknowledged that in attributing blood use to case groups by the rules
described here, an inference is made about the actual reason for transfusion.
5.3.1. Rule for attributing blood use to surgical procedure case groups
The first case group addressed in the study defined a population of patients who were
admitted to hospital for the principal reason of undergoing a major surgical intervention, be
that an operation or related procedure for which red blood cell units might be transfused. A




Time of blood assignment
The first part of the surgical blood attribution rule defined the temporal relationship
between transfusion day records of red blood cell use and SMR01-CD records. Because
transfusion day records do not specify the date upon which blood components were used
the date of blood component assignment was used as the proxy for date of use. The likely
period in which blood assignments would be made in the event of blood being required for
surgery was defined as the period from seven days prior to admission to the date of the
procedure, thereby including pre-admission blood assignments. This timeframe was
subsequently extended to the period from seven days prior to admission to the date of
discharge to include pre-admission blood assignments and blood assignments that may be
made during the post-operative period. Figure 5.3 illustrates the temporal relationship
between the date of blood assignment and admission, operation and discharge dates.
To reiterate, the transfusion day record and SMR01-CD record were related to one another if
the date of blood component assignment fell between seven days prior to admission date
and the date of discharge.












Red blood cell units are attributed to a red cell using procedure if the date of blood
use falls within 7 days prior to admission and date of discharge
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Defining the case group by identifying the appropriate red cell using procedure
The second part of the rule addressed the identification of a clinical case group to which the
transfusion event could be attributed. Blood use was attributed to the relevant procedural
information coded in the OPCS-4 variables of SMR01-CD records that had been identified as
satisfying the temporal part of the surgical blood attribution rule. Here the term
"procedures" refers to both surgical operations and surgical procedures coded using OPCS-4;
"red cell using procedures" herein refers to the specific surgical case groups defined for this
study that were expected to be important users of blood (Table 5.4).
Table 5.4 Surgical procedures and OPCS-4 codes defined as red cell using
procedures
Red cell using procedure OPCS-4 code(s)
Operations on tissue of brain A01 -A10
Operations on thyroid or parathyroid glands B08-B16
Open placement of prosthesis in trachea E41
Excision of lung E54
Open extirpation of lesion of lung E55
Other operations on lung E59
Open operations on oesophagus G01-G13
Excision of colon H04-H11
Excision of rectum H33
Transplantation of liver J01
Partial excision of liver J02
Transplantation of heart K01-K02
Operations on valves of heart and adjacent structures K25-K38
Open bypass graft operations (minus revisions & revisions) K40-K46
Emergency replacement or bypass of aneurysmal segment of aorta L18, L20
Other operations on aorta L16, L19, L21-25
Reconstruction of renal artery L41-L43
Transplantation of kidney M01
Open operations on prostate M61-M64
Hysterectomy Q07-Q08
Open reduction of fracture W10-W23
Closed reduction of fracture W24-W26
Total hip replacement (minus revisions & revisions) W37-W39
Total knee replacement (minus revisions & revisions) W40-W42
Replacement of head of femur W46-W47
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The red cell using procedures was defined experientially from evidence in the published
literature, and in particular using clinical data in Maximum Surgical Blood Order Schedules
(MSBOS) (McClelland, personal communication). Maximum Surgical Blood Order
Schedules are guidelines for the maximum number of red blood cell units that can be cross¬
matched pre-operatively for a range of common elective, surgical procedures. Lists of this
sort were developed in order to facilitate reductions in the number of red blood cell units
cross-matched for surgery and represent potential targets for reducing blood utilisation, and
hence major blood using procedures (SIGN, 2001).
The assumption that the red cell using procedure may be coded in any one of the four
available OPCS-4 variables was tested to assess whether multiple red cell using procedures
per SMR01-CD might be identified thereby resulting in competition between surgical case
groups to which blood could be attributed. An instance where more than one red cell using
procedure is coded in a single SMR01-CD record is termed intra-episode competition (Figure
5.4a). Given that Opl-4 are coded with a convention of priority where Opl is the principal
variable intra-episode competition was addressed by accepting the first red cell using
procedure encountered in the episode, when reading from variable Opl to Op4 in order, as
the defining red cell using procedure.
An instance where more than one SMR01 record containing (at least) one red cell using
procedure can be related to a single transfusion day record according to the surgical blood
attribution date rule is termed inter-episode competition (Figure 5.4b). Despite the use of the
temporal date rule to determine an appropriate relationship between transfusion day
records and SMR01-CD records the issue of inter-episode competition arises where a patient
has closely occurring or contiguous inpatient admissions episodes, such as in the case of a
continuous inpatient stay. Because the temporal date rule is not confined to linking the date
of transfusion to within an episode and instead allows a period of seven days before the date
of admission in which a transfusion event may occur, transfusion events may be related to
more than one SMR01 record if this window of seven days overlaps with a previous episode.
However, if this is the case but the previous episode did not contain a red cell using
procedure, then inter-episode competition between red cell using procedures does not arise.
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Figure 5.4 SMR01-CD record intra-episode and inter-episode competition
a. Intra-episode competition
Transfusion day record can be linked by date rule with an SMR01-CD record that contains two
red cell using procedures (highlighted by boxes). By surgical rule, blood is attributed to Op2
of SMR episode 1.
Patient Transfusion Day Record SMR01 -CD record SMKQ1 -CD record
SMR episode 1 SMR episode 2
A Transfusion 1 Op1 I Op2 Op3 j Op4 Op1 Op2 Op3 Op4
b. Inter-episode competition
Transfusion day record can be linked by date rule with two SMR01/cancer/ death records that
each contains a red cell using procedure (highlighted by boxes). By surgical rule, blood is
attributed to Op2 of SMR episode 1.
Patient Transfusion Day Record SMR01-CD record SMR01 -CD record
SMR episode 1 SMR episode 2
A Transfusion 1 Op1 Op2 Op3 Op4 Op1 Op2 j Op3 Op4
7 days
For the study dataset inter-episode competition for surgical red blood cell use was assessed
by calculating the total number of red cell using procedures that could potentially be related
to each transfusion day record. Whilst informing the methods at this stage the findings for
analyses of inter-episode competition are reported in full in section 8.3 for the sake of clarity
and completeness of understanding of results. In summary, the findings suggest that inter-
episode competition rarely occurs and so it was not considered to affect the interpretation of
blood use by procedural case group. Further, in these scenarios episodes are close together
and so the underlying clinical condition in each is likely to be the same anyway: that is, it is
considered unlikely in these instances that choosing one red cell procedure over another will
affect the type of procedure to which blood is attributed. Inter-episode competition was
addressed using the same approach as was used for intra-episode competition: blood was
attributed to the first occurring red cell using procedure across Opl-4 variables of the first
episode to link by date rule to the transfusion day record is chosen.
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To conclude, the steps required to attribute red blood cell use to a red cell using procedure
so that red blood cell use by surgical case group can be quantified are summarised in Table
5.5. If an SMR01-CD record could be linked by the surgical blood attribution date rule to a
transfusion day record of red blood cell units used and it contained an OPCS-4 code(s) for a
red cell using procedure case group then the red blood cell units were attributed to that case
group (Table 5.5). If more than one red cell using procedure could be linked to a single
transfusion day record of red bloud cell use then units were attributed to tire first occurring
red cell using procedure as described in the explanation for the resolution of intra-episode
and inter-episode competition (Figure 5.4).
Table 5.5 Summary of attribution of red blood cell units to clinical case groups









to clinical case group:
Transplantation of kidney Yes Yes 1 Transplantation of kidney*
Transplantation of kidney Yes No 1 No
Transplantation of kidney No Yes 1 No
None Yes Yes 0 No
Transplantation of kidney &
Excision of bladder
Yes Yes 2 Transplantation of kidney*
* If Transplantation of kidney is first occurring red cell using procedure in episode or across episodes
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5.3.2. Rule for attributing blood use to patients with haematological conditions
The second category of clinical case groups identified for analysis of blood use attributed to
clinical reason defined a subset of patients diagnosed with chronic pre-malignant and
malignant haematological conditions. The diagnoses included in the study were malignant
neoplasms of lymphoid, haematopoietic or related tissue, and of uncertain or unknown
behaviour, and the pre-malignant conditions were myelodysplastic syndromes and
polycythaemia vera (Table 5.6).
Table 5.6 Diagnoses of malignant and pre-malignant conditions defined as
haematological case groups




Myelodysplastic syndromes Polycythaemia vera D45 & D46
Some patients may have had other medical conditions coded in SMR01-CD records but the
haematological conditions defined here were considered to be of particular clinical interest
and relevance to transfusion practice. The rule for the attribution of blood to haematological
case groups made the assumption that a diagnosis of malignant neoplasm of lymphoid or
haematopoietic tissue, myelodysplastic syndromes or polycythaemia vera was the
underlying cause for any red blood cell transfusion during the whole study period (one year)
because of the nature of the conditions and treatment protocols that require multiple
transfusions over a protracted period of time. Therefore, if a patient was diagnosed with one
of the haematological conditions defined here then all transfusion events during the study
period were attributed to the diagnosis (Figure 5.5).
Where a patient is diagnosed with more than one blood using haematological condition
during the study period, competition was resolved in the same way as was used for
competition between surgical case groups, that is, by attributing blood use to the first such
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diagnosis in the patient's SMR01-CD records in the study period. Competition between
haematological diagnoses was assessed and the findings reported in full in section 8.3. In
summary, few patients were diagnosed with more than one of these conditions and where
competition did occur the combinations of diagnoses reflect changes that might be expected
in response to the development of symptoms and progression of disease. The attribution of
red blood cell use to haematological diagnoses is summarised in Table 5.7.
Figure 5.5 Haematological blood attribution: summary
Clinical rule: Specified haematological disease coded in any episode in study period
Date rule: All transfusion day records during study period
Episode






One year (Whole study period)
Table 5.7 Summary of attribution of red blood cell units to clinical case group
according to the haematological malignancy blood attribution rule
Clinical case group
RBC Number of potential RBC units attributed









* If Leukaemia is first occurring procedure in episode or across episodes
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5.4. Analytical functions in SPSS and other analytical tools
The common processes in the computer software package, SPSS, that were used to
investigate the study dataset, include frequencies and descriptive statistics in order to report
the mean, standard deviation, range and sum for selected variables. The sum of variables,
for example blood component units used by red cell using procedure or number of patients
per age group could also be explored using the aggregate function.
Further, the aggregate function was used to analyse data at the patient, rather than record
level by aggregating by patient identifier, and by a similar method, at the hospital level and
by age group. When aggregating by patient identifier, the first age at time of transfusion,
first age group or first sex code from the patient's multiple records was returned in the
aggregate as summary variables for subsequent analysis at the patient level. The maximum
error incurred in doing so in the case of age was one year (such as if a patient had a
transfusion day record at the very start and another at the very end of the year) and was the
difference between one age group and the next for age group analysis (such as if patients
were in the upper year of the age band and aged further whilst in the study). The effect on
the sex variable was expected to be negligible as discrepancies in sex coding are rare.
Aggregating data in this way was the best approximation that could be made to analyse data
on a patient basis.
Data generated by analytical functions in SPSS was also exported to Microsoft Office Excel
(2003) for further analysis.
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5.5. Overview of methods employed in study
The surgical and haematological blood attribution rules and subsequent analyses by clinical
case group enabled an inference to be made about a likely reason for transfusion. However,
it did not preclude blood component units that could be attributed to surgical and
haematological case groups from being attributed to other, alternative or additional clinical
case groups. Using the methods described here, transfusion day records were flagged as
being related to particular clinical case groups but were effectively still available for
attribution to other potential clinical case groups in subsequent analyses. Indeed, as will be
seen from the findings reported in section 8.4, some transfusion day records could be linked
to both surgical case groups and haematological case groups and the overlap of blood
component units between the two was quantified. Therefore, the methods employed to
analyse blood use by clinical case group enabled different views of the data to be described
simultaneously, and further, allows for the flexibility of making future changes to methods
in response to changes in factors that might influence the blood attribution rules.
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6. RESULTS: STUDY DATASET
6.1. Descriptions of component data of study
6.1.1. Transfusion record data
Blood bank transfusion records of blood component assignments (1st January 2000 to 31st
December 2000, inclusive) were extracted from the computer system utilised by SNBTS
blood banks and were compacted into 24-hour transfusion day records (section 4.3).
Transfusion day records were provided for analysis in a 3.79MB SPSS file. Descriptive
statistics of transfusion day records of units assigned and units used are given in Table 6.1.
Less than half of patients with transfusion day records were male, the average age was
approximately 60 years old and each patient had on average two records. 58.7% of patients
with a transfusion day record of blood component assignment had a transfusion day record
of blood component use.
Table 6.1 Descriptive statistics for the transfusion day records available for study
Statistic
TDR units TDR units
assigned used
Patients (n) 21,309* 12,514
Transfusion day records (n) 41,431* 27,172
Transfusion day records per patient (range) 1-227 1-227
Transfusion day records per patient (mean, SD) 1.94, 3.23 2.17-3.92
Sex (% Male) 48.6 46.4
Age in years (range) 0.1-101.5 0.1-101.5
Age in years (mean, SD) 59.62, 22.00 64.2, 20.4
* Cross-reference with Figure 4.4 SD: standard deviation
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Initial investigations identified two coding issues within transfusion day records: both were
easily addressed in the early stages of the study. In one transfusion day record the age in
years at time of transfusion was recorded as a negative number, -0.1. This may have been
the result of an entry error in the decade of birth (meaning that the patient was actually 99.9
years old), or could simply have meant that the patient was 0.1 years old. This patient was
transfused with just one blood component unit of fresh frozen plasma. Further, the
transfusion day record could not be linked to an SMR01-CD record which may have been
because the patient had a different type of SMR record, for example, maternity and neonatal
(SMR02 and SMR11) data for which was not available for the study at the time of data
extraction. Together these facts suggested that the patient was a neonate. The age was
subsequently corrected to 0.1 years.
Secondly, calculating the number of units used (equal to units assigned minus deassigned)
for the blood component cryoprecipitate resulted in negative values. It was evident that for
all transfusion day records the number of units of cryoprecipitate assigned had been
incorrectly labelled as deassigned and vice versa. The original variable names were not
changed but the calculation for units of cryoprecipitate used was altered to units deassigned
minus assigned thereby giving positive values for cryoprecipitate use. There were no
obvious anomalies such as extremely large numbers in the number of blood component
units recorded for the assigned or deassigned, and consequently used blood component
variables at both a record and patient level. Table 6.2 reports the number of units assigned
and the number of units used for each blood component. Approximately half of the red
blood cell units assigned are assumed to have been transfused, whereas approximately 95%
of all other blood component units assigned are assumed to have been transfused.
Table 6.2 Blood component units assigned and used: transfusion day records linked
to at least one SMR01-CD record
Units Units used
Blood component assigned (% of assigned)
(n=135,607) (n=76,130)
Red blood cells 118,727 60,130 (50.6)
Platelets 5,051 4,795 (94.9)
Fresh frozen plasma 9,983 9,446 (94.6)
Cryoprecipitate 1,846 1,759(95.3)
93
6. Results: Study dataset
6.1.2. SNBTS supply data
Using the Scottish National Blood Transfusion Service (SNBTS) supply data it was calculated
that a total of 86,369 red blood cell units were supplied to SNBTS/Progesa blood banks that
were representative of the study data (Table 6.3). Therefore, the study transfusion data
relates to blood component use for hospitals in Eastern regions of Scotland (total 60,130 red
blood cell units used) which represents approximately 38% of the 225,422 red blood cell
units supplied by SNBTS to the whole of Scotland in the year 2000. The assumption applied
in this study is that red blood cell supply and use is uniform across all of Scotland and
therefore, for the purposes of predicting red blood cell use for the whole of Scotland, the
study data represents 38% of the Scottish population. Therefore, the estimated number of
red blood cell units used in the whole of Scotland in 2000 is 158,863, which equates to the use
of 70% of the red blood cell units supplied: this is comparable with the use of 62.0% to 77.7%
of the red blood cell units supplied to the blood banks included in the study (Table 6.3).
The number of red blood cell units supplied per 1,000 head of population for the study
population was 44.9. The number of red blood cell units used per 1,000 head of population
for the study population was 56.4 overall; 66.4 red blood cell units used per 1,000 head of
population for males and 49.6 red blood cell units used per 1,000 head of population for
females.
Table 6.3 Context of study dataset: SNBTS supply data and study dataset blood use
data
RBC units RBC units RBC units
Area
supplied used used/ supplied
Inverness blood bank 8,827 5,635 63.8%
Aberdeen blood bank 23,724 18,443 77.7%
Dundee blood bank 21,857 13,560 62.0%
Edinburgh blood bank 31,961 22,443 70.2%
Sub-total study 86,369 60,081* 69.6%
Sub-total non-study* 139,053
Total all Scotland 225,422
t Calculated from total RBC units supplied to all Scotland minus total supplied
to blood banks included in study. * 60,130 RBC units in study dataset in total:
49 RBC units for non-SNBTS/Progesa hospitals not reported in Table 6.3.
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6.1.3. ScottishMorbidity Record data
Two files of SMR01 records and related cancer and death records were available for study.
One was a large SPSS file (213MB) of all year 2000 SMR01-CD records for the whole Scottish
population; the second was an SPSS file (14.8MB) of all SMR01-CD records for the year 2000
that had undergone internal record linkage and could be linked to patient identities in the
file of transfusion day records of unit assignments. Descriptive statistics for the two SMR01-
CD datasets are given in Table 6.4. Patients with SMR01-CD records and who could be
linked to transfusion day records of units assigned had on average more than twice as many
SMR01-CD records per patient, included a higher proportion of males, and were on average
seven years older than inpatients who could not be linked to transfusion day records of units
assigned.
As with transfusion day records, minor irregularities in coding were identified within the
linked SMR01-CD records. Three patients had a mixed sex coding: all were initially coded as
male and were coded in subsequent SMR01-CD records as female. The recorded sex was not
adjusted for this study as it was not considered to have a bearing on interpretation of data at
the individual record level, and, when data was aggregated to the patient level, the first sex
code per patient was always selected (that is, upon aggregation the patients with anomalous
sex entries were all considered to be male).






SMR01-CD per patient (range) 1-142 1-123
SMR01-CD per patient (mean, SD) 1.78, 2.07 3.76, 4.22
Sex (% Male) 48.1 51.1
Age in years (range) 0-111 0-101
Age in years (mean, SD) 53.42, 23.54 60.74, 20.56
{ SMR01-CD: SMR01/cancer/death records, t Linked to patient identities
with transfusion day records of assigned blood component units. * Cross-
reference with Figure 4.4.
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Multiple SMR01-CD records per patient and the large amount of clinical data recorded in
each SMR01-CD record were identified as likely to cause data handling issues. Intra- and
inter-episode competition has been described previously (Figure 5.4). In order to
understand the extent of intra-episode competition, the relative importance of each red cell
using procedure and blood using diagnosis code to others in the same SMR01 record was
determined by exploring the frequency of coding across the multiple procedure and
diagnosis variables in relation to the number coded in the relevant primary variable. All red
cell using procedures defined in this study, with the exception of transplantation of heart
(which includes transplantation of heart and lung), were coded in the primary OPCS-4
procedure variable, Opl, more than 50% of the time, and 17 of those 28 red cell using
procedures were coded in Opl more than 90% of the time (Table 6.5). Transplantation of
heart and lung (KOI) and transplantation of heart (K02) were not coded in any OPCS-4 field
in any SMR01-CD record in the source data: this procedure does not appear in the findings
of any further analyses. The four malignant or pre-malignant haematological conditions
(lymphoma, myeloma, leukaemia, and polycythaemia and myelodysplastic syndromes)
were coded in the primary ICD-10 diagnosis variable, Diagl, between 75% and 92% of the
time (Table 6.6).
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Table 6.5 Coding of red cell using procedures: number of times coded in primary
procedure variable compared with all instances in Opl-4
Number of times coded in variable:
Red cell using procedure
Op1 Op2 0p3 Op4 Op1/Total
Open placement of prosthesis in trachea 4 0 0 0 100.0%
Total knee replacement (minus revisions) 508 2 2 0 99.2%
Total hip replacement (minus revisions) 1,294 10 3 2 98.9%
Transplantation of kidney 63 2 0 0 96.9%
Replacement of head of femur 445 13 4 1 96.1%
Total hip replacement revisions 213 6 2 2 95.5%
Transplantation of liver 42 1 1 0 95.5%
Excision of lung 192 8 1 1 95.0%
Open operations on prostate 38 0 1 1 95.0%
Total knee replacement revisions 54 2 1 0 94.7%
Open bypass graft operations revisions 16 1 0 0 94.1%
Emergency replacement or bypass of
aneurysmal segment aorta
94 2 3 1 94.0%
Hysterectomy 392 17 8 1 93.8%
Excision of colon 610 36 8 1 93.1%
Other open operations on kidney 158 9 2 1 92.9%
Operations on valves of heart and adjacent
structures
322 18 6 1 92.8%
Excision of rectum 358 23 8 2 91.6%
Closed reduction of fracture 582 57 12 10 88.0%
Operations on thyroid or parathyroid glands 45 7 0 1 84.9%
Other operations on aorta 193 30 6 0 84.3%
Open extirpation of lesion of lung 14 2 1 0 82.4%
Open reduction fracture 671 120 26 0 82.1%
Open operations on oesophagus 117 22 4 3 80.1%
Other operations on lung 87 16 7 1 78.4%
Partial excision of liver 66 17 4 1 75.0%
Operations on tissue of brain 157 40 15 13 69.8%
Reconstruction of renal artery 31 9 5 1 67.4%
Open bypass graft operations (minus revisions) 1,183 897 178 21 51.9%
Transplantation of heart (includes heart and lung) 0 0 0 0 n/a
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Table 6.6 Coding of red cell using haematological diagnoses: number of times coded
in primary diagnosis variable compared with all instances in Diagl-6
Number of times coded in variable:
Haematological diagnosis
Oiagt Diag2 Diag3 Diag4 Diag5 Diag6 Diagl/Total
Lymphoma 1,938 102 57 9 5 2 91.7%
Myeloma 943 50 37 10 4 2 90.2%
Leukaemia 2,375 252 76 15 12 2 86.9%
Polycythaemia &
myelodysplastic syndromes
548 82 61 17 14 5 75.4%
Anomalous coding of transplantation ofheart and lung and transplantation ofheart
Because transplantation of heart, and heart and lung, were not coded in any SMR01-CD
record in the study dataset the coding for these procedures was checked for the whole of
Scotland in the year 2000. Data available for all SMR01-CD records for the whole of Scotland
in the year 2000 contained records coded with one heart and lung transplant (K01) and five
heart transplants (K02), all of which are found in the primary OPCS-4 variable, Opl.
However, upon further investigation the heart and lung transplant and three of the heart
transplants appear to have been coded erroneously. The heart and lung patient had one
SMR01 record in the year 2000 for an admission to a Glasgow hospital in which they entered
hospital one day and were discharged the next, an unexpected period of admission
considering the coding of allotransplantation of heart (K011) in the primary procedure field.
Further, no other procedures were coded in the remaining OPCS-4 variables. The admission
profile bore more relevance to the unrelated and unexpected diagnosis coded in the primary
ICD-10 variable: K011, impacted teeth. Therefore it is assumed that the diagnostic code K011
was erroneously recorded in the procedure variable where it takes on a completely different
meaning. A summary of the SMR01 records in which transplantation of heart is coded in
Opl is given in Table 6.7. By looking at the diagnoses recorded for these patients it was
possible to identify where the apparent K02 code had been correctly entered against patients
given that in two cases the diagnoses were for heart related conditions and their inpatient
patterns consisted of multiple admissions. Two erroneous cases were patients at dental
hospitals with single day admissions who also had diagnosis codes for dental caries, which,
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if coded in the procedure variable are mistaken for heart transplants. In a third case a
double coding error had occurred: because the admission was again at a dental hospital it is
presumed that the K02 coding in the procedure variable ought to have been coded in the
diagnosis variable to indicate dental caries. However, the actual code that was entered in
the diagnosis variable is also presumed to be incorrect given that the patient is an eight year
old for whom a delirious mental state due alcohol withdrawal is unexpected.




of SMR01 Diagnosis (code & description) Coding summary
Royal Infirmary 18 I259 Chronic ischaemic heart
disease, unspecified
Correct coding in Op1
Royal Infirmary 17 I420 Dilated cardiomyopathy Correct coding in Op1
Dental Hospital 1 K029 Dental caries Diagl wrongly coded in Op1
Dental Hospital 1 K029 Dental caries Diagl wrongly coded in Op1
Dental Hospital 1 F104 Mental & behavioural
disturbance due alcohol:
withdrawal state with delirium
Diaglwrongly coded in Op1
plus erroneous Diagl
Op1: Primary OPCS-4 (procedure) variable; Diagl: Primary ICD-10 (diagnosis) variable
99
6. Results: Study dataset
6.2. Description of study dataset
6.2.1. Records included in study dataset
This section describes the study dataset that was created by linking transfusion day records
of units assigned and SMR01-CD records (section 5.2). 41,431 transfusion day records of
blood component assignments and 73,934 SMR01-CD records were linked and then the
dataset was reduced to transfusion day records of units used. Table 6.8 reports the
descriptive statistics for the study dataset which are therefore based on transfusion day
records of blood component units used. The final study dataset contains the transfusion and
clinical data for 11,994 patients (Figure 6.1). Overall, 96.8% of all blood component units
used that were recorded in the source data of transfusion day records could be linked to at
least one SMR01-CD record in the study dataset. 70.9% of the SMR01-CD records in the
source data were included in the final, study dataset.
Figure 6.1 Number of records and patients at stages of study dataset creation















TDR 2: 1 unit assigned & SMR01-CD
Transfusion Day Records = 39,142
SMR/Cancer/ Death Records = 73,934
Patients = 19,639
Select TDR > 1 unit BC units used
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TDR 2; 1 unit used & SMR01-CD
(Study dataset)
Transfusion Day Records = 26,269
SMR/Cancer/ Death Records = 52,450
Patients = 11,994
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Table 6.8 Descriptive statistics for the study dataset
Statistic Study dataset
Patients 11,994
Transfusion day records 26,269
SMR01 -CD records 52,450
Transfusion day records per patient (range) 1-227
SMR01-CD per patient (range) 1-123
Sex'(% male) 51.4
Age* in years (range) 0-101.4
Age in years (mean, SD) 61.5,21.3
* Statistics for sex and age from Transfusion day records
Figure 6.2 Records per patient in the study dataset
a. Transfusion day records of units used b. SMR01/cancer/death records
1 2-4 5-9 10+ 1 2-4 5-9 10+
TDR of units used per patient SMR01-CD records per patient
The number of transfusion day records of units used and SMR01-CD records per patient are
described in Table 6.8 and Figures 6.2a and 6.2b. Most patients in the study dataset have one
transfusion day record of units used and the average is 2.19 (SD 3.97) transfusion day
records of units used. For SMR01-CD records, most patients have two to four and the
average is 4.37 (SD 4.75) SMR01-CD records in the study year. The use of blood component
units by age, gender and intensity of transfusion are described, for each blood component
separately, in Chapter 7.
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6.2.2. Records not included in study dataset
Here, the populations of patients with transfusion or clinical records that could not be linked,
and therefore do not appear in the study dataset, are described: first, patients with SMR01-
CD records but no transfusion day records of blood component units used, and second,
patients with transfusion day records of blood component units used but no SMR01-CD
records.
The non-transfused patients were those who had at least one SMR01-CD record in the year
2000 but who could not be linked to a transfusion day record. The statistics that describe the
non-transfused subgroup are given (Table 6.9). In the year 2000, 1,128,242 SMR01-CD
records represented 655,022 patients who had at least one inpatient hospital stay as recorded
in SMR01 during that year but who did not have a transfusion day record of any blood
component units assigned during that year. 21,484 SMR01-CD represented 7,645 patients
who had 12,873 transfusion day records of a blood component unit assigned but who could
not be linked to a transfusion day record of units used (Table 6.9). SMR01-CD records that
could be linked to transfusion day records of unit assignments but not use represent patients
who were at risk of being transfused (by virtue of blood request and assignment being made)
but the decision was made not to transfuse. On average, these patients had more inpatient
admissions, fewer were male and the average age was older in comparison with patients
with transfusion day records of unit assignments.
A small number of patients who had transfusion day records of blood component use but
who could not be linked to an SMR01-CD record in the year 2000 are described in Table 6.10.
The blood may have been given as an out patient transfusion or the patients may have had
an inpatient record for an admission type not included in the SMR01 data scheme. For
example, if patients' hospital interaction was coded in maternity or neonatal records (SMR02
and SMR11) instead of inpatient records (SMR01), then the clinical data was not available
because these other data schemes could not be linked at the time that the data was extracted
for this study. If this explanation is true for some of the unlinked records, then a young
population with a high percentage of females would be expected, a hypothesis which indeed
the data supports (average age, 44.4 years; 67.4% female) (Table 6.10).
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Table 6.9 Patients with SMR01-CD records but not transfused
Statistic
No units Units assigned
assigned but not used
Patients 655,022 7,645
SMR01-CD records 1,128,242 21,484
SMR01 -CD records per patient (range) 1-142 1-199
SMR01-CD records per patient (mean, SD) 1.72,1.94 2.81,2.99
Sex (% Male) 52.1 48.2
Age in years (range) 0-111 0-100
Age in years (mean, SD) 52.94,23.64 57.79,20.52
Table 6.10 Transfusion recipients not linked to SMR01-CD records in year 2000
Statistic
No SMR01-CD
record in year 2000
Patients 520
Transfusion day records* 903
Transfusion day records* per patient (range) 1-27
Transfusion day records* per patient (mean, SD) 1.74, 2.55
Sex (% Male) 32.6
Age in years (range) 0.1-101.5
Age in years (mean, SD) 44.43, 29.55
Units used (% of total in originally extracted TDR):
Red blood cells 2,188(3.5)
Platelets 115(2.3)
Fresh frozen plasma 143(1.5)
Cryoprecipitate 39 (2.2)
1 Transfusion day records of units used
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6.3. Overview of study dataset
The aim of the study was to create a dataset that could be used for subsequent analysis of
blood component use. The results reported in this chapter demonstrate that it is possible to
link data from routine sources to create a study dataset that contains both transfusion and
clinical data and that the data can be used to describe the patients included in the study,
who received blood and had an inpatient admission in the year 2000. The final, linked study
dataset (section 6.2) and the patients defined by records that could not be linked (section 6.3)
were described here. Further objectives of the study were to use the study dataset to
describe blood component use by age, gender and intensity of transfusion (Chapter 7) and to
describe the use of blood components by clinical case group, specifically for surgical
procedures and haematological conditions (Chapters 8 and 9).
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7. RESULTS: TRANSFUSION DATA
7.1. Introduction to blood component transfusion
In Chapters 6 it was shown that it was possible to link transfusion and clinical records from
routine sources to create a study dataset for blood use analysis. In this chapter, blood
component use by age, gender and intensity of transfusion of blood component recipients is
described for the transfusion day records of used units that were included in the study
dataset (69.5% of RBC units used in the original, extracted transfusion day records).
Findings are reported separately for each blood component (sections 7.2-7.5).
Table 7.1 Any use of blood: patient, transfusion day record and blood use data
Statistic
RBC units PLT units FFP units CRYO units
used used used used
Patients 11,567 1,422 1,266 253
Transfusion day records 22,471 4,084 2,171 328
Transfusion day records per patient (range) 1-53 1-92 1-223 1-7
Transfusion day records per patient (mean, SD) 1.9, 2.3 2.9, 5.6 1.7, 6.4 1.3, 0.8
Transfusion day records per patient (mode) 1 1 1 1
Sex by transfusion day record (% male) 50.3 57.0 62.8 61.6
Sex by patient (% male) 47.1 62.4 61.0 61.3
Age in years (range) 0-101.4 0-97.3 0-97.7 0-95.1
Age in years per transfusion day record (mean, SD) 63.0, 21.0 51.9,21.8 57.2, 18.3 52.5, 22.5
Age in years per patient (mean, SD) 65.2, 19.6 57.4, 21.0 60.2, 19.4 52.9, 22.6
Units used * 60,130 4,795 9,446 1,759
Units used per transfusion day record (range) 1-72 1-8 1-34 1-40
Units used per transfusion day record (mean, SD) 2.6, 2.1 1.2, 0.5 4.4, 3.4 5.4, 5.7
Units used per transfusion day record (mode) 2 1 3 1
Units used per patient (range) 1-144 1-93 1-1,776 1-95
Units used per patient (mean, SD) 5.2, 6.9 3.4, 6.3 7.5, 51.6 7.0, 10.3
Units used per patient (mode) 2 1 3 1
Age group transfused with max units used per 10-39 30-39 40-49 20-29
patient per age group (years)
Units used per patient per age group (max) 6.7 5.7 20.3 13.9
* Units used refers to the units of the relevant blood component reported by column of table: patients with
transfusion day records of RBC units used, the figure reported for units used is the number of RBC units used.
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First, in this section measures of transfusion day records and blood use for patients of
different subgroups are described. The findings for any use of blood components are
described: for example, for red blood cells, any transfusion day record of at least one unit of
red blood cells used either alone or in any combination with other blood component types
(Table 7.1). The findings for the use of individual blood components are also described: for
example, for red blood cells, any transfusion day record of red blood cell use only and no
platelet, FFP or cryoprecipitate units used (Table 7.2). 86% of patients who receive red blood
cell units during the year receive only red blood cell units, whereas 16% of platelet recipients,
12% of FFP recipients and just 1% of cryoprecipitate recipients were transfused with solely
those respective blood component types. The age and sex distributions for each blood
component type are approximately the same for patients who received any transfusion
compared to patients who received one blood component type only, except for
cryoprecipitate, where far fewer males received cryoprecipitate alone (33.3%) than received
any cryoprecipitate transfusion (61.3%).











Patients (% only/any*) 10,003 (86) 224 (16) 155(12) 3(1)
Transfusion day records 16,915 586 194 3
Transfusion day records per patient (range) 1-33 1-56 1-18 1
Transfusion day records per patient (mean, SD) 1.69, 1.67 2.62, 5.27 1.25, 1.42 1.00, 0
Transfusion day records per patient (mode) 1 1 1 1
Sex by patient (% male) 44.9 60.3 62.6 33.3
Age in years per patient (range) 0-101.4 0-93.1 0-88.8 35.0-76.9
Age in years per patient (mean, SD) 66.3, 19.2 58.0,21.4 66.2, 18.0 55.0,21.0
Units used 41,115 656 666 21
Units used per patient (range) 1-91 1-56 1-145 1-10
Units used per patient (mean, SD) 4.11,4.46 2.92, 5.44 4.30, 12.0 7.0, 5.20
Units used per patient (mode) 2 1 2 10
Blood component (BC) use aggregated by patient ID and then selected if:
RBC only=RBC>0 & (PLT=0 & FFP=0 & CRYO=0)
PLT only=PLT>0 & (RBC=0 & FFP=0 & CRYO=0)
FFP only=FFP>0 & (RBC=0 & PLT=0 & CRYO=0)
CRYO only=CRYO>0 & (RBC=0 & PLT=0 & FFP=0)
* Percentage of patients transfused with blood component who were transfused only with that blood component
type: for example 86% of patients transfused with red blood cell units (n=11,567) were transfused with only red
blood cell units and received no other blood component type (n=10,003).
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Table 7.3 Combinations of blood component use: patient, transfusion day record






Patients 10,003 1,564 427 11,994
Transfusion day records 16,915 8,500 854 26,269
TDR per patient (range) 1-33 1-227 1-56 1-227
TDR per patient (mean, SD) 1.69, 1.67 5.43, 9.31 2.00, 3.99 2.19, 3.97
TDR per patient (mode) 1 2 1 1
Sex (% male by patient) 44.9 60.9 61.1 47.6
Age in years (range) 0-101.4 0-97.7 0-93.1 0-101.4
Age in years (mean, SD by patient) 66.3, 19.2 58.1, 23.0 60.8, 20.9 65.0, 19.7
Units used" 41,115 33,357 1,658 76,130
Units used per patient (range) 1-91 2-1,899 1-1,484 1-1,899
Units used per patient (mean, SD) 4.11, 4.46 21.3, 53.0 3.88, 9.15 6.35, 20.5
Units used per patient (mode) 2 6 1 2
Blood component (BC) use aggregated by patient ID and then selected if:
RBC + other BC=RBC>0 & (PLT>0 or FFP>0 or CRYOO)
RBC only=RBC>0 & (PLT=0 & FFP=0 & CRYOO)
Other BC only=RBC=0 & (PLT>0 or FFP>0 or CRYO>0)
Any=RBC>0 or PLT>0 or FFP>0 or CRYO>0
* Cross reference Table 7.2. ** Cross reference Table 6.8 for total study dataset data: Table 6.8
reports age and sex per TDR, Table 7.3 age and sex per Patient. Units used = all relevant blood
component units by combination of BC reported in column of table. BC: Blood component.
Further, the use of different combinations of blood component types that are clinically
meaningful are reported: red blood cell use alone, red blood cell and other components
combined, and any combination of other blood components excluding red blood cells
(platelet, FFP and cryoprecipitate); subgroups that together total all transfusion day records
in the study dataset (final column)(Table 7.3). It is helpful to consider blood component use
in this way such as for analysis of donor exposure (section 10.6) or particular resource
planning contexts.
In the following sections the findings that are reported for analyses of blood component use
by age, gender and intensity relate to all blood component transfusions (sections 7.2-7.5).
The age distributions for blood component use are described and the estimated total blood
use for Scotland is reported by age and gender for each blood component. The age and
gender specific rates of transfusion for each blood component were obtained from the study
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data and were applied to the population age structure for Scotland in the year 2000. The
calculation had to account for the proportion of the population that was transfused, based on
the approximation that the study dataset represents 38% of the red blood cell units supplied
by SNBTS to the whole of Scotland in the year 2000, and hence the study dataset represents
approximately 38% of the Scottish population, if transfusion practice is presumed to be
uniform throughout the country (SNBTS blood supply data; Table 6.3).
The term "intensity of transfusion" is defined for this study as the number of blood
component units used per patient during the study, which equates to the number of blood
component units used per patient per year as the study period is one year. The findings for
intensity of transfusion for each blood component are reported in full presently but briefly
the data demonstrates that many patients are transfused at a low intensity and the total units
accounted for is small, and conversely, few people are transfused intensively accounting for
a large proportion of the units used.
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7.2. RED BLOOD CELL USE
The study dataset contained 22,471 transfusion day records of at least one red blood cell unit
used, that represented 11,567 patients (red cell recipients) and 60,130 used units of red blood
cells (Table 7.4 and Figures 7.1a-c). 50.3% of these red cell recipients were males who
accounted for 52.2% of red blood cell units used. On average red cell recipients had 1.9
transfusion day records of red blood cell units used and the mean number of red blood cell
units used per patient during the year was 5.2. Red cell recipients also used 1,636 units of
platelets, 4,392 units of fresh frozen plasma and 1,182 units of cryoprecipitate. The mean
number of all blood component types used per red cell recipient was 6.0 units
20,763 (92.4%) transfusion day records of at least one red blood cell unit used contained no
other blood component units used, that is, 10,003 (86.4%) patients transfused with red blood
cells only received red blood cells. The findings of descriptive analyses for the population
transfused with red blood cells only was summarised previously in Table 7.2 and 7.3.
Table 7.4 Population transfused with red blood cell by age group.
Age group TDR (%) Patients (%) TDR / RBC units (%) RBC units/
Years n=22,471 n=11,567 Patient n=60,130 Patient *
0-9 937 (4.2) 303 (2.6) 3.1 1,482 (2.5) 4.9
10-19 469 (2.1) 190(1.6) 2.5 1,275 (2.1) 6.7
20-29 570 (2.5) 283 (2.4) 2.1 1,896 (3.2) 6.7
30-39 1,031 (4.6) 471 (4.1) 2.2 3,145 (5.2) 6.7
40-49 1,611 (7.2) 783 (6.8) 2.1 4,588 (7.6) 5.9
50-59 2,769 (12.3) 1,402 (12.1) 2.0 7,831 (13.0) 5.6
60-69 4,852 (21.6) 2,478 (21.4) 2.0 13,119(21.8) 5.3
70-79 6,059 (27.0) 3,176 (27.5) 1.9 16,266 (27.1) 5.1
80-89 3,471 (15.4) 2,014(17.4) 1.7 8,842 (14.7) 4.4
90+ 702 (3.1) 467 (4.0) 1.5 1,686 (2.8) 3.6
*
Average intensity of transfusion (units per patient per year) per age group
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7.2.1. Age distribution of red blood cell recipients
The average age at the time of transfusion was 63.0 years (SD 21.0 years), the oldest average
age of patients transfused for any of the blood component types. Variation in red blood cell
use by age group is described in Table 7.3, and is illustrated by age and gender in Figure 7.1.
The rates of transfusion obtained from the study data were applied to the population age
structure for Scotland in the year 2000, accounting for the appropriate proportion of the
population that is transfused based on the study data (Figure 7.2). The age group 70-79
years had the largest number of patients and had the largest share (27.1%) of total red blood
cell units used. However, those patients in age bands 10-39 years received the highest
number of red blood cell units per patient (6.7) over the period of one year (Figure 7.1).
Figure 7.1 Average red blood cell units used per patient by age group and gender
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99 100+
Age group
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7.2.2. Distribution of intensity of transfusion of red cell recipients
The distribution of red blood cell units and red cell recipients transfused by intensity is
reported (Table 7.5a). The most common intensity of red blood cell use accounted for by
34.8% of patients, was two units per patient per year. 25,416 red blood cell units were used
by 1,311 red cell recipients transfused at an intensity of ten or more units per patient per year,
that is, 11.3% of red cell recipients were transfused with ten or more units during the year
which accounts for 42.3% of the total red blood cell units used in the study (Table 7.5b). The
number of patients transfused with zero red blood cell units but transfused with other blood
components was 427, 3.6% of patients in the study dataset
Table 7.5a Intensity of red blood cell use
Units/ RBC units (%) Patients (%)
patient / year n=60,130 n=11,567
1 668(1.1) 668 (5.8)
2 8,054(13.4) 4,027 (34.8)
3 4,896 (8.1) 1,632(14.1)
4 6,856(11.4) 1,714(14.8)
5 3,505 (5.8) 701 (6.1)
6 3,714 (6.2) 619(5.4)
7 2,464 (4.1) 352 (3.0)
8 2,640 (4.4) 330 (2.9)
9 1,917(3.2) 213(1.8)
10-19 11,732 (19.5) 898 (7.8)
20-29 5,369 (8.9) 225(1.9)
30-39 3,038 (5.1) 92 (0.8)
40-49 1,933 (3.2) 45 (0.4)
>50 3,344 (5.6) 51 (0.4)
Table 7.5b Summary of intensity of red blood cell use
Intensity 1-4 units 5-9 units >10 units
Red blood cell units (%) n=60,130 34.0 23.7 42.3
Red blood cell recipients (%) n=11,567 69.5 19.2 11.3
111
7. Results: Transfusion data
7.3. PLATELET USE
In the study dataset there were 4,084 transfusion day records of at least one unit of platelets
used representing 1,422 patients (platelet recipients) and 4,795 used platelet units. 57.0% of
these patients were males who accounted for the use of 57.4% of platelet units. On average
patients had 2.9 transfusion day records of platelet use and the average intensity of platelet
use was 3.4 units per patient per year. These patients also used 6,708 red blood cell units,
3,286 fresh frozen plasma units and 1,041 cryoprecipitate units. 14.3% of transfusion day
records of used platelet units and 15.7% of platelet recipients were transfused with platelets
only (Table 7.2).
7.3.1. Age distribution of platelet recipients
The average age of patients with transfusion day records of used platelet units was 51.9
years (SD 21.8 years). Variation in platelet use by age group is described in Table 7.6. As for
red blood cell use, age group 70-79 years was the largest in terms of the number of patients
(24.0%) but age group 60-69 years, which also accounted for the largest proportion of
transfusion day records (23.3%), received the largest share (22.9%) of total platelet units used
by age group. Patients in age band 30-39 years used the highest number of platelet units
used per patient (5.7) and platelet use per patient was particularly predominant in females
for this age group (Figure 7.3). The age and gender specific rates of platelet transfusion were
applied to the population age structure of Scotland for year 2000 for the appropriate
proportion of transfusion recipients to illustrate total platelet use by age and gender for
Scotland (Figure 7.4).
The data presented in Table 7.6, and Figures 7.3a and 7.4a, includes all platelet recipients but
the data suggests that there are female patients in age group 30-39 years with extreme values
for platelet use which may lead to a misrepresentation of platelet use overall. The outlying
values for platelet use per patient were considered to be 26 units, 39 units and 90 units.
These patients were also transfused with a total of 145 red blood cell units, 25 FFP units and
ten cryoprecipitate units. Together the "outlier" patients were linked to 47 SMR01-CD
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records and 156 transfusion day records. One patient had a primary diagnosis code (ICD-10)
in their first SMR01-CD record in the study dataset for aplastic anaemia and two had
diagnosis codes for acute myeloid leukaemia; the procedural codes were blood transfusion,
bone marrow extraction and central venous catheter insertion. No date of death was
available for these patients at the time of data extraction. Data after the removal of these
outliers are shown in Figures 7.3b and 7.4b.
Table 7.6 Population transfused with platelets by age group
Age group TDR (%) Patients (%) TDR / PLT units (%) PLT units/
Years n=4,084 n=1,422 Patient n=4,795 Patient *
0-9 327 (8.0) 75 (5.3) 4.4 339 (7.1) 4.5
10-19 139 (3.4) 35 (2.5) 4.0 160 (3.3) 4.6
20-29 256 (6.3) 64 (4.5) 4.0 297 (6.2) 4.6
30-39 360 (8.8) 80 (5.6) 4.5 459 (9.6) 5.7
40-49 425 (10.4) 156(11.0) 2.7 509 (10.6) 3.3
50-59 754 (18.5) 221 (15.5) 3.4 876(18.3) 4.0
60-69 952 (23.3) 326 (22.9) 2.9 1,098 (22.9) 3.4
70-79 670 (16.4) 341 (24.0) 2.0 797 (16.6) 2.3
80-89 194 (4.8) 119(8.4) 1.6 253 (5.3) 2.1
90+ 7 (0.2) 5 (0.4) 1.4 7(0.1) 1.4
* Average intensity of transfusion (units per patient per year) per age group
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Figure 7.3 Average platelet units used per patient by age group and gender
Figure 7.4 Platelet units used by age group and gender for all Scotland in 2000
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7.3.2. Distribution of intensity of transfusion of platelet recipients
The distribution of used platelet units and platelet recipients by intensity of platelet use
demonstrated that 53.0% of platelet recipients received one unit of platelets per patient per
year (Table 7.7a). 6.8% of platelet recipients received ten or more units during the year,
accounting for 42.4% of the total platelet units used in the study (Table 7.7b). This echoes the
pattern for red blood cell use in which a few patients were transfused intensively and
accounted for a large proportion of units used. 88.1% of patients in the study were not
transfused with platelet units.
Table 7.7a Intensity of platelet use
Units/ PLT units (%) Patients (%)
patient / year n=4,795 n=1,422
1 754 (15.7) 754 (53.0)
2 468 (9.8) 234(16.5)
3 408 (8.5) 136 (9.6)
4 280 (5.8) 70 (4.9)
5 215(4.5) 43 (3.0)
6 162 (3.4) 27 (1.9)
7 196 (4.1) 28 (2.0)
8 136 (2.8) 17 (1.2)
9 144 (3.0) 16 (1.1)
10-19 838 (17.5) 60 (4.2)
20-29 549(11.4) 24(1.7)
30-39 212 (4.4) 6 (0.4)
40-49 83 (1.7) 2(0.1)
>50 350 (7.3) 5 (0.4)
Table 7.7b Summary of intensity of platelet use
Intensity 1-4 units 5-9 units >10 units
Platelet units (%) n=4,795 39.8 17.8 42.4
Platelet recipients (%) n=1,422 84.0 9.2 6.8
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7.4. Fresh frozen plasma use
The study dataset contained 2,171 transfusion day records of at least one used unit of fresh
frozen plasma (FFP). These records represent 1,266 patients (FFP recipients), with an average
of 1.7 records of FFP use per patient and an average intensity of FFP use of 7.5 units per
patient per year, the highest average transfusion rate of all blood components. 62.8% of FFP
recipients were male and accounted for 66.8% of used FFP units, the highest proportions
across all blood components. FFP recipients also used 6,777 red blood cell units, 1,140
platelet units and 1,252 cryoprecipitate units. 155 (12.2%) patients transfused with FFP
received no other blood component, that is were transfused with FFP only (Table 7.2).
7.4.1. Age distribution of fresh frozen plasma recipients
The average age of patients transfused with fresh frozen plasma was 57.2 years (SD 18.3
years). The variation in FFP use by age group and by gender is reported (Table 7.8 and
Figure 7.5). Age group 70-79 years had the largest proportion (26.5%) of patients, as was the
case for both red cell and platelet transfusion. Almost half of all FFP recipients (49.2%) were
aged 60-69 and 70-79 years. However, the age group that received the highest number of
FFP units per patient (20.3) during the study period as well as the largest share of total FFP
units used (28.5%) was 40-49 years, younger than for red blood cell or platelet use. The
highest intensity of transfusion (20.3) is more than double the next highest (10.0 FFP units
per patient per year for age group 20-29 years) and more than eleven times the lowest (1.8
FFP units per patient per year for age group 0-9 years). Total FFP use by age and gender for
the whole of Scotland in the year 2000 was quantified (Figure 7.6).
The data presented in Table 7.8, and Figures 7.5a and 7.6a, includes all patients transfused
with at least one unit of FFP during the study year. The data indicates that for males aged
40-49 years there are large, outlying values for FFP use that could cause FFP use overall to be
misinterpreted.
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Table 7.8 Population transfused with fresh frozen plasma by age group
Age group TDR (%) Patients (%) TDR / FFP units (%) FFP units/
Years n=2,171 n=1,266 Patient n=9,446 Patient *
0-9 44 (2.0) 34 (2.7) 1.3 62 (0.7) 1.8
10-19 42(1.9) 27 (2.1) 1.6 142(1.5) 5.3
20-29 91 (4.2) 49 (3.9) 1.9 490 (5.2) 10.0
30-39 151 (7.0) 77 (6.1) 2.0 622 (6.6) 8.1
40-49 451 (20.8) 133(10.5) 3.4 2,694 (28.5) 20.3
50-59 336 (15.5) 181 (14.3) 1.9 1,501 (15.9) 8.3
60-69 442 (20.4) 287 (22.7) 1.5 1,902 (20.1) 6.6
70-79 439 (20.2) 336 (26.5) 1.3 1,515(16.0) 4.5
80-89 164 (7.6) 134(10.6) 1.2 490 (5.2) 3.7
90+ 11 (0.5) 8 (0.6) 1.4 28 (0.3) 3.5
* Average intensity of transfusion (units per patient per year) per age group
The outlying values for FFP use per patient are 76 units, 145 units and 1,776 units: the
patients were also transfused with a total of 112 red blood cell units, five platelet units and
ten cryoprecipitate units. Together the three patients had 255 transfusion day records of
units used and 19 SMR01-CD records. One patient had a primary diagnosis codes (ICD-10),
in their first SMR01-CD record in the study database, for chronic renal failure and
unspecified renal failure; another patient was diagnosed with thrombotic microangiopathy;
the third was diagnosed with thrombotic microangiopathy and thrombocytopenia. The
respective procedural codes for these patients were: plasma transfusion, upper
gastrointestinal tract endoscopy and total splenectomy. Figures 7.5b and 7.6b report FFP use
by age group and gender with these outliers removed.
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Figure 7.5 Average FFP units used per patient by age group and gender
a. Full study data b. Outliers removed
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79
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Figure 7.6 FFP units used by age group and gender for all Scotland in 2000
a. Full study data b. Outliers removed
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7.4.2. Distribution of intensity of transfusion of fresh frozen plasma
The variation in the number of FFP units used per patient in a year shows that the most
common intensity of transfusion for FFP, received by 27.4% of FFP recipients, was three
units per patient per year, the highest mode of intensity of all blood components in the study
(Table 7.9a). 10.8% of patients transfused with FFP used ten or more units in the year,
accounting for 56.3% of all units of FFP used in the study (Table 7.9b). 35.6% of units were
transfused at an intensity of 50 or more FFP units per patient per year to 15 patients. The
intensity of FFP use is explored further in relation to thrombotic thrombocytopenic purpura,
a condition characterised by abnormal platelet clot formation, for which the normal
treatment protocol implicates high use of FFP transfusion (section 10.5). 89.4% of all patients
in the study were transfused with blood component types other FFP.
Table 7.9a Intensity of fresh frozen plasma use
Units/ FFP units (%) Patients (%)
patient / year n=9,446 n=1,266
1 33 (0.3) 33 (2.6)
2 552 (5.8) 276 (21.8)
3 1,041 (11.0) 347 (27.4)
4 948(10.0) 237 (18.7)
5 270 (2.9) 54 (4.3)
6 480 (5.1) 80 (6.3)
7 245 (2.6) 35 (2.8)
8 320 (3.4) 40 (3.2)
9 243 (2.6) 27 (2.1)
10-19 1,190 (12.6) 94 (7.4)
20-29 495 (5.2) 21 (1.7)
30-39 175(1.9) 5 (0.4)
40-49 91 (1.0) 2 (0.2)
>50 3,363 (35.6) 15(1.2)
Table 7.9b Summary of intensity of FFP use
Intensity 1-4 units 5-9 units >10 units
FFP units (%) n=9,446 27.2 16.5 56.3
FFP recipients (%) n=1,266 70.5 18.7 10.8
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7.5. CRYOPRECIPITATE USE
328 transfusion day records of at least one used unit of cryoprecipitate represent 253 patients
(cryoprecipitate recipients) and 1,759 used cryoprecipitate units in the study dataset. 61.6%
of cryoprecipitate recipients were males who accounted for 62.0% of all cryoprecipitate units
used in the study. Patients transfused with cryoprecipitate also used 2,502 red blood cell
units, 387 platelet units and 1,278 units of fresh frozen plasma. Patients had an average of
1.3 transfusion day records of cryoprecipitate use and average intensity of transfusion of 7.0
units of cryoprecipitate per year. Three cryoprecipitate recipients (1.2% of all cryoprecipitate
recipients) were transfused with cryoprecipitate units only, the lowest proportion for any
blood component (Table 7.2).
7.5.1. Age distribution of cryoprecipitate recipients
The average age of cryoprecipitate recipients was 52.5 years (SD 22.5 years). Variation in
cryoprecipitate use by age group is described in Table 7.10, and is illustrated by age and
gender in Figures 7.7. Further, cryoprecipitate use by age and gender for all of Scotland is
reported, calculated by appropriately applying the rates of cryoprecipitate transfusion to the
population age structure for Scotland for 2000 (Figure 7.8). As for all other blood component
types, age group 70-79 years accounted for the largest proportion of cryoprecipitate
recipients (20.2%) and this was the age group that used the largest proportion (24.0%) of
cryoprecipitate units. Patients in age band 20-29 years were transfused at the highest
intensity of cryoprecipitate units per patient per year (13.9), and accounted for 15.7% of
cryoprecipitate units used.
The data reported in Table 7.10, and Figures 7.7a and 7.8a, includes all patients transfused
with at least one unit of cryoprecipitate during the study year. The data indicates areas
where there are outlying values for cryoprecipitate use which could lead to the
misinterpretation of cryoprecipitate use overall. For males in age group 20-29 the highest
number of cryoprecipitate units used per patient was 95. The next highest in this age-sex
group was 30 cryoprecipitate units. Figures 7.7b and 7.8b report cryoprecipitate use by age
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group and gender with the data for this one patient, identified as a high cryoprecipitate user,
removed. This patient had 17 SMR01-CD records and 27 transfusion day records of units
used and was also transfused with 47 red blood cell units and three FFP units. The first
primary diagnosis (ICD-10) recorded in the study dataset (patient's second SMR01 record in
2000) was polyarteritis nodosa, an autoimmune condition characterised by inflammation of
blood vessels notably affecting the skin, liver, heart and kidneys. During that admission the
patient also underwent a kidney biopsy procedure.
Table 7.10 Population transfused with cryoprecipitate by age group
Age group TDR (%) Patients (%) TDR / CRYO units (%) CRYO units/
Years n=328 n=253 Patient n=1,759 Patient *
0-9 21 (6.4) 17(6.7) 1.2 34(1.9) 2.0
10-19 8 (2.4) 8 (3.2) 1.0 57 (3.2) 7.1
20-29 36 (11.0) 20 (7.9) 1.8 277(15.7) 13.9
30-39 28 (8.5) 24 (9.5) 1.2 146 (8.3) 6.1
40-49 38 (11.6) 31 (12.3) 1.2 147 (8.4) 4.7
50-59 45(13.7) 39(15.4) 1.2 184(10.5) 4.7
60-69 63 (19.2) 44(17.4) 1.4 345(19.6) 7.8
70-79 67 (20.4) 51 (20.2) 1.3 423 (24.0) 8.3
80-89 21 (6.4) 18 (7.1) 1.2 145 (8.2) 8.1
90+ 1 (0.3) 1 (0.4) 1.0 1 (0.1) 1.0
* Average intensity of transfusion (units per patient per year) per age group
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Figure 7.7 Average cryoprecipitate units used per patient by age group and gender
a. Full study data b. Outlier removed
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Figure 7.8 Cryoprecipitate units used by age group and gender for all Scotland in
2000
a. Full study data b. Outlier removed
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7.5.2. Distribution of intensity of cryoprecipitate use
Intensity of cryoprecipitate transfusion is reported in Table 7.11a. The most common
intensity of transfusion, representing 38.3% of patients, was one cryoprecipitate unit per
patient per year. 25.3% of patients used ten units of cryoprecipitate per patient per year,
representing the largest share (36.4%) of cryoprecipitate units used in the study. Like the
distribution of transfusion intensity for all other blood components, a large proportion of
units was used by an intensely transfused minority: 82.1% of cryoprecipitate units were
transfused at an intensity of ten or more units per patient per year to 37.6% of
cryoprecipitate recipients (Table 7.11b). The mode number of units per transfusion day
record and mode number of units per patient for cryoprecipitate use regardless of other
blood component units used is one, and for cryoprecipitate use alone is 10 suggesting that
when patients receive cryoprecipitate units only they receive many more units when
compared to patients transfused with cryoprecipitate units who may also receive other
blood components (Table 7.2). This disparity may represent the transfusion of
cryoprecipitate units for different clinical reasons. 97.9% of patients in the study did not
receive cryoprecipitate transfusion.
Table 7.11a Intensity of cryoprecipitate use
Units/ CRYO units (%) Patients (%)
patient / year n=1,759 n=253
1 97 (5.5) 97 (38.3)
2 56 (3.2) 28 (11.1)
3 27 (1.5) 9 (3.6)
4 32 (1.8) 8 (3.2)
5 10 (0.6) 2 (0.8)
6 54 (3.1) 9 (3.6)
7 14 (0.8) 2 (0.8)
8 24 (1.4) 3(1.2)
10 640 (36.4) 64 (25.3)
11-19 165 (9.4) 12(4.7)
20 200(11.4) 10(4.0)
>21 440 (25.0) 9 (3.6)
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Table 7.11b Summary of intensity of cryoprecipitate use
Intensity 1-4 units 5-9 units £10 units
Cryoprecipitate units (%) n=1,759 12.1% 5.8% 82.1%
Cryoprecipitate recipients (%) n=253 56.1% 6.3% 37.6%
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7.6. Overview of blood component use
The findings reported here in Chapter 7 address the objective of analysing the demographics
of patients transfused with each blood component for the study population in order to show
that the study dataset can be utilised in this way. Here the demographics of transfusion
recipients and the use of blood component units for the sub-groups of recipients by blood
component type are described.
The findings identify high users by age group and gender as well as individual patients with
blood component use considered to be of outlying value in comparison with rates by age
and gender overall. Further, the number of units used per age group and gender was
applied to the appropriate proportion of transfusion population for the population age
structure of Scotland in the year 2000 to quantify the population's use of blood by age and
gender.
Table 7.12 Summary of intensity of transfusion for each blood component
Transfusion day records of units used
Statistic
RBC PLT FFP CRYO
Modal intensity (units used per patient per year) 2 1 3 1
Percentage of units transfused 13.4 15.7 11.0 5.5
Percentage of patients transfused 34.8 53.0 27.4 38.3
Intensity level < 10 units per patient per year
Percentage of units transfused 57.7 57.6 43.7 17.9
Percentage of patients transfused 88.7 93.2 89.2 62.4
Intensity level ^10 units per patient per year
Percentage of units transfused 42.3 42.4 56.3 82.1
Percentage of patients transfused 11.3 6.8 10.8 37.5
Distributions of patients and units by intensity of transfusion are summarised for the
proportion of patients and units transfused for the mode intensity, for the intensity level of
ten or more units per patient per year, and the intensity level of less than ten units per
patient per year, for each blood component (Table 7.12). The findings show that for the
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mode intensity, that is, the most common number of units used per patient per year, the
proportion of patients transfused at this level is greater than the proportion of units used
whereas for intensity level ten or more units per patient per year the proportion of units
used is greater than the proportion of patients transfused at this level. In summary, this
indicates that many patients are transfused at a low intensity and the total units accounted
for is small, and conversely, few people are transfused intensively accounting for a large
proportion of the units used.
The findings of analyses of blood use by clinical case group, specifically, surgical red cell
using procedures (Chapter 8) and by haematological conditions (Chapter 9), are described
and illustrated in subsequent chapters.
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8. RESULTS: RULE FOR ATTRIBUTING BLOOD USE TO SURGICAL
PROCEDURE CASE GROUPS
8.1. Introduction
The findings reported in previous chapters (Chapters 6 and 7) have shown that transfusion
day records and SMR01-CD records can be linked to create a dataset that can be used to
describe the groups of patients who use blood components. Further, this study aimed to
utilise the dataset to describe the use of blood by clinical case groups that represent the
clinical reasons that are likely to explain the patient's underlying requirement for red blood
cell transfusion. The specific methods employed were described in full elsewhere (section
5.3.1).
Previous published reports described the use of blood for various categories of surgical
intervention and stated surgery to be a notable area of blood use. The development of
strategies for the conservation of red blood cell use, such as the implementation of MSBOS,
support the assessment of blood use for surgical events as an important requirement for
informing the clinical and transfusion practice. As such a surgical blood attribution rule
incorporating temporal and clinical factors was defined and validated for use in attributing
transfusion day records of red blood cell units used to specified red cell using procedures
(Table 5.4). The attribution was made if the date of transfusion fell during the period
starting seven days prior to admission and ending on the date of discharge and if the
SMR01-CD record that satisfied that date rule contained a coding for a red cell using
procedure specified for this study.
The findings reported here describe red blood cell use for transfusion day records that can
be attributed to only one red cell using procedure (section 8.2) and red blood cell use for
transfusion day records that can be attributed to more than one red cell using procedure,
that is, the findings of the investigations into inter-episode competition (section 8.3). Finally
an overview of all results is provided in which instances of inter-episode competition were
resolved according to the surgical blood attribution rules (section 8.4).
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In total the study dataset contained 22,471 transfusion day records of red blood cell units
used (85.5% of all transfusion day records of any component use) that represented 11,567
patients. A summary of the number of transfusion day records of red blood cell units used,
patients and red blood cell units used, as well as patient demographics for the different
subgroups of findings just described (and reported in the following sections) is given in
Table 8.1. Data for transfusion day records of red blood cell use that can be attributed to one
red cell using procedure and those that can be attributed to more than one red cell using
procedure are reported both separately and combined, along with the data for transfusion
day records of red blood cell use that cannot be attributed to any red cell using procedure in
this study.
Table 8.1 Summary of findings for the attribution of blood to red cell using
procedures
Attributed by surgical blood attribution rule to ...
Statistic One RBC More than 1 RBC One or more RBC No RBC
using procedure using procedure using procedures using
(section 8.2) (section 8.3) (section 8.4) procedures
Patients 4,282 28 4,293 7,790
Transfusion day records 5,841 41 5,882 16,589
Sex (% male) 48.7 61.0 48.8 50.9
Age in years (range) 0-101.1 2.7-88.4 0-101.1 0-101.4
Age in years (mean, SD) 67.1, 16.2 50.6, 22.3 67.0, 16.3 61.6, 22.3
RBC units used 17,122 281 17,403 42,727
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8.2. Red blood cell use attributed to a single SMR01-CD record that contains a
red cell using procedure
Table 8.2 Red blood cell use by procedure where blood can be attributed to a single
SMR01-CD record containing a red cell using procedure









Open bypass graft operations (minus revisions) 3,634 (21.2) 1,240 (21.2) 2.9
Total hip replacement (minus revisions) 1,766 (10.3) 800 (13.7) 2.2
Operations on valves of heart and adjacent structures 1,383 (8.1) 395 (6.8) 3.5
Open reduction of fracture 1,294 (7.6) 512 (8.8) 2.5
Excision of colon 1,279 (7.5) 462 (7.9) 2.8
Other operations on aorta 950 (5.5) 240 (4.1) 4.0
Closed reduction of fracture 947 (5.5) 366 (6.3) 2.6
Emergency replacement of aneurysmal segment of aorta 843 (4.9) 112(1.9) 7.5
Excision of rectum 762 (4.5) 268 (4.6) 2.8
Total hip replacement revisions 731 (4.3) 230 (3.9) 3.2
Total knee replacement (minus revisions) 522 (3.0) 243 (4.2) 2.1
Replacement of head of femur 483 (2.8) 236 (4.0) 2.0
Hysterectomy 421 (2.5) 152(2.6) 2.8
Transplantation of liver 395 (2.3) 44 (0.8) 9.0
Other open operations on kidney 307 (1.8) 97 (1.7) 3.2
Partial excision of liver 280(1.6) 55 (0.9) 5.1
Open operations on oesophagus 277(1.6) 102(1.7) 2.7
Operations on tissue of brain 272 (1.6) 75(1.3) 3.6
Excision of lung 120 (0.7) 55 (0.9) 2.2
Open operations on prostate 116(0.7) 35 (0.6) 3.3
Total knee replacement revisions 97 (0.6) 42 (0.7) 2.3
Transplantation of kidney 84(0.5) 25 (0.4) 3.4
Open bypass graft operations revisions 58 (0.3) 14 (0.2) 4.1
Reconstruction of renal artery 54(0.3) 19(0.3) 2.8
Other operations on lung 23 (0.1) 12(0.2) 1.9
Operations on thyroid or parathyroid glands 21 (0.1) 8(0.1) 2.6
Open extirpation of lesion of lung 3 (<0.1) 2 (<0.1) 1.5
Note: Transplantation of heart (including transplantation of heart and lung) not coded in any SMR01-CD record in
study dataset and so blood component use could not be attributed to that procedural case group
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5,841 transfusion day records of red blood cell use could be attributed to a single SMR01-CD
record that contained a red cell using procedure. These events accounted for 17,122 red
blood cell units used (28.5% of used red blood cell units in the study dataset) and relate to
4,282 patients with an average age of 67.1 years (SD 16.2, range 0-101.1 years) and of whom
48.7% are male (Table 8.1). The results for the number of red blood cell units used, number
of transfusion day records and red blood cell units used per transfusion day record where
blood can be attributed to a single red cell using procedure are reported in Table 8.2. In this
analysis the largest proportion of blood was attributed to primary open bypass graft
operations (excluding revisions) (21.2% of RBC units attributed to a single red cell using
procedure). The highest value for the average number of red blood cell units used per
transfusion day record was 9.0 units, for liver transplant procedures (Table 8.2).
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8.3. Red blood cell use attributed to two competing SMR01-CD records that
each contains a red cell using procedure
By applying the surgical blood attribution rule to the study dataset there was the potential
for a transfusion day record of red blood cell units used to be linked with more than one
SMR01-CD record that contained a red cell using procedure: the extent to which such inter-
episode competition (Figure 5.4) occurred in the study was assessed and the results reported
here.
41 transfusion day records of red blood cell use were attributed to more than one SMR01-CD
record that contained a red cell using procedure and in all cases each transfusion day record
was attributed to two SMR01-CD records, thereby being attributed to two red cell using
procedures. These cases of inter-episode competition represented 28 patients with an
average age of 50.6 years (SD 22.3, range 2.7-88.4 years) and of whom 61.0% are male:
patients was younger and had a higher proportion of males than the group of patients for
whom transfusion day records were attributed to a single red cell using procedure (Table
8.1). Red blood cell use by the first occurring red cell using procedure is reported (Table 8.3)
and is explored in further detail by combination of competing procedures (Table 8.4).
Table 8.3 Red blood cell use by procedure for cases of inter-episode competition: by
patient's first occurring red cell using procedure









Other operations on aorta 79 (28.1) 6 (14.6) 13.2
Open of reduction fracture 71 (25.3) 7(17.1) 10.1
Transplantation of liver 52(18.5) 6(14.6) 8.7
Operations on tissue of brain 36(12.8) 7(17.1) 5.1
Excision of rectum 10 (3.6) 1 (2.4) 10.0
Excision of colon 9(3.2) 3 (7.3) 3.0
Operations on valves of heart and adjacent structures 8 (2.8) 2 (4.9) 4.0
Open operations on oesophagus 4(1.4) 2 (4.9) 2.0
Closed of reduction fracture 4(1.4) 2 (4.9) 2.0
Total hip replacement (minus revisions) 2 (0.7) 2 (4.9) 1.0
Total knee replacement (minus revisions) 2 (0.7) 1 (2.4) 2.0
Open bypass graft operations (minus revisions) 2 (0.7) 1 (2.4) 2.0
Hysterectomy 2 (0.7) 1 (2.4) 2.0
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Table 8.4 Red blood cell use by procedure for cases of inter-episode competition: by
combination of competing procedures
RBC units used TDR
Red cell using procedure combinations (% RBC use) (%TDR)
n=281 n=41
Two procedures are the same
Open reduction of fracture 71 (25.3) 7(17.1) 10.1
Transplantation of liver 39(13.9) 3 (7.3) 13.0
Other operations on aorta 9 (3.2) 2 (4.9) 4.5
Operations on valves of heart and adjacent structures 8 (2.8) 2 (4.9) 4.0
Open operations on oesophagus 4(1.4) 2 (4.9) 2.0
Total hip replacement (minus revisions) 3(1.1) 2 (4.9) 1.5
Excision of colon 3(1.1) 1 (2.4) 3.0
Operations on tissue of brain 3(1.1) 1 (2.4) 3.0
Subtotal (Two procedures are the same) 140 (49.8) 20 (48.8)
Two procedures are related
Excision of colon / Excision of rectum 6(2.1) 2 (4.9) 3.0
Closed reduction fracture / Open reduction fracture 4(1.4) 2(4.9) 2.0
Total hip replacement (minus revisions) /
Total hip replacement revisions
1 (0.4) 1 (2.4) 1.0
Subtotal (Two procedures are related) 11 (3.9) 5(12.2)
Two procedures are not related
Other operations on aorta / Excision of colon 41 (14.6) 2(4.9) 20.5
Other operations on aorta / Excision of rectum 39 (13.9) 3(7.3) 13.0
Operations on tissue of brain / Transplantation of liver 33(11.7) 6 (14.6) 5.5
Operations on tissue of brain / Open reduction of fracture 13(4.6) 3 (7.3) 4.3
Open bypass graft operations (minus revisions) /
Excision of colon
2 (0.7) 1 (2.4) 2.0
Hysterectomy / Excision of rectum 2 (0.7) 1 (2.4) 2.0
Subtotal (Two procedures are not related) 130 (46.3) 16 (39.0)
Cases of inter-episode competition between red cell using procedures accounted for 281
used red blood cell units which equates to 1.6% of all red blood cell units attributed to red
cell using procedures and 0.5% of all red blood cell units used in the study. For three red cell
using procedures, the number of red blood cell units used per transfusion day record in
cases of competition (when procedure was the first red cell using procedure) was much
higher than the number of red blood cell units used per transfusion day record when no
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competition arose: these were "operations on aorta" (13.2 versus 4.0 RBC units per TDR),
"open reduction of fracture" (10.1 versus 2.5 RBC units per TDR) and "excision of rectum"
(10.0 versus 2.8 RBC units per TDR) (Tables 8.2 & 8.3). Similarly, there were two
combinations of procedures for which the number of red blood cell units used per
transfusion day record was much higher than for the procedures involved when there was
no competition: these are, competition between "other operations on aorta" and "excision of
colon" (20.5 versus 4.0 or 2.8 RBC per TDR), and competition between "other operations on
aorta" and "excision of rectum" (13.0 versus 4.0 or 2.8 RBC per TDR), than (Table 8.4).
There were eight different combinations of procedures where the two competing red cell
using procedures were in fact the same and competition could evidently be resolved (Table
8.4). These examples accounted for 20 transfusion day records and the use of 140 red blood
cell units thereby effectively reducing the number of red blood cell units attributed to
competing procedures to 141 (0.8% of red blood cell units attributed to red cell using
procedures). There were a further three combinations where the two competing procedures
were within the same specialty or could be otherwise related to each other in terms of
anatomical site, for example, "excision of colon" and "excision of rectum" are both related to
the gastrointestinal tract. If it was considered appropriate to combine competing procedures
such as these into single red cell using procedure case groups reflecting the relevant
specialty and/or anatomical site then the number of used red blood cell units attributed to
competing procedures could be reduced to 130 (0.7% of red blood cell units attributed to red
cell using procedures). For the remaining combinations of competing procedures the red
cell using procedures could not be instantly or intuitively related to one another and inter-
episode competition was considered to be irresolvable.
By addressing inter-episode competition in this way a maximum of 99.3% of used red blood
cell units attributed to red cell using procedures could potentially be attributed to a single
red cell using procedure case group or related surgical group that may have to be redefined.
This result indicates that the issue of competing red blood cell using procedures does not
have a large influence on the overall quantification of red cell use in surgery. Therefore, the
initial suggestion that transfusion day records be attributed to the first occurring red cell
using procedure to satisfy the surgical blood attribution rule was accepted and utilised in
subsequent analyses using the surgical blood attribution rule (section 8.4).
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8.4. Overview of results for attribution of blood to surgical case groups
The findings reported in this section describe the overall use of red blood cell units in
relation to the number of operations performed for the specific group of red cell using
procedures defined for this study. Table 8.5 and Figure 8.1 report the overall distribution of
the 17,403 transfused red blood cell units that could be attributed to red cell using
procedures according to the surgical blood attribution rule defined in this study. In Figure
8.1 the data is reported by surgical category rather than individual procedure.
A total of 5,882 transfusion day records of used red blood cell units, representing 28.9% of
the red blood cell units used in the study, could be attributed to red cell using procedures
according to the surgical blood attribution rule. In addition, 11.5% of platelet units, and
20.0% of fresh frozen plasma and cryoprecipitate units combined were recorded as
transfused in these transfusion day records. 42,727 used red blood cell units could not be
attributed to any red cell using procedure by the surgical blood attribution rule.
As was demonstrated in the previous sections the majority of transfusion day records could
be attributed to just one red cell using procedure but for a small number there was inter-
episode competition between two red blood cell using procedures. The surgical blood
attribution rule accounted for competition by attributing red blood cell units to the first red
cell using surgical procedure that occurs in the first occurring SMR01-CD record
(chronologically) that satisfies the temporal part of the surgical blood attribution rule.
Investigation of the nature of competing red cell using procedures was examined and in
most cases the competing procedures were the same, or were of similar specialty or
anatomical site. By considering these combinations as a single procedural case group, the
number of used red blood cell units accounted for by inter-episode competition was just
0.7% of all used red blood cell units attributed to surgical procedures.
The number of operations reported in Table 8.5 is the number of individual procedures
carried out during the year 2000 for the relevant study population. These figures were
obtained from the denominator data selected from the file of all SMR01-CD records for the
whole of Scotland in the year 2000 (ISD, online). The denominator file contains all year 2000
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SMR01-CD records (regardless of whether the individual patients could be linked to a
transfusion record) for hospitals for which the majority of transfusion events were included
in the study dataset. Hospitals for which a small number of transfusion day records
appeared in the dataset due to assignments of specially typed blood component units were
not included in the denominator file because including them would cause the number of
operations performed for the denominator population to be overestimated and would
subsequently underestimate the proportion of operations transfused. The number of
operations is the number of SMR01-CD records that contain a coding of the relevant
procedures: that is, in cases where a single procedure is coded more than once in an SMR01-
CD record the procedure is accounted for once and is counted as one operation. The number
of red blood cell units used per operation gives an indication of the average rate of
transfusion for each procedure, for example, transplant of liver (10.2 red blood cell units per
operation performed) appears to be more heavily transfused on average than total hip
replacement (1.1 units per operation performed), though more red blood cell units are used
overall for total hip replacements because more of them are performed.
The findings reported here demonstrate that the surgical blood attribution rule defined for
the study can successfully attribute the use of red blood cell units to specified surgical case
groups that are likely to represent the underlying clinical indication that explains why the
patient was transfused. By surgical category mapped roughly to surgical specialty the main
areas of red blood cell use are the cardiac and circulatory (41%) and orthopaedic (34%)
specialties; the next largest are gastroenterology (13%) and abdominal organs (6%) (Figure
8.1).
The next chapter presents the data for the use of use of blood for chronic haematological
conditions hypothesised to be another well-defined set of clinical case groups that can
explain a further appreciable proportion of blood use for the study population (Chapter 9).
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Table 8.5 Overall results for red blood cell use per operation for red blood cell
using procedures









Transplantation of liver 447 (2.6) 44 (0.3) 10.2
Emergency replacement of aneurysmal segment of aorta 843 (4.8) 104 (0.7) 8.1
Other operations on aorta 1,029 (5.9) 222(1.4) 4.6
Operations on valves of heart and adjacent structures 1,391 (8.0) 332 (2.1) 4.2
Open bypass graft operations revisions 58 (0.3) 16 (0.1) 3.6
Partial excision of liver 280(1.6) 82 (0.5) 3.4
Total hip replacement revisions 731 (4.2) 242 (1.5) 3.0
Open bypass graft operations (minus revisions) 3,636 (20.9) 1,241 (7.9) 2.9
Open operations on prostate 116(0.7) 44 (0.3) 2.6
Open operations on oesophagus 281 (1.6) 171 (1.1) 1.6
Excision of rectum 772 (4.4) 468 (3.0) 1.6
Excision of colon 1,288 (7.4) 837 (5.3) 1.5
Total knee replacement revisions 97 (0.6) 68 (0.4) 1.4
Other open operations on kidney 307(1.8) 227(1.4) 1.4
Operations on tissue of brain 308(1.8) 255 (1.6) 1.2
Total hip replacement (minus revisions) 1,768 (10.2) 1,647(10.5) 1.1
Transplantation of kidney 84 (0.5) 81 (0.5) 1.0
Replacement of head of femur 483 (2.8) 675 (4.3) 0.7
Total knee replacement (minus revisions) 524 (3.0) 1,022 (6.5) 0.5
Excision of lung 120 (0.7) 239(1.5) 0.5
Open reduction of fracture 1,365 (7.8) 2,752(17.6) 0.5
Closed reduction of fracture 951 (5.5) 2,875(18.3) 0.3
Hysterectomy 423 (2.4) 1,292 (8.2) 0.3
Reconstruction of renal artery 54 (0.3) 167(1.1) 0.3
Other operations on lung 23 (0.1) 181 (1.2) 0.1
Open extirpation of lesion of lung 3 (<0.1) 24 (0.2) 0.1
Operations on thyroid or parathyroid glands 21 (0.1) 368 (2.3) 0.1
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n=17,403 red blood cell units
Category Red cell using procedure
Abdominal organs Transplantation of liver Transplantation of kidney
Partial excision of liver Other open operations on kidney
Cardiac & Circulatory Valves & adjacent structures Emergency replacement of aortic aneurysm
Other operations on aorta Open bypass graft operations revisions
Reconstruction of renal artery Open bypass graft operations
(minus revisions)
Neurology & Endocrinology Thyroid or parathyroid Operations on tissue of brain
Gastrointestinal Excision of colon Open operations on oesophagus
Excision of rectum
Male reproductive Open operations on prostate
Obstetrics & Gynaecology Hysterectomy
Orthopaedics Open reduction of fracture Total hip replacement (minus revisions)
Closed reduction of fracture Total hip replacement revisions
Replace head of femur Total knee replacement (minus revisions)
Total knee replacement revisions
Respiratory Excision of lung Open extirpation of lesion of lung
Other operations on lung
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9. RESULTS: RULE FOR ATTRIBUTING BLOOD USE TO PATIENTS
WITH HAEMATOLOGICAL CONDITIONS
9.1. Introduction
In Chapter 8 red blood cell use that could be attributed to a group of red cell using
procedures was described: 28.9% of red blood cell units in the study dataset were attributed
to surgical events. In this chapter the use of blood for diagnostic case groups that may
necessitate a high requirement for red blood cells and other blood components is reported.
The diagnostic case groups are the malignant haematological conditions lymphoma,
myeloma, and leukaemia, and the pre-malignant haematological conditions myelodysplastic
syndromes (MDS) and polycythaemia vera (PCV). The blood attribution rule devised for
this group of conditions attributed all transfusion events in the study period, that belong to a
patient, to one of the haematological case groups if the patient had a coding of one of the
specified haematological conditions in any ICD-10 variable at any time during the study
period (section 5.3.2). In the event that a patient was diagnosed with more than one of these
conditions, blood use was attributed to the first such diagnosis in the patient's SMR01-CD
records occurring chronologically during the study period.
The findings of analyses of red blood cell use that could be attributed to a haematological
case group (section 9.2) and specifically more than one different haematological case group
during the study year (section 9.3) are reported here.
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9.2. Blood component use linked to patientswith diagnoses of malignant
and pre-malignant haematological conditions
726 patients with a diagnosis of a pre-malignant or malignant haematological condition
could be linked with at least one transfusion day record of used blood component units. The
characteristics of patients diagnosed with each condition (referred to as haematological
patients, herein) are reported in Table 9.1. Results are reported by patients' first
haematological diagnosis in the study which for most cases was the only specified
haematological condition that was diagnosed during the study. The patients who were
diagnosed with more than one type of haematological condition are explored separately
(section 9.3).
The number of SMR01-CD records linked to patients with haematological conditions was
quantified in two ways: the total number of SMR01-CD records linked to patients with
diagnoses of haematological conditions and the number of SMR01-CD records that
contained a coding of a haematological diagnosis. 88.3% of haematological patients' total
SMR01-CD records for the year 2000 contain an actual haematological diagnosis. This view
of the data is indicative of the hospital activity prior to diagnosis (or potentially following
resolution of the relevant condition).
The largest group of haematological patients was those diagnosed with leukaemia.
Leukaemia accounted for 36% of all haematological patients, 50.1% of transfusion day
records and 39.7% of SMR01-CD records that can be related to haematological diagnoses.
Leukaemia patients had the highest proportion of males and the highest average number of
transfusion day records per patient. Because of this finding leukaemia patients were
assessed separately by type of leukaemia: the two predominant types being lymphoid and
myeloid leukaemia (Table 9.2). Patients in the study who were diagnosed with lymphoid
leukaemia had on average more inpatient hospital admissions (SMR01-CD records) than
others and myeloid leukaemia patients accounted for more transfusion day records.
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Table 9.1 Characteristics of patients with a diagnosis of a malignant or pre-
malignant haematological condition
All
conditions Lymphoma Myeloma Leukaemia MDS/PCV
Patients 726 196 126 261 143
Transfusion day records 4,584 964 427 2,324 869
SMR01-CD records (total) 7,063 2,149 1,107 2,731 1,076
SMR01-CD records (haematological) 6,235 1,961 1,033 2,496 745
Sex* (% male) 54.3 49.5 48.4 62.8 50.3
Age* in years (range) 0.8-97.2 4.6-93.0 31.1-93.7 0.8-93.9 19.7-97.2
Age in years (mean, SD) 64.2, 21.4 61.5,18.0 70.8, 11.5 56.1,26.5 76.6,13.1
TDR per patient (range) 1-105 1-49 1-19 1-105 1-62
TDR per patient (mean, SD) 6.31, 9.68 4.92, 6.50 3.39, 3.33 8.90, 12.8 6.10, 9.49
SMR01-CD per patient (range) 1-123 1-80 1-36 1-123 1-50
SMR01-CD per patient (mean, SD) 9.73, 11.5 11.0,12.8 8.79, 6.88 10.5, 13.6 7.52, 7.44
MDS: myelodysplastic syndromes. PCV: polycythaemia vera. * Sex and age by patient















Lymphoid leukaemia 134 722 5.4 1,494 1,610
Myeloid leukaemia 116 1,497 12.9 939 1,012
Other leukaemias of
specified cell type
5 24 4.8 7 34
Other leukaemias of
unspecified cell type
6 81 13.5 56 75
A total of 4,584 transfusion day records representing 7,286 used red blood cell units (12.1%
of red blood cell units used in study), 2,299 (47.9%) used platelet units, 168 (1.8%) used fresh
frozen plasma units and 144 (8.2%) used units of cryoprecipitate could be attributed to the
haematological conditions (Table 9.3). Of the 7,286 red blood cell units used 107 (1.5%)
could also be attributed to a red cell using procedure as defined for the surgical blood
attribution rule (Chapter 8). Blood component use for leukaemia patients by specific type of
leukaemia is reported separately in Table 9.4.
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Table 9.3 Blood component use for patients with a haematological diagnosis: by












Lymphoma 1,639 452 20 1 2,112
Myeloma 953 66 10 20 1,049
Leukaemia * 2,778 1,533 118 113 4,542
MDS/PCV 1,916 248 20 10 2,194
* Blood use by sub-division of Leukaemia reported in Table 9.4
Table 9.4 Blood component use for patients diagnosed with leukaemia by specific













Lymphoid leukaemia 1,059 388 38 14 1,499
Myeloid leukaemia 1,541 1,106 80 99 2,826
Other leukaemias of
specified cell type
65 0 0 0 65
Other leukaemias of
unspecified cell type
113 39 0 0 152
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9.3. Blood component use linked to patients with more than one type of pre-
malignant or malignant haematological condition
33 transfusion recipients were diagnosed with more than one type of haematological
condition during the study period: they accounted for 264 transfusion day records and 434
SMR01-CD records of which 376 contained an actual haematological diagnosis (Tables 9.5 &
9.6). All available SMR01-CD records for the year 2000 for the patients with more than one
haematological diagnosis were examined to gain an insight into how the combinations of
diagnoses occur and in order to determine whether combinations are clinically relevant. The
illustrated examples show how the diagnoses made in SMR01 records change over time and
how they relate to the cause of death (Figure 9.1).















Lymphoma 8 66 8.3 122 126
Myeloma 3 8 2.7 29 31
Leukaemia 6 45 7.5 95 99
MDS/PCV 16 145 9.1 130 178
Table 9.6 Patients with more than one type of haematological condition diagnosed:















Leukaemia & Myeloma 4 15 3.8 92 91
Lymphoma & Leukaemia 8 41 5.1 91 88
Lymphoma & MDS/PCV 2 34 17.0 12 10
Myeloma & MDS/PCV 2 4 2.0 20 18
Leukaemia & MDS/PCV 17 170 10.0 219 169
* Order reported in table does not reflect order in SMR01-CD records i.e. leukaemia & myeloma does
not relate only to situations where leukaemia is the diagnosis made before myeloma, rather includes all
instances of leukaemia & myeloma or myeloma & leukaemia combined diagnoses.
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In the first example, the patient had four consultant episodes within a period of 44 days and
received a total of 14 red blood cell units. The diagnosis reported in the SMR01 records of
the first three consultant episodes was classified in this study as lymphoma, which changed
to leukaemia in the fourth consultant episode. However, the fourth consultant episode
finished when the patient died at which point the cause of death was recorded as
unspecified peripheral & cutaneous T-cell lymphomas. The difference between the
diagnoses could reflect uncertainties in classifying the diagnosis or reflect perceived changes
in the manifestation of the disease as the condition progresses. Uncertainty or a true
inability to classify the condition is alluded to in that the specific cause of death is reported
to be of unspecified type.
The second example illustrates a patient who had six consultant episodes over a four month
period during which time the patient was transfused with 17 units of red blood cells. The
diagnosis reported during the first four consultant episodes was classified in this study as
"myelodysplastic syndromes or polycythaemia vera", the pre-malignant haematological
conditions. The diagnosis changed to leukaemia in the final two consultant episodes and the
cause of death recorded one month later was unspecified myelodysplastic syndrome.
Myelodysplastic syndromes (at one time referred to clinically as preleukaemia) variably
transforms and progresses to acute myeloid leukaemia, thus the changing diagnoses
reported in SMR01 records are likely to be reasonable.
Finally, the third example is of a patient who had several consultant episodes throughout the
course of almost eight months ending with the death of the patient. In the first ten
consultant episodes the recorded diagnosis was classified as myeloma, in the eleventh and
final consultant episode the diagnosis was reported as lymphoma and the cause of death
was recorded as plasma cell leukaemia. The changes in diagnoses are clinically intuitive as
plasma cell leukaemia is related to multiple myeloma, another form of cancer that affects
plasma cells: approximately one in 50 myeloma patients will eventually develop a leukaemia
transformation (Leukaemia Research Foundation, online).
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Figure 9.1 Examples of patient with more than one type of haematological condition
Example a.
Units used Date of admission Date of Discharge Haematological diagnosis
5 RBC 02 June 2000 10 June 2000 Lymphoma
2 RBC 20 June 2000 21 June 2000 Lymphoma
4 RBC 27 June 2000 29 June 2000 Lymphoma
06 July 2000 16 July 2000 Leukaemia
Date and cause of death 16 July 2000 Peripheral & cutaneous T-
cell lymphomas, unspecified
Example b.
Units used Date of admission Date of Discharge Haematological diagnosis
3 RBC 12 January 2000 21 January 2000 MDS/PCV
4 RBC 03 February 2000 04 February 2000 MDS/PCV
3 RBC 02 March 2000 04 March 2000 MDS/PCV
3 RBC 20 March 2000 21 March 2000 MDS/PCV
04 April 2000 13 May 2000 Leukaemia
4 RBC 11 April 2000 14 April 2000 Leukaemia
Date and cause of death 13 May 2000 Acute myeloid leukaemia
Example c.
Units used Date of admission Date of Discharge Haematoiogical diagnosis
4 RBC 06 March 2000 08 March 2000 Myeloma
08 March 2000 31 March 2000 Myeloma
06 April 2000 11 April 2000 Myeloma
3 RBC 16 April 2000 19 April 2000 Myeloma
20 April 02 May 2000 Myeloma
23 May 2000 23 May 2000 Myeloma
29 June 2000 29 June 2000 Myeloma
24 July 2000 27 July 2000 Myeloma
3 RBC 29 July 2000 10 August 2000 Myeloma
4 RBC 25 September 2000 03 October 2000 Myeloma
17 October 2000 30 October 2000 Lymphoma
Date and cause of death 30 October 2000 Plasma cell leukaemia
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The numbers of transfusion day records and SMR01-CD records that were linked to patients
with more than one type of haematological condition diagnosed during the study are
reported by first diagnosis (Table 9.5) and by combination of diagnoses (Table 9.6). If
reported by first diagnosis most patients (16 out of 33) are classified in the myelodysplastic
syndromes or polycythaemia vera case group (MDS/PCV). The findings indicate that all
types of haematological condition defined here are found to be diagnosed in combination
with MDS/PCV, the most common combination of case groups being leukaemia and
MDS/PCV. Further, these findings support the descriptive investigations of SMR01-CD
records described here (Figure 9.1). These combinations of diagnoses are considered to be
reasonable given that MDS and PCV are pre-malignant conditions. However, the data does
suggest that to classify patients by their first haematological diagnosis during the study will
potentially overestimate blood use for MDS/PCV conditions and underestimate for the other
conditions where a subsequent diagnosis of lymphoma, myeloma or leukaemia is made.
The small number of patients who were diagnosed with more than one type of
haematological condition in the year 2000 represented a small amount of blood component
use: 1.4% of red blood cell units, 2.0% of platelet units, 1.2% of FFP units and 0.7% of
cryoprecipitate units that were attributed overall to haematological conditions. The findings
for blood component use by first diagnosis and by combination of haematological diagnoses
are reported in Tables 9.7 and 9.8.
Table 9.7 Blood component use for patients with more than one type of
haematological condition diagnosed: by patients' first recorded diagnosis
Diagnosis
RBC units PLT units FFP units CRY units All units
n=399 n=131 n=0 n=0 n=530
Lymphoma 107 23 0 0 130
Myeloma 24 0 0 0 24
Leukaemia 44 28 0 0 72
MDS/PCV 224 80 0 0 304
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Table 9.8 Blood component use for patients with more than one type of
haematological condition diagnosed: by combination of diagnosis
Diagnosis RBC units PLT units FFP units CRY units All units
combinations * n=399 n=131 n=0 n=0 n=530
Leukaemia & Myeloma 30 2 0 0 32
Lymphoma & Leukaemia 49 27 0 0 76
Lymphoma & MDS/PCV 60 7 0 0 67
Myeloma & MDS/PCV 10 0 0 0 10
Leukaemia & MDS/PCV 250 95 0 0 345
* Order reported in table does not reflect order in SMR01-CD records i.e. leukaemia & myeloma
does not relate only to situations where leukaemia is the diagnosis made before myeloma, rather
includes all instances of leukaemia & myeloma or myeloma & leukaemia combined diagnoses.
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9.4. Overview of results for attribution of blood to Haematological case
groups
This chapter reports on blood use for a small group of haematological diagnoses that were
identified as representing the underlying clinical reason to explain why the patient was
transfused, irrespective of other diagnoses and surgical procedures, because they are chronic
diseases of the blood and blood forming organs for which blood transfusion is a usual
treatment. The diagnostic blood attribution rule devised for the study states that all units of
red blood cells transfused to a patient in the one year study period be attributed to the
haematological diagnosis if the patient had a clinical coding of a diagnoses of malignant
neoplasm of lymphoid or haematopoietic tissue, myelodysplastic syndromes or
polycythaemia vera at any time during the study period. If a patient was diagnosed with
more than one type of haematological condition blood use was attributed to the first such
diagnosis in the patient's SMR01-CD records for the study period. Instances in which a
patient had more than one type of haematological diagnosis were assessed separately but
account for a small percentage of all red blood cell units used by haematological patients.
Figure 9.2 illustrates the overall distribution of the 7,286 red blood cell units (12.1% of total
red blood cell units in the study) used by the 726 patients diagnosed with haematological
conditions in the study population. Further, 47.8% of all platelet units, and 2.8% of all
combined fresh frozen plasma and cryoprecipitate units, were transfused to these patients
(Figure 9.3).
Examination of combinations of haematological diagnoses demonstrated that many
instances were explained by the diagnosis of pre-malignant MDS/PCV conditions in
combination with subsequent diagnoses of lymphoma, myeloma and leukaemia
malignancies. This issue raises again the question as to what ought to be considered as the
underlying reason for transfusion. It could be argued equally for haematological conditions
that the use of blood results from either the treatment for the initial condition or for
subsequent related or supplementary conditions, and even related procedures. However,
because the number of patients implicated is very small and because the combinations of
haematological conditions largely represent clinical progression of disease or similar
underlying clinical requirements, the decision for the purposes of this study to attribute
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blood use to the first occurring haematological diagnosis, echoing the rule for resolution of
competing red cell using procedures, was validated.
In the study denominator data there were 1,061 patients (0.06% of the denominator
population) with SMR01-CD records that contained a haematological diagnosis, as defined
in this chapter. The study dataset contains transfusion data for 726 haematological patients:
that is, approximately 68.4% of haematology patients in the study were transfused. In the
data for all of Scotland for 2000 there were 4,686 patients (0.1% of the total Scottish
population) with SMR01-CD records that contained a haematological diagnosis, a slightly
higher proportion of haematology patients in the population than was described for the
study denominator population. This can be explained because, in terms of haematology
patients particularly, the study data is not representative of the whole of Scotland: in the east
of Scotland one of the major centres for cancer patients is the Western General Hospital
(WGH), Edinburgh, data for which is not included in this study. In the WGH alone, in 2000,
there were 622 patients (13% of all haematological patients identified in all Scotland SMR01-
CD records for 2000).
Furthermore, it was also possible to use the study dataset to quantify the overlap between
surgical and haematological blood use. That is, for patients with diagnoses of
haematological conditions during the study period, the amount of blood that could also be
linked to surgical procedures they may also have had during the study period was
quantified. The overlap of used units was small: 0.2% of red blood cell units, 0.3% of platelet
units, and 0.1% of combined fresh frozen plasma and cryoprecipitate units could be
attributed to both surgical events and haematological diagnoses. Figure 9.3 shows the
distribution of used units of each blood component between the surgical and haematological
case groups, and illustrates for the first time the remainder of used blood component units in
the study dataset that are not attributable to either of the two clinical case groups defined for
the study. The remaining units represent the future stages of analysis of the study dataset
for which new clinical case groups will have to be defined and new approaches considered;
opportunities that are discussed further in section 11.4
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Figure 9.2 Red blood cell units used by haematological condition calculated
according to the diagnostic blood attribution rule
n=7,286 red blood cell units
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10. RESULTS: APPLICATIONS USING STUDY DATASET IN ANALYSES
OF BLOOD COMPONENT USE
10.1. Overview of additional applications using study dataset
The results presented thus far have demonstrated that it is possible to link records from
routine datasets and to use the data to describe blood use for well-defined clinical case
groups. Further, the study dataset can be used to investigate a range of scenarios relating to
the use of blood. The areas investigated here are:
■ Best practice indicator: Total hip replacement surgery (section 10.2)
Intra-operative cell salvage: Primary CABG surgery (section 10.3)
Changes to the demographics of the Scottish population (section 10.4)
Special interest case I: Thrombotic thrombocytopenic purpura (section 10.5)
Special interest case II: Donor exposure (section 10.6)
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10.2. BEST PRACTICE AND THE AGEING POPUALTION: TOTAL HIP REPLACEMENT SURGERY
10.2.1. Introduction to total hip replacement surgery
This section reports on analyses of red blood cell use for total hip replacement procedures,
modelled to reflect a hypothetical situation in which procedures were to be transfused in
accordance with best practice. Total hip replacement procedures were selected because they
are commonly performed and are notable users of blood, as substantiated by findings
reported for the surgical blood attribution rule (Chapter 8). Further, this modelling analysis
is pertinent since both primary and revision hip replacement procedures are likely to
become more common as the population ages.
Hip replacements involve the artificial replacement of inflamed and degenerating cartilage
and bone of hip joints such as results from osteoarthritis and rheumatoid arthritis, and may
also be used to repair hip fractures commonly caused by falls, particularly in old age when
the bone is more brittle. These conditions cause chronic pain and reduced mobility. Primary
hip replacements are successful and frequently performed procedures but eventually the
replacement will fail because the materials wear out or because the artificial replacement is
otherwise loosened, for example due to infection (National Audit Office, 2000). As a result
revision hip replacements are necessary: these are usually more complex surgeries and are
associated with higher failure rates. The number of primary and revision hip replacements
being performed is rising as a direct consequence of the ageing population. More primary
hip replacement procedures are required because people are living longer and more people
are affected by typical conditions of old age such as osteoarthritis, or suffer falls as a result of
unsteadiness and restricted mobility. It follows that as people with hip replacements live
longer there will also be a requirement for more revision hip replacement procedures.
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10.2.2. Methods used to examine the use of a best practice indicator in total hip
replacement surgery
The analyses carried out for this study explored primary and revision total hip replacement
procedures (OPCS-4 codes W37-W39), for which red blood cell use was described previously
for the study data (section 8.4, Table 8.5). To explore the effect of changing practice to
remove practice variation between hospitals, a series of best practice figures for red blood
cell use per procedure performed were applied to a model of blood use for total hip
replacement procedures across Scotland (Table 10.1). The number of procedures performed
is the number of SMR01-CD records in which the procedure is coded in any procedural
variable; an SMR01-CD record is counted once, irrespective of whether there is more than
one primary or revision total hip replacement recorded during the same episode.
10.2.3. Results for the use of a best practice indicator in total hip replacement surgery
The total number of primary and revision total hip replacement procedures performed in the
year 2000 for the denominator population for the study dataset was 1,890 (1,803 patients):
1,725 patients had one procedure, 72 patients had two procedures, three patients had three
procedures and three patients had four procedures. The age and gender distribution of total
hip replacement procedures for the study population is reported in Figure 10.1 which clearly
illustrates that these are procedures associated with older age, and that in absolute numbers
more females than males have hip replacements.
In the study dataset 1,034 transfusion day records accounting for 2,499 red blood cell units
used could be attributed to 838 patients who had at least one transfused primary or revision
total hip replacements. These 838 patients underwent a total of 895 primary or revision total
hip replacement procedures during the year 2000. However, due to the structure of the
dataset and the way calculations were made it is not possible to identify in an automated
way for individual patients, the exact primary or revision total hip replacement procedure(s)
transfused if patients had more than one procedure in the study to which a single
transfusion event could be attributed to: calculations can be made manually or with
152
10. Applications
additional programming beyond the scope of this study. Therefore, data is described with
respect to all procedures performed rather than procedures transfused (Table 10.1).
Figure 10.1 Total hip replacement procedures for study denominator population by
age and gender
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
Age group
Based on 838 patients transfused and 1,803 patients operated, in the study at least 46% of
primary or revision total hip replacements that were performed were transfused. The
average number of red blood cell units used per procedure transfused was estimated to be
2.9 and the average number of red blood cell units used per procedure performed was 1.3.
In the whole of Scotland for the year ending 31 March 2001 the number of primary and
revision total hip replacement procedures performed was 5,127 (ISD, online). If it is
assumed that these were transfused at the same rate as was determined for this study (1.3)
then the national red blood cell use for primary or revision total hip replacements would
have been 6,665 units.
Table 10.1 Red blood cell use for primary and revision total hip replacement

























Notel: Figures in italics are estimates calculated from the known data. Figure in bold italics is
study rate applied to model, t ISD, online
153
10. Applications











Raigmore 303 189 0.6
Woodend 564 1,222 2.2
Ninewells 157 302 1.9
Princess Margaret Rose 675 664 1.0
Edinburgh Royal Infirmary 86 56 0.7
Others* 105 66 1.6
* Hospitals where a small number of procedures performed: includes 5
procedures performed and 46 RBC units used at Aberdeen Royal Infirmary.
The findings reported in Table 10.2 are for variation in red blood cell use per total hip
replacement procedure performed by hospital, within the study dataset: in this study red
blood cell use per total hip replacement procedure performed ranged from 0.6 units to 2.2
units. By assuming that best practice is equivalent to the lowest rate observed in the study
(0.6 RBC units per procedure performed), and by modelling this as the average rate of
transfusion all total hip replacement procedures in Scotland in 2000, an estimated saving of
3,076 red blood cell units would be expected. This equates to a 53.8% saving in the number
of red blood cell units used for all total hip replacement procedures in Scotland in 2000
compared to observed practice (Table 10.3). The amount of red blood cell units used for total
hip replacements in Scotland in 2000 if a best practice indicator of 0.6 RBC units per
procedure performed is applied is 2.1% of the estimated total red blood cell use for all
Scotland in the year 2000.
The following examples model the effect of applying a best practice value that is not the
lowest rate observed in the study but a similarly low value that could be considered to be an
achievable rate for all hospitals. The hypothetical best practice example value of 1.0 red
blood cell unit per procedure performed was applied to two models for the study data:
firstly, to all hospitals in the study (23.1% saving in RBC use) and secondly, to only those
hospitals with a higher observed practice and applying original, observed values to hospitals
with a lower observed practice (29.1% saving in RBC use) (Table 10.3). In the first of these
two models, the blanket rate of one red blood cell unit used per procedure performed for all
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hospitals would reduce the number of units used by Woodend and Ninewells but would
increase the number of units used by Raigmore and Edinburgh Royal Infirmary (Table 10.2).
Thus it is most desirable to reduce the practice of the high users to meet best practice targets
whilst encouraging previously low users to continue with current practice until further
review of transfusion practices and guidelines is carried out.











Study (procedures performed = 1,890)
Average rate across all hospitals 1.3* 2,457
Applying lowest rate across all hospitals 0.6 1,134 1,323 (53.8)
Applying example target rate across all hospitals 1.0 1,890 567 (23.1)
Applying example target rate by higher users
& original rate by lower users
1.0 1,743 714(29.1)
Scotland (procedures performed = 5,127)
Average rate across all hospitals 1.3 6,665
Applying lowest rate across all hospitals 0.6 3,076 3,589 (53.8)
Applying example target rate across all hospitals 1.0 5,138 1,538 (23.1)
Note 1. "Others" (Table 10.2) considered as a single institution for purposes of these
calculations. *2,499 RBC units/1,890 procedures = 1.32 RBC units per procedure performed,
rounded to 1.3. t Saving relative to average rate of RBC units used per procedure performed
across all hospitals = 2,457 RBC units used for Study and 6,665 for Scotland.
10.2.4. Overview of the use of a best practice indicator in total hip replacement surgery
While it might be thought that the best practice target rate of transfusion should be the
lowest observed value, best practice targets are not simply about reducing blood use but also
must take into consideration issues of clinical effectiveness and patient outcome. Using the
data in this study 0.6 red blood cell units per procedure performed was the lowest reported
rate but a target of, for example, 1.0 red blood cell units per procedure performed may be a




10.3. Consideration of intra-operative cell salvage in coronary artery bypass
surgery
10.3.1. Introduction to coronary artery bypass graft surgery and intra-operative cell
salvage
This section explores the impact of potential blood saving interventions on red blood cell use
for a group of procedures that collectively represent high users of blood, coronary artery
bypass grafts (CABG, OPCS-4 codes K40-46, Table 10.4). CABG procedures use grafts made
from a healthy section of leg vein to bypass a damaged or diseased coronary artery, with the
result of improving blood flow to the heart and reducing the chance of a heart attack.
Coronary artery bypass graft procedures were included in the analysis of red blood cell use
for surgical case groups (Chapter 8). The findings of those analyses revealed that CABG
procedures used the highest proportion of red blood cell units that could be attributed to a
surgical case group, 21.2% (primary and revision procedures combined). Because of their
high demand for blood, CABG procedures are a good example for investigating the use of
alternative techniques and interventions that have been suggested for reducing allogeneic
blood use. Here the impact of applying a best practice model to red blood cell use in CABG
surgery is compared with the potential savings that could be made using a mechanical
intervention, intra-operative cell salvage (IOCS).
Table 10.4 Coronary artery bypass graft procedures included in analyses
OPCS-4 code Coronary artery bypass graft procedure
K40 Saphenous vein graft replacement of coronary artery
K41 Other autograft replacement of coronary artery
K42 Allograft replacement of coronary artery
K43 Prosthetic replacement of coronary artery
K44 Other replacement of coronary artery
K442 Revision of replacement of coronary artery
K45 Connection of thoracic artery to coronary artery
K456 Revision of connection of thoracic artery to coronary artery
K46 Other bypass of coronary artery
K465 Revision of implantation of thoracic artery into heart
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Intra-operative cell salvage enables blood that is recovered during surgery to be collected,
processed and reinfused into the patient rather than being discarded as waste. In the
processing stage the cell salvage device adds an anticoagulant in saline solution to the
recovered blood which is then washed to remove byproducts and waste substances, and
finally centrifuged to separate the red blood cells (McGill et al, 2002). Intra-operative cell
salvage is increasingly endorsed for use in cardiothoracic and cardiovascular, as well as
orthopaedic, surgeries for which the loss of blood is likely to be high (Carless et al, 2006 ). By
reinfusing a patient with their own salvaged blood the risks associated with exposure to
allogeneic transfusion and the pressure on donor resources can be reduced, although the
risks associated with a new, mechanical intervention should also be considered. Because of
this, of great interest is the potential savings in blood use due to intra-operative cell salvage.
10.3.2. Methods used to assess the use of intra-operative cell salvage in coronary artery
bypass graft surgery
Red blood cell use for CABG procedures was analysed by hospital (Aberdeen Royal
Infirmary and Edinburgh Royal Infirmary) to examine variation in practice. Figures for
estimated savings achievable by using intra-operative cell salvage during CABG surgery
were obtained from various sources and were applied to the data for the number of
procedures performed and red blood cell units used per CABG procedure as determined for
the whole Scottish population. The impact of intra-operative cell salvage on red blood cell
use is compared with a best practice intervention for transfusion of coronary artery bypass
graft procedures (Table 10.5).
10.3.3. Results for the use of intra-operative cell salvage in coronary artery bypass graft
surgery
The use of red blood cells in CABG procedures for the study data is reported in Table 10.5.
The majority of procedures were carried out in Aberdeen Royal Infirmary or Edinburgh
Royal Infirmary. The findings for Aberdeen Royal Infirmary and Edinburgh Royal
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Infirmary combined do not include two patients in the study data who underwent one
CABG procedure each at Ninewells hospital, one of whom was transfused with four red
blood cell units (the other was not transfused with red blood cell units). Therefore, in total
1,254 procedures performed of which 899 (71.7%) were transfused.
Each CABG patient underwent one CABG procedure and so the number of procedures
equals the number of patients: with regards to processing, this meant that the complication
of determining how many procedures were transfused for patients undergoing multiple
procedures, as was encountered for total hip replacement procedures transfused (section
10.1), was not encountered in this analysis. Therefore, the number of procedures performed
and the number of procedures (patients) transfused are reported in Table 10.6. Further, the
following models in which best practice values and intra-operative cell salvage savings are
applied are based on red blood cell units per patient transfused because that is the form in
which values are expressed in previous studies. The number of procedures performed is
calculated as any instance where a CABG procedure is coded in an SMR01-CD record,
though the record is only counted once regardless of the number of CABG procedures coded
in it. The number of procedures transfused is any instance where the CABG procedure is the
first red cell using procedure coded in an SMR01-CD record that can be related by the
surgical blood attribution rule to a transfusion day record of red blood cell use.
Table 10.5 Red blood cell use for Coronary artery bypass graft procedures: study data,














Aberdeen Royal Infirmary 637 443 206 1.4 3.1
Edinburgh Royal Infirmary 3,051 809 692 3.8 4.4
Study (ARI + ERI)* 3,688 1,252 898 2.9 4.1
All Scotland 8,3271 2,832f 2,031 2.9 4.1
Notel: Figures in italics are estimates calculated from the known study data. Figure in bold italics is study
rate applied to model. * Excludes 2 patients who underwent one CABG procedure each (total 2 procedures)
at Ninewells hospital; transfusion data is available for one of these patients, who received 4 RBC units, }




The total number of CABG procedures performed in the whole of Scotland (year ending 31
March 2001) was reported by ISD as 2,832 (ISD, online). Therefore, 44% of the CABG
procedures performed in the whole of Scotland were included in the study data. It was
expected that the study would represent approximately half of the CABG procedures
performed in Scotland because the study data includes clinical and transfusion records for
two (Aberdeen Royal Infirmary and Edinburgh Royal Infirmary) of the four main hospitals
in Scotland where these procedures are performed. The remaining CABG procedures are
performed in Glasgow Royal Infirmary and Glasgow Western Infirmary. The findings
reveal differences between Aberdeen Royal Infirmary and Edinburgh Royal Infirmary in the
number of units used per procedure performed (1.4 versus 3.8) and per procedure transfused (3.1
versus 4.4) (Table 10.5). Using the average number of red blood cell units used per procedure
performed for the study data, 2.9, and making the assumption that the Glasgow hospitals
transfuse CABG procedures at this average rate, the total red blood cell use estimated for the
1,578 CABG procedures performed in Glasgow is 4,576 units.
The average number of red blood cell units transfused per procedure transfused for the study
data was 4.1: each patient had one CABG procedure and so the average number of red blood
cell units transfused per patient transfused for the study data was also 4.1. Thus, a saving of
1.0 red blood cell unit per patient transfused could have been made if all CABG procedures
performed in Scotland in the year 2000 had been transfused at the lower rate of Aberdeen
Royal Infirmary (3.1 RBC units per patient transfused). At these rates the total red blood cell
usage for total hip replacement operations in Scotland would have been 6,296 units; an
estimated saving of 2,031 units (24.4% saving compared to study result of 8,327 RBC units)
(Table 10.6).
Further, figures for potential savings made by using IOCS were obtained from a variety of
sources. First, two studies of intra-operative cell salvage in cardiac surgery carried out ten
years apart are described (Bell et al, 1992 and McGill et al, 2002). Bell et al described a median
reduction of one unit of red blood cells in male patients, and two units in female patients
undergoing first-time (primary) cardiac procedures who received intra-operative cell
salvage compared to controls. However, there was no reduction in red blood cell use when
all procedures were considered together (that is, including revisions) and there was no
change in the number of other blood component units used. For the purposes of this
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analysis the figure of 1.0 unit saved (best overall value) and 1.5 units saved (average of males
and females) were modelled. McGill et al compared red blood cell transfusion between
control patients, patients receiving intra-operative cell salvage, and patients receiving intra¬
operative cell salvage and acute normovolaemic haemodilution during elective CABG
surgery. The study found that the proportion of patients transfused during CABG reduced
from 51% in the control group to 31% in those patients who received intra-operative cell
salvage (20% reduction in patients transfused), and the number of units used by transfused
patients was reduced from 1.07 units per patient in the control group to 0.68 units per
patient in the intra-operative cell salvage group (0.39 RBC units saved per patient) (McGill et
al, 2002). Using these figures, the modelling analysis here demonstrates a total saving of
35.7% of red blood cell units (Table 0.6).
Table 10.6 Summary of red blood cell use for CABG procedures in Scotland based on













As per Aberdeen Royal Infirmary 1.00
Intra-operative cell salvage
Belief a/, 1992 1 1.00
Belief a/, 1992 11 1.50f
McGill et al, 2002 J 0.39
















Note. Analyses based on 4.1 RBC units used/patient transfused and 2,031 patients transfused. * Percentage
saving based on 8,327 units used for Scotland, 2000, estimated using 4.1 RBC units used per procedure
transfused and 2,031 procedures transfused (Table 10.4.2). t Average of male (1.0) and female (2.0) savings
reported in study. $ Based on 51% of patients (1,444) transfused i.e. 20% reduction in number of patients
transfused.
A Cochrane review entitled "Cell salvage for minimising peri-operative allogeneic blood
transfusion" was published in 2006 (Carless et al, 2006). The meta-analysis of controlled
trials of intra-operative cell salvage in elective surgery gave an overall figure of 0.67 units
(95% CI 0.45 to 0.89 units saved) for the savings made by using intra-operative cell salvage.
23 of the studies reviewed in the Cochrane report investigated cell salvage in cardiac surgery
specifically: the reduction in blood use was 0.64 units (0.39 to 0.90 units saved) per patient.
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A larger reduction was made in orthopaedic surgery specifically (0.89 units per patient; 95%
CI 0.39 to 1.40 units saved), and no statistically significant reduction was observed in
vascular surgery (0.02 units per patient; 95% CI 0.34 units saved to 0.38 units more required).
The review also concluded that the methodology of studies included in the meta-analysis
was poor and potentially biased in favour of cell salvage.
In this study all patients had one CABG procedure and so if the Cochrane review figures for
procedures transfused are used as a proxy for the number of patients transfused and the value
for a saving of 0.64 units per patient transfused is applied (Carless et al, 2006), 2,031 CABG
patients would be transfused with an average of 3.46 units, which results in a total use of
7,027 red blood cell units, and gives a saving of 1,300 units (15.6%) by this model (Table 10.6).
10.3.4. Overview of the use of intra-operative cell salvage in coronary artery bypass
graft surgery
The percentage savings reported for various estimates of red blood cell reductions using
intra-operative cell salvage in CABG surgery described here ranges from 15.6% to 36.6%.
These savings equate to between 1,300 units to 3,046 units, or 0.8% to 1.8% of the total red
blood cell use in Scotland for the year 2000 estimated in this study. The smallest and
greatest savings were achieved using the figures that estimate the impact of intra-operative
cell salvage; applying a best practice model based on the number of units transfused by
Aberdeen Royal Infirmary in the year 2000 gives a result that lies in the middle of the range
and is equal to one of the intra-operative cell salvage estimates.
The evidence suggests that the use of intra-operative cell salvage in CABG procedures can
achieve notable savings in allogeneic red blood cell use for these procedures, but equally,
changing practice could have comparable savings. Furthermore, by reducing allogeneic
transfusion, recipients' donor exposure and hence the risk of transfusion-transmitted
infection are reduced, and red blood cell stocks are conserved.
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10.4. CHANGES TO DEMOGRAPHICS OF THE SCOTTISH POPULATION
10.4.1. Introduction to demographic change in Scotland
Variations in blood component use by age group and gender were described in Chapter 7.
In particular the findings showed that older age groups (over 60 years of age) receive the
highest number of red blood cell units per patient. Population projections show that
Scotland has an ageing population that is characterised by significant increase in the older
age groups (GRO, online; ESRC, 2004). Given the high rate of transfusion in older patients
the future impact of an ageing population on red blood cell use in Scotland is explored. The
effect of the ageing population makes it particularly important to monitor blood use for total
hip replacement procedures given that they are most commonly performed for patients over
60 years of age.
10.4.2. Method used to assess impact of demographic change on blood use
Red blood cell use, as observed in the study dataset, was applied to revised mid-year
population estimates for years 2000 (published in July 2007), accounting for the proportion
of the population that was transfused, to determine rates of red blood cell use for the
Scottish population in the year 2000, separately for each ten year age group and for males
and females. These rates show an increase in units used per head of population with
advancing age (Figure 10.3). A comparison was made of projected and revised mid-year
population estimates for the Scottish population in 2000 (GRO, online). There was little
difference between the overall predicted and actual population figures, though there was
some variation by age group. The predicted population had overestimated the number of
males aged 80-89, and underestimated for age groups 0-9, 20-29, and 90 plus for both sexes.
Thus, the analyses reported here were carried out using the revised mid-year population
estimates for 2000. The above comparison alerts to potential errors in the projections for the
2016 and 2031 populations. Indeed GRO are careful to highlight the uncertainty in
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projections due to unpredicted changes in demographic trends, and this should be
considered when interpreting the findings of this study.
Figure 10.3 Red cell units used per head of population (based on study data)
- Males - Females
0.000
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Age group
The age and gender specific rates of red blood cell use for the Scottish population in the year
2000 (Figure 10.3) were then applied to projected population estimates for 2016 and 2031
(based on predicted 2004 data) (GRO Scotland, online). The year 2031 was chosen because it
is the furthest forward for which the GRO Scotland has made population projections at this
time; 2016 is included as a mid-way reference point. The 2016 and 2031 projections provide
population figures for estimating changes in blood use assuming that the pattern of blood
use within age groups is unchanged, that is, assuming that the clinical indications for which
blood is used, and/or transfusion practice with respect to blood use for these indications, is
unchanged.
The population figures for the three years, 2000, 2016 and 2031 for the total population and
separately for males and females are shown (Figure 10.4a-c). The population data shows a
marked decrease in the size of the younger age groups over the period 2000 to 2031, and a
marked increase in the older age groups over the years from 2000 to 2031. The particular
increase in the number of older males also causes a gender effect: between 2000 and 2016 red
blood cell use is predicated to increase by 23.7% for males compared with 13.4% for females
(17.4% overall increase in RBC units used).
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To assess the effect of the changing population demographics in Scotland on the use of blood
for hip replacements, the age and gender specific use of red blood cell units per procedures
performed per head of population obtained from the study's denominator data were applied
to the projected population structure for the year 2031. Red blood cell use was calculated
based on the best practice figure obtained from analyses above and the analysis carried out
for primary and revision procedures separately.
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10.4.3. Results for impact of demographic change on blood use
Red blood cell use is predicted to decline in the younger age groups, but there is a larger
predicted increase in the use of blood by the older age groups (over 60 years), particularly
for males, reflecting the population expansion in these age groups (Figures 10.5a & 10.5b).
The estimated number of red blood cell units used in the whole of Scotland in 2000 was
158,863 (70% of RBC units supplied, section 6.1.2). The absolute figures for red blood cell
use in 2000, 2016 and 2031 are shown (Figure 10.6). Overall, between 2000 and 2016 there is
a predicted increase in red blood cell use of 17.4% (approximately an additional 28,000 RBC
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Figure 10.5b view showing reduction in use for age groups 0-9 to 40-49 years
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Figure 10.6 Red blood cell use in 2000,2016 and 2031 by gender
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Considering the population data and projected red blood cell use figures together reveals
that between 2000 and 2016 a 1.3% growth in the size of the population is matched by a
17.4% increase in red blood cell use. Between 2016 and 2031 the population is estimated to
decrease by 1.2% (0.08% per year) and red blood cell use is estimated to increase by 17.9%
(1.2% per year). Although the overall size of the population in 2000 and 2031 is predicted to
be approximately the same it is estimated that 37.8% more red blood cell units
(approximately an additional 60,000 RBC units overall) will be used in 2031 than were used
in 2000 if current patterns of usage are maintained.
One surgical procedure that is most common in the elderly is total hip replacement. This has
already been considered in terms of savings that could be made by encouraging orthopaedic
surgeons to agree and utilise a best practice target value for the use of blood for total hip
replacement surgery (section 10.1). Further to analysis of best practice, the effect of the
ageing Scottish population on the use of red blood cell units between 2000 and 2031 for total
hip replacements was assessed here. The estimated number of red blood cell units used for
all total hip replacement procedures in 2031 was 27,250, which equates to 11.5% of the
estimated total red blood cell use for Scotland in that year, and an estimated increase in the
use of red blood cells for total hip replacement procedures of 30.5% between years 2000 and
2031 (Table 10.7). The percentage change in red blood cell use between 2000 and 2031 is
greater for revision procedures than primary procedures. Further, for revision procedures
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the change in use is greater in males than in females, which echoes the greater population
expansion of older males compared with females. For primary procedures the change in use
for males and females is roughly equal, though slightly greater for females.
Table 10.7 Estimated red blood cell units used in 2031 and percentage change






% change in RBC use
(2000 to 2031)
Male Female All persons
Primary THR 9,113 14,733 23,846 28.1 30.4 29.5
Revision THR 1,497 1,906 3,403 47.0 31.5 37.9
All THR procedures 10,610 16,639 27,249 30.5 30.5 30.5
1THR: Total hip replacement
10.4.4. Overview of impact of demographic change on blood use
The findings indicate that large increases in red blood cell use in Scotland are accounted for
by the expanding population in the older age groups (typically over age 60 years) for whom
the use of red blood cell units per patient is higher than for other age groups. Concurrently,
the population and total red blood cell units used by the under 60s is predicted to decline;
the decline in the size of the population in the younger age groups will also affect the donor
population and hence add to pressures working to reduce the supply of blood.
The saving in red blood cell use for total hip replacement procedures that could be achieved
with best practice targets was estimated to be as much as 23%; and perhaps even as high as
54% if all hospitals in Scotland transfused total hip replacement procedures at the lowest
rate observed for this study (section 10.1). Thus, the anticipated increase in red blood cell
use due to the ageing population, and specifically for total hip replacement procedures
could be negated by considering the use of blood conservation strategies, such as applying
best practice targets, in the future.
The projections reported here were made on the assumption that the pattern of red cell use
by age will remain the same. However, it should be emphasised that the use of blood is
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influenced by the epidemiology of disease, by changes to clinical practice and treatment
protocols, and by changes in transfusion practice including the use of new and alternative
techniques and interventions. Where appropriate estimates for these changes are available,
alternative models of future blood use could be made to account for such factors.
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10.5. Special interest case i: Thrombotic thrombocytopenic purpura
10.5.1. Introduction to Thrombotic thrombocytopenic purpura
This section describes the use of the data in examining the use of blood components for a
medical condition known to have a very low incidence but a very high associated use of
blood components, specifically fresh frozen plasma. Thrombotic thrombocytopenic purpura
(TTP) is a rare condition in which there is deficiency in the function of an enzyme (ADMS-2)
that cleaves von Willebrand factor resulting in the inappropriate formation of platelet
clumps. The deficiency may be inherited and therefore symptomatic in childhood
(extremely rare) or it can be acquired later in life (1-3 cases per million per year;
approximately 5-15 cases in Scotland). Patients suffer complex disturbances of haemostasis
and haemolysis of red blood cells (Pisoni & Remuzzi, 2000).
The treatment for TTP involves repeated plasma exchanges in which patients' plasma is
replaced with donor fresh frozen plasma (FFP). Each treatment involves the use of about
five litres of fresh frozen plasma and patients may require serial courses of treatment each
lasting five days (one exchange per day). One unit of FFP is 0.25 litres, therefore 20 units of
FFP are given in each exchange and in total 100 units of FFP are required for every five day
treatment course. Recent evidence questions the general prophylactic use of FFP and
proposes that TTP is the only condition for which there is evidence that treatment using FFP
transfusion is effective (Stanworth et al, 2004).
There is currently no specific, routine test for TTP and instead the diagnosis is made on the
basis of symptoms and tests for non-specific markers in blood. Further, there is no specific
ICD-10 code for recording a diagnosis of TTP in clinical records. TTP would be expected to
fall under ICD-10 section "D69: Purpura and other haemorrhagic conditions" (Table 10.8); it
may also be coded as a thrombotic microangiopathy (ICD-10 code "M311"), a term that
describes syndromes caused by impaired platelet aggregation, including thrombotic
thrombocytopenic purpura and haemolytic uremic syndrome (Pisoni & Remuzzi, 2000).
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Table 10.8 D69 sub-chapter of ICD-10: Purpura and other haemorrhagic conditions
ICD -10 code Purpura and other haemorrhagic conditions
D690 Allergic purpura
D691 Qualitative platelet defects
D692 Other non-thrombocytopenic purpura
D693 Idiopathic thrombocytopenic purpura
D694 Other primary thrombocytopenia
D695 Secondary thrombocytopenia
D696 Thrombocytopenia, unspecified
D698 Other specified haemorrhagic conditions
D699 Haemorrhagic condition, unspecified
10.5.2. Methods used to examine fresh frozen plasma use by patients with Thrombotic
thrombocytopenic purpura
Because of the lack of specific clinical coding and because the condition requires treatment
consisting of high use of FFP, a D69 code in combination with a large number of FFP units
used may be indicative of a diagnosis of thrombotic thrombocytopenia purpura. For this
analysis, patients with any coding of D69 in SMR01-CD records were selected and their FFP
use and additional clinical data were examined. Further, because the condition was not well
characterised or recognised at the time (2000), other diagnostic information in the clinical
records of FFP users was considered for its ability to identify of potential or probable TTP
patients. This step helped to identify thrombotic microangiopathy as an indicator for
thrombotic thrombocytopenia purpura and so the FFP use of patients with any coding of
M311 in the diagnostic variables of SMR01-CD records was also examined.
Therefore, evidence of the indicators "D69" and "M311" coding, and FFP high use in the
study dataset was examined to identify TTP patients. Groups defined by each of these
indicators are described separately first, following which, patients common to two or more
groups are summarised. Once identified, the FFP use of these patients was quantified to
identify the proportion of all FFP units used in the study that could be attributed to this
condition for which there is recent evidence to suggest it as the only condition that can be
effectively treated with FFP transfusion.
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10.5.3. Results for fresh frozen plasma use by patients with Thrombotic
thrombocytopenic purpura
In the study dataset 171 patients with a D69 code in any diagnosis (ICD-10) variable were
linked to transfusion day records of blood component use. The total number of SMR01-CD
records for these patients was 459. Specifically, 25 patients with a D69 coding (55.6% male,
mean age 53.8 years (s.d. 11.87 years, range 26-88.3 years)) could be related to 72 transfusion
day records (471 units) of FFP use. A summary of D69 codes and FFP use by patient is given:
two patients who were transfused with a large number of FFP units in comparison with the
others in this group can be identified (patients 12 and 16, Table 10.9).
Table 10.9 Patients with SMR01 records in which there is a D69 code: breakdown of
D69 codes and total FFP use







1 D696 D695 2 29 16
2 D696 D696 D696 3 7 12
3 D696 1 3 6
4 D696 D696 2 8 2
5 D696 D696 D696 3 4 5
6 D696 D696 2 16 4
7 D696 1 2 2
8 D696 D696 D696 D696 4 4 6
9 D696 1 6 3
10 D696 1 1 3
11 D696 1 3 11
12 D696 1 3 145
13 D696 D696 D696 D694 D696 5 8 8
14 D696 D696 2 8 7
15 D696 1 13 7
16 D694 D694 D694 3 7 197
17 D696 D696 2 7 3
18 D696 D696 2 3 3
19 D696 1 2 2
20 D696 D696 2 8 4
21 D965 1 4 10
22 D696 D693 2 3 2
23 D696 1 1 6
24 D696 1 21 4
25 D696 1 1 3
* The SMR01 records in which D69 diagnoses were coded are not necessarily consecutive.
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a 28 0 278 0 306
b 4 0 158 0 162
c 112 1 1,776 10 1,899
d 15 0 124 0 139
e 0 0 145 0 145
f 14 0 197 0 211
It was hypothesised that by examining the SMR01-CD records of patients transfused with
more than 100 units of FFP during the study period, patients who, while not coded with a
D69 diagnosis, but were coded with other diagnoses that are indicative of pre-thrombotic
thrombocytopenia purpura conditions such as haemolytic disease (which can be caused by
E-coli 0157 infection), renal failure (implicated in childhood cases of haemolytic uraemic
syndrome) and neurological conditions, may be identified (Table 10.10). These patients
include two (listed as patients "c" and "e") that were considered to be outliers in the analysis
of FFP use by age and gender because of their high use of FFP units, and were subsequently
removed from the data reported elsewhere (section 7.4.2). A third patient also considered to
be an outlier in section 7.4.2 was transfused with 76 units of FFP: the primary diagnosis in
the patient's first SMR01-CD record in the study dataset was chronic renal failure, a
condition linked with the development of thrombotic thrombocytopenia purpura. Given
this diagnosis, and that the patient may have received additional FFP transfusions beyond
the time-scale of this study, this patient could also be considered to be a potential TTP
patient but does not meet the criteria required for this specific analysis. Similarly, patient
"d" (Table 10.10) was transfused with 124 FFP units but could not be linked to a D69 or
M311 diagnosis and so although the patient was diagnosed with nephrotic syndromes,
indicative of renal disease, they too are excluded from this specific analysis. Patient "f" was
transfused with 197 FFP units and although the principal diagnoses (reported in Table 10.5.4)
do not contain a TTP-related condition, the patient was diagnosed with E-coli infection and
has D694 and D593 (haemolytic-uraemic syndrome) codes recorded in the fourth and third
diagnoses variables of three SMR01-CD records. Thus, patients "a-c" and "e-f" do meet the
selection criteria for this analysis.
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Table 10.11 Summary of primary diagnosis of patients transfused with more than 100
units of FFP during the study period






a 278 25.9.00 27.9.00 Haemolytic-uraemic syndrome
27.9.00 28.9.00 Haemolytic-uraemic syndrome
28.9.00 6.10.00 Thrombotic microangiopathy
6.10.00 7.11.00 Thrombotic microangiopathy
23.11.00 1.12.00 Preparatory care for dialysis
3.12.00 14.12.00 Chronic renal failure
14.12.00 17.12.00 Chronic renal failure
17.12.00 19.12.00 Chronic renal failure
b 158 8.10.00 12.10.00 Thrombotic microangiopathy
12.10.00 26.10.00 Thrombotic microangiopathy
c 1,776 1.5.00 2.5.00 Fracture of vault of skull
2.5.00 4.5.00 Thrombotic microangiopathy
4.5.00 7.5.00 Pneumonia, unspecified
7.5.00 19.6.00 Thrombotic microangiopathy
19.6.00 19.6.00 Other and unspecified intestinal obstruction
19.6.00 20.6.00 Thrombotic microangiopathy
20.6.00 4.7.00 Thrombotic microangiopathy
4.7.00 11.9.00 Thrombotic microangiopathy
11.9.00 20.9.00 Thrombotic microangiopathy
20.9.00 8.10.00 Thrombotic microangiopathy
8.10.00 9.10.00 Other and unspecified intestinal obstruction
11.10.00 14.10.00 Thrombotic microangiopathy
14.10.00 16.10.00 Other specified disorders of thyroid
d 124 15.9.00 21.9.00 Nephrotic syndrome
21.9.00 26.9.00 Nephrotic syndrome
1.11.00 8.11.00 Nephrotic syndrome
10.12.00 11.12.00 Nepthrotic syndrome
11.12.00 13.12.00 Focal and segmental glomerular lesions
13.12.00 19.12.00 Respiratory failure
19.12.00 22.12.00 Focal and segmental glomerular lesions
22.12.00 28.12.00 Unspecified acute lower respiratory infection
e 145 29.12.99 1.1.00 Thrombocytopenia, unspecified
11.1.00 11.1.00 Thrombotic microangiopathy
28.2.00 28.2.00 Thrombotic microangiopathy
f 197 3.5.00 5.5.00 Anaemia
5.5.00 14.5.00 Anaemia
9.5.00 9.5.00 Anaemia
19.6.00 21.6.00 Enterotoxigenic Escherichia coli infection
21.6.00 22.6.00 Enterotoxigenic Escherichia coli infection
22.6.00 29.6.00 Other bacterial infections of unspecified site
29.6.00 14.7.00 Enterotoxigenic Escherichia coli infection
* Patients are the same patients as those included in Table 10.10
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Patients with any diagnosis of thrombotic microangiopathy (M311) are summarised in Table
10.12; together they use 2,366 FFP units. The group includes one patient who was transfused
with nine FFP units and who is therefore not considered to be a likely TTP patient. However,
this patient was not transfused with more FFP units because they died, aged 95 years, just 13
days after the date of admission and first diagnosis of thrombotic microangiopathy.








i 5 8 278
ii 2 2 158
iii 14 14 1,776
iv 2 3 145
V 1 2 9
10.5.4. Overview of fresh frozen plasma use by patients with Thrombotic
thrombocytopenic purpura
The exploration of D69 coding (purpura and other haemorrhagic conditions), M311
(thrombotic microangiopathy) and high use of FFP (typically more than 100 units) in the
study dataset, identified five patients (Table 10.13). In total these patients used 2,554 FFP
units, 27.0% of all FFP units used in the study. With recent evidence suggesting that this is
the only condition for which treatment with FFP is effective, there is potential for a 73.0%
saving in FFP units if used only for treatment of the TTP-related conditions described here.










A* 0 5 8 278
B 0 2 2 158
C 0 14 14 1,776
D 1 2 3 145
E* 3 0 7 197
* Also have ICD-10 code for diagnosis of haemolytic-uraemic syndromes
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10.6. Special interest case ii: Donor exposure
10.6.1. Introduction to donor exposure
Donor exposure is a measure of the number of donors to whom blood recipients are exposed
via blood transfusion over a specified time period (lifetime, for example). This is important
when considering the combined risks of infection faced by patients throughout their lifetime,
particularly so for patients who receive high numbers of transfused units. This section
explores how the data can be used to calculate and describe donor exposure in the context of
transfusion-transmissible infections. Thus, this section goes beyond describing the use of
blood to examine one aspect of the impact of the use of blood on transfusion recipients.
Donor exposure is calculated from the total number of blood component units transfused to
a recipient. A unit of red blood cells, a donation, is comprised of red blood cells from one
blood donor given during a single donation. Thus for a patient transfused with one unit of
red blood cells the donor exposure is one. The case is the same for fresh frozen plasma: one
unit of FFP is the plasma obtained from a single unit of whole blood from a single donor and
so the donor exposure is one.
However, the production and blood bank assignment processes are different in the cases of
platelet, cryoprecipitate and paediatric red blood cell units. Platelet units are produced in
one of two ways: platelet units are either obtained from a single donor by apheresis or are
pooled from multiple whole blood donations. Apheresis is a process in which whole blood
is removed from the donor, the required portion is separated off and the remaining
components are transfused back into the donor. A unit of platelets obtained in this way
comes from a single donor and has a donor exposure of one. However, an adult dose unit of
pooled platelets is derived from multiple, usually five, different whole blood units because
there is only a small volume of platelets in whole blood donations, insufficient to produce a
whole unit. This means that a single unit of pooled platelets actually represents five donors
and the donor exposure of pooled platelet recipients is five times higher than for platelet
units produced by apheresis (Figure 10.2). In this study platelet units are adult dose
equivalent units derived from pooling multiple (five) donations. Therefore, the number of
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platelet units must be multiplied by five to quantify the actual donor exposure (Figure 10.7).
Cryoprecipitate is also produced by pooling units from separate donations to produce an
adult dose unit, in this case from six donors. Therefore, the number of cryoprecipitate units
must be multiplied by six to get the correct measure of donor exposure presented by one
cryoprecipitate unit.
Figure 10.7 Relationship between unit preparation and donor exposure
Platelet units: Apheresis Platelet units: Pooled whole blood donation
□
1 donor =
1 donor platelet pack =
1 platelet unit








1 donor platelet pack =
1 platelet unit
1 pooled platelet unit exposure = 5
This scenario is the same for cryoprecipitate except six donor
units are pooled to make one i.e. 1 pooled cryoprecipitate unit
exposure has a donor exposure = 6
Red blood cell units: Adult dose Red blood cell units: Paedipacks
1 donor =
—> 1 donor RBC pack =
1 RBC unit








1 donor RBC pack =
5 RBC paedipack units
1 paedipack exposure = 1
5 serial paedipacks exposure = 1
Red blood cells are transfused to paediatric patients in the form of "paedipacks". These are
small volume donor packs produced by splitting a single adult red blood cell unit into five
paedipacks thereby providing volumes suitable for transfusion to paediatric patients (Figure
10.2). Paedipacks were primarily developed to reduce the donor exposure of paediatric
patients, who may require multiple transfusions and are especially vulnerable to infection
risks, as well as to reduce wastage and aid transfusion of small volumes. Thus, a paediatric
patient who receives one paedipack transfusion of red blood cells is exposed to a single
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donor, and moreover, the donor exposure remains one for subsequent, serial transfusions
with red blood cell paedipacks from the same original donor pack up to the transfusion of all
five paedipacks. Only at the sixth transfusion does donor exposure increase to two.
A single adult red blood cell donor pack gives rise to five paedipacks that should be
recorded individually by the blood bank as they are assigned. The proportion of red blood
cell units assigned in the form of paedipacks is not given in the study's transfusion data and
thus the magnitude of the overestimation of donor exposure for red blood cell units cannot
be calculated. For the purposes of this study no adjustment was made to take into
consideration the impact of paedipacks on donor exposure calculations i.e. all units of red
blood cells were calculated as having a donor exposure of one.
10.6.2. Methods used to examine donor exposure
Donor exposure for patients in the study dataset was calculated using the multiplication
factors illustrated in Table 10.14: red blood cells and FFP are multiplied by a factor of one,
platelets by a factor of five and cryoprecipitate by a factor of six. The unadjusted and
adjusted donor exposure figures are reported for all patients (Table 10.15). Furthermore,
donor exposure and infection risks are considered together to describe the actual risk of
infection to the patient (Table 10.16). In addition, adjusted donor exposure figures are
reported for surviving and non-surviving patients according to date of death available at the
time of data extraction in 2004 (Table 10.17).
Table 10.14 Examples of conversion of blood component units to donor exposure
Units (recorded in transfusion day record) Donor exposure (after multiplication)
RBC PLT FFP CRYO Total RBC PLT FFP CRYO Total
1 1 1 1
1 1 5 5
1 1 1 1
1 1 6 6
1 1 2 1 5 6
1 1 1 3 1 5 1 7
1 1 1 1 4 1 5 1 6 13
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10.6.3. Results of donor exposure analyses
Examples of the multiplications required to calculate patients' donor exposure are illustrated
in Table 10.14. Even these simple examples illustrate the impact of multiple units of platelets
or cryoprecipitate on patients' total donor exposure. A low level of red blood cell
transfusion represents a low donor exposure but this can be particularly increased by the
additional transfusion of even a small number of platelet or cryoprecipitate units. First,
unadjusted and adjusted figures for total donor exposure in the year 2000 are compared for
all patients in the study dataset (Table 10.15). It is acknowledged that the study data is
representative of a single year and so the total donor exposure is the minimum exposure that
these patients will experience in their lifetime. A proportion will have already been exposed
to other transfusions prior to the start of the year 2000 and a proportion of the surviving
patients will have gone on to have further transfusions after the end of the year 2000.
Table 10.15 Patients in study dataset grouped by total donor exposure: unadjusted and
adjusted values
Total Donor Patients (% all patients)
Exposure (n=11,994)
in 2000 Unadjusted* Adjusted*
1-9 10,331 (86.1) 9,988 (83.3)
10-19 1,035 (8.6) 1,110(9.3)
20-29 275 (2.3) 347 (2.9)
30-39 133 (1.1) 135(1.1)
40-49 90 (0.8) 79 (0.7)
50-59 43 (0.4) 58 (0.5)
60-69 18 (0.2) 42 (0.4)
70-79 19(0.2) 35 (0.3)
80+ 50 (0.4) 200 (1.7)
'Unadjusted figures calculated from original data for units
used; Adjusted figures account for platelet units x5 and
cryoprecipitate units x6.
The proportion of all patients in the study dataset who had a donor exposure of less than ten
blood component units in the year 2000 was 86.1% by the original, unadjusted data and
83.3% when the correct adjustment for platelets and cryoprecipitate units was made (Table
10.15). The corresponding figures for the number of patients who had a donor exposure of
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80 or more blood component units in the year were 0.4% and 1.7%: that is, by not accounting
for the adjustment required for platelet and cryoprecipitate units, there was a four-fold
underestimation of the proportion of patients with a donor exposure of 80 or more blood in
the year (Table 10.15).
The adjustment required to account for the use of platelet and cryoprecipitate units was also
considered in the context of published figures for the risk of transfusion-transmitted
infection. The published figures are for the risk per donated unit rather than per used unit:
therefore, because platelet and cryoprecipitate units are created from pooled donations, the
risk per platelet unit and cryoprecipitate unit used is underestimated unless the relevant
adjustment is made (Table 10.16).
Table 10.16 Risk of transfusion-transmissible infections: risk per donated blood
component unit and actual risk to patient








Hepatitis B around 1 in 100,000 0.00001 0.00001 0.00005
Hepatitis C less than 1 in 400,000 0.0000025 0.0000025 0.0000125
Bacterial around 1 in 500,000 0.000002 0.000002 0.00001
Malaria around 1 in 1,000,000 0.000001 0.000001 0.000005
HIV less than 1 in 4,000,000 0.00000025 0.00000025 0.00000125
* McClelland, 2007. HIV: Human immuno-deficiency virus
Whilst full survival analyses have not been attempted for the study data it was calculated
that 48% of all patients in the study dataset had died during the four years between the
study year and the year of data extraction and linkage with GRO death records (2004). 132
of the 200 patients (66%) who had a donor exposure of 80 or more had died by 2004. More
patients would have died in the intervening years between 2004 and the current year, 2007: a
new record linkage with GRO death records is required to update this information. The
limitations of the study data notwithstanding, the donor exposure of patients with and














(% patients died +)
n=5,798
% Patients to have died by
stated date *
1-9 5,407 (87.3) 4,581 (79.0) 45.9% died by 30.03.04
10-19 464 (7.5) 646 (11.1) 58.2% died by 15.03.04
20-29 138 (2.2) 209 (3.6) 60.2% died by 25.02.04
30-39 39 (0.6) 96 (1.7) 71.1% died by 08.04.03
40-49 27 (0.4) 52 (0.9) 65.8% died by 15.03.03
50-59 21 (0.3) 37 (0.6) 63.8% died by 10.01.04
60-69 16 (0.3) 26 (0.4) 61.9% died by 09.12.03
70-79 16 (0.3) 19 (0.3) 54.3% died by 16.08.03
80+ 68(1.1) 132 (2.3) 66.0% died by 11.02.04
Note: All adjusted figures, that is, accounting for corrections for platelet and cryoprecipitate units,
t Correct at time of study data extraction, March 2004
10.6.4. Overview of donor exposure analyses
Donor exposure is a measure of the number of donors to whom blood recipients are exposed
via transfusion over a specified period of time. It is calculated as the number of units used
for adult dose red blood cell and fresh frozen plasma but for platelets and cryoprecipitate an
additional multiplication factor must be taken into account because a unit of each is pooled
from five and six donor sources respectively.
Donor exposure is important to quantifying total, residual infection risks posed to recipients
of multiple units of transfused blood components. Particularly, current concerns focus on
the risk of infection with vCJD transmitted through blood transfusion, a risk which is
apparent but small, and largely unquantifiable as it depends on the prevalence of infection
in the population and subsequent patterns of donation and transfusion. The findings
reported here show how the risk of infection per unit of blood donated underestimates the
actual risk per patient. However, the public health impact of high use of blood components




10.7. Overview of alternative applications using study data for analyses of
blood component use
The findings reported in this chapter describe a range of applications for which the study
dataset could be used to further analyse blood component use. Two practice interventions
were described: the use of a best practice indicator for transfusion in total hip replacement
(THR) surgery and the use of intra-operative cell salvage in coronary artery bypass graft
surgery (CABG). Practice variations were reported in the number of red blood cell units
used per procedure performed in both settings (THR practice range, 0.6-2.2 RBC units per
procedure performed; average 1.3 RBC units; CABG practice range, 1.4-3.8 RBC units per
procedure performed; average 2.9 RBC units). Furthermore, the findings of the modelling
analyses reported potential reductions in red blood cell use when the interventions were
applied to transfusion practice. Particularly, the modelling analyses for coronary artery
bypass graft surgery demonstrated that by utilising a best practice target, savings could be
achieved (24.4% RBC units saved) that were comparable to the potential savings that could
be achieved using intra-operative cell salvage (range 15.6%-36.6% RBC units saved). Further,
the analysis of the condition Thrombotic thrombocytopenic purpura demonstrated how
blood component use for a group of patients with a specific condition could be identified
and revealed that there are potentially large savings in fresh frozen plasma use (73.0% total
FFP units) to be made if transfusion guidelines were to be reconsidered in the light of new
evidence for effective and appropriate use of plasma. Together, these findings demonstrate
the importance of ongoing efforts to reduce the use of blood by revising and implementing
transfusion protocols that should be based on appropriate, comparable evidence of the
effectiveness of interventions in reducing the need for allogeneic transfusion whilst avoiding
detriment to the patient.
Perhaps the largest influencing factor on future blood use is the ageing population.
Modelling analyses were used to describe the contrasting use of blood by the young and
elderly; for the Scottish population's total red blood cell use, it was demonstrated that a
marked increase in red blood cell use in future years (1.2% increase in RBC units per year) is
predicted in comparison with, relatively, very small fluctuations in the size of the population.
Specifically, the trend of increasing use of blood in future years was described for total hip
replacement procedures, a common surgery in the elderly. Furthermore, the impact of an
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ageing population on the blood supply is likely to be aggravated by the predicted reduction
in the size of the younger population that represents potential blood donors.
Finally in this chapter, patients' total donor exposure for one year was described for all
transfusion recipients in the study. Donor exposure is a topic of particular pertinence given
current concerns regarding the transmission of vCJD through blood transfusion. The study
dataset was used to identify patients with a high total donor exposure as a result of the
transfusion of multiple units of blood or, specifically, the high use of platelet and
cryoprecipitate units. The number of patients with a donor exposure of 80 or more is four
times greater than initially expected, after the adjustment to donor exposure calculations is
made to account for the use of platelet and cryoprecipitate units. In addition, it was
demonstrated that it is important to use and report the correct data for total blood use,
specifically in relation to the residual transfusion-transmitted infection risks posed by a
single unit of used blood, compared to risk values published for units of donated blood.
Thus, the findings emphasise the need for safe and effective transfusion that is given only
where clinical benefit outweighs the risks of transfusion.
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11. DISCUSSION
11.1. Overview of discussion
The study reports on the population of transfusion recipients at hospitals served by SNBTS
blood banks using the MAK-Progesa (SNBTS/Progesa) computer system in Eastern regions
of Scotland for one year, 2000, for which clinical data in the form of SMR01-CD records was
available. The characteristics of transfused and non-transfused populations, the use of
individual blood components, and blood use attributed to surgical and haematological case
groups have been described. Alternative applications of the study data were explored and
modelling analyses to estimate the impact of changes in factors affecting transfusion practice
were undertaken.
The following discussion describes the results for blood component use and specifically for
red blood cell use that was attributed to surgical and haematological case groups in the
context of previous published evidence; discusses the additional applications for which the
data was used to explore the effect of methods to reduce allogeneic transfusion; addresses
the strengths and weaknesses of available data and the methodology developed and
employed in this study; and describes areas of future work in which alternative or additional
approaches are considered.
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11.2. Discussion of results of study
In this section the key findings reported for this study are discussed in the context of the
findings of previously published evidence. The study dataset was described in Chapter 6,
the findings illustrating that it was possible to link two independent, routine datasets to
create a single dataset that could be used to analyse blood component use. Chapter 6 also
presents the findings of analyses of clinical coding variables that were carried out to gain an
understanding of the available clinical data and further, to validate the inclusion of major
red blood cell using procedures and haematological conditions that were defined for the
study. The red cell using procedures were most often coded in the primary OPCS-4 variable,
and the haematological malignancies were often coded in the primary ICD-10 variable. The
findings support the ISD coding convention for the order of priority by which clinical data
should be coded in clinical variables in SMR01 records, thereby supporting the decision to
select those particular red cell using procedures to describe important clinical events. The
rules devised to resolve issues of competition are discussed separately in section 11.3.4,
where it is concluded that the methods employed in this study were appropriate.
Further, the study dataset was used to describe the population of patients who were
transfused with red blood cells, platelets, fresh frozen plasma and cryoprecipitate thereby
providing blood use data for the study population and demonstrating that the study dataset
and methods could be successfully employed for this sort of analysis (Chapter 7) (section
11.2.1). Objectives of this study also included exploring blood component use by clinical
case group, and specifically, red blood cell use by surgical case group and haematological
case group were described (Chapters 8 and 9) (section 11.2.2 & 11.2.3). Finally, other
potential areas of applications for the study dataset in blood component analysis were
explored (Chapter 10) (section 11.2.4). The results of analyses that address each objective are
discussed here with reference to previously published reports and to the clinical importance
of the findings
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11.2.1. Describing the transfusion of red blood cells, platelets, fresh frozen plasma or
cryoprecipitate units
The findings reported in Chapter 7 provide comprehensive data on the use of blood by age,
gender and intensity of transfusion for each blood component type. The data described
relates to transfusion day records of units used that were included in the dataset and
therefore underestimates the use of blood components by not including those transfusion
recipients for whom no SMR01-CD could be linked (Table 6.10). The findings are discussed
here in the context of previously published evidence, with a particular focus on red blood
cell use. Red blood cell transfusion is the most common blood component transfusion;
specific studies of other blood components are available too but from a resource planning
perspective red blood cell transfusion has the largest impact on donor, clinical and
transfusion services.
The transfusion data that can be used to describe transfusion recipients, transfusion day
records and blood component use are reported in two ways: red blood cell, platelet, FFP and
cryoprecipitate use are reported separately for each approach. Using red blood cell use as an
example, the findings are reported for any transfusion day record of red blood cell units
used regardless of the use of other blood components recorded in the same transfusion day
record (Table 7.1) and for patients transfused only with red blood cell units when
component use was aggregated by patient (Table 7.2). The findings indicate that during the
study year most patients (86.5%) transfused with red blood cell units only receive red blood
cell units. Conversely, patients transfused with the other blood component types are usually
transfused with a combination of blood components, and this is particularly true for
cryoprecipitate which is almost never transfused alone: 15.8%, 12.2% and 1.2% of patients
transfused with platelets, FFP and cryoprecipitate, respectively, are transfused with those
components alone. Blood component use and single blood component use, such as was
described here, are not reported for any comprehensive, descriptive studies of clinical blood
use reviewed in the this study (section 3.5).
In this study the 47.1% of red blood cell recipients who were male received 52.0% of the total
red blood cell units used in the study: total red blood cell use by males and females is
roughly equal in this study (Table 11.1). For some studies it is reported that females are
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more often transfused, or transfusion recipients are more often female, but the actual
number of units transfused by gender shows that males are transfused at a higher rate and
therefore the overall proportions of units transfused by gender are roughly equal, as in this
present study (Cook & Epps 1991; Mathoulin-Pelissier et al, 2000; Palo et al, 2006a & 2006b;
Vamvakas & Taswell, 1994). The variation between studies might be due to differences in
the study setting and population as well as a temporal effect given the broad range of years
for which data is reported. Unlike the present study, few studies report both the percentage
of patients and percentage of units transfused by age and gender.
Table 11.1 Comparison of transfusion recipient demographics










Cook, 1991 49 49
Vamvakas, 1994 45 48 54 53
Zimmerman, 1997 60 37
Mathoulin-Pelissier, 2000 50 57
Wells, 2002 51 57
PhD STUDY, 2007
(data for 2000)
48 52 59 56
Notel: Study reference is first author and year of publication. Note2: Reports reviewed in
section 3.5 only.
Blood component use by age, and especially by the older age groups, has been commonly
reported in previous studies. In the present study patients who were aged 65 years or over
constituted 58.6% of red blood cell recipients and used 56.1% of red blood cell units used in
the study. Thus, the findings of this study indicate that a high proportion of red blood cell
use is by older age groups. Earlier studies report slightly lower proportions of patients and
red blood cell units used by recipients aged 65 and over which likely reflects the changing
demographics over time but relevant denominator data is not reported in the studies to be
able to determine this with accuracy (Table 11.1). In general the findings of this study are
similar to published reports; furthermore, there may be population differences that make the
elderly in some populations have a higher demand for blood, thereby accounting for
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variation between studies. For example, Scotland's high rates of heart disease (which
requires high blood using CABG surgery) and alcohol abuse (which implicates increased
liver transplantation, also a high blood using surgery) mean that the affected age groups
would have a high demand for blood, further to the growth in the size of the elderly
population.
The importance of quantifying the use of blood by patients aged over 65 years in response to
a growing, ageing population was reported for the USA many years ago (Friedman, Burns &
Schork, 1979). Older patients are recognised as a group with the potential to use a high
proportion of blood because anaemia is less likely to be tolerated well and because of the
likelihood of complications of primary disorders. Thus, for an ageing population, such as
that of the UK, the impact of demographic change on clinical and transfusion practices is
important. Specific calculations of the five year age group data reported by Wells et al (2002)
gives a value of 65.8% of red blood cell use is transfused to patients aged 60 years or over,
which is in good agreement with the findings of the present study. Further, interest in the
effect of recipient age on blood component use has been demonstrated in a recently
published report claiming to be the first population-based study of blood use by patients
aged 65 years and over (Anderson et al, 2007). The report described increasing use of red
blood cell units per patient up to the age of 85 after which the average red blood use per
patient declined, which may be due to the patients being too frail to tolerate surgery or high
volume transfusions. Further, the study reported a strong correlation between surgical
procedures and blood use. This finding contrasts with other reports that describe increasing
blood use for medical conditions in relation to advancing age (Wells et al, 2002; Wallis, Wells
& Chapman, 2006). The age-related distribution of blood use for surgical and medical case
groups was not investigated in this study: however, it was noted that the average age for red
blood cell recipients who could be linked with one red cell using procedure was slightly
higher (67.0 years, SD 16.2) than those recipients who had two red cell using procedures
(50.6 years, SD 22.3), and red blood cell recipients who underwent one or more procedure
were similar in age (66.6 years, SD 16.6) to those who had any haematological medical
condition during the study year (64.2 years, SD 21.4) (Tables 8.1 & 9.1).
The use of blood components by age was explored further by modelling the effect of the
ageing demographic profile of Scotland on the future use of red blood cell units (findings
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described in section 10.6). In summary, the estimates suggest that between 2000 and 2016 a
1.2% rise in the growth of the population corresponds to an overall increase in red blood cell
use of 18.8%, and between 2016 and 2031 a decrease in the size of the population of 1.2%
corresponds to a further 17.9% increase in red blood cell use. The detailed findings describe
a decline in the population of younger age groups (under 40 years in 2006 and under 60
years in 2031), the very age group providing the potential blood donor population, as well as
an expansion in the older age groups for whom a high rate of transfusion has been described.
Therefore, by projection of the population alone a double-edged effect of reduced blood
supply and increased demand for blood can be anticipated for the future. Ongoing
investment in strategies for donor services and the effective use of blood is likely to be
required.
It is acknowledged that the projections modelled for this analysis were based simply on the
age and gender specific rates of red blood cell transfusion reported in this study and do not
take into consideration changes in clinical and transfusion practice or changes in the
epidemiology of disease in the population. Wells et al (2002) also applied population
projections to age specific rate of transfusion to estimate the change in the future demand for
red blood cells, citing the issue of the ageing UK population as a driving force for the
analysis; no specific alterations were reported to have been made to account for changes in
other factors that may affect the future use of blood. The time frame examined was shorter
than that examined for the present study: red blood cell use was estimated to increase by
2.0% between 2000 and 2003 and increase by 4.9% between 2000 and 2008, which equates to
red blood cell use increases of 0.7% and 0.6% per year compared to the greater increase of
1.2% per year estimated for the longer projection in the present study (Wells et al, 2002). The
difference in results could be due to differences in the patient case mix or transfusion
practice of the two study settings, or due to the variation in population projections employed.
In addition to age and gender distributions, the intensity of blood component use was
described for recipients. The intensity of transfusion was defined in this study as the
number of units of individual blood component used in the study year by a patient.
Transfusion day records were aggregated by patient identifier and all transfusion day
records in the study dataset were included. Therefore, all transfusion events are included,
regardless of whether patients have, for example, a single transfused surgical episode or
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whether the event was followed by unrelated transfusion events during the year for other
surgical procedures or medical conditions.
Overall, for red blood cells, platelets and fresh frozen plasma, but not cryoprecipitate, the
distribution of recipients by intensity of transfusion demonstrates a positive skew such that
a small proportion of patients (6.8%-11.3% of blood component recipients) are transfused
intensively and account for a substantial proportion of blood component units used (42.3%-
56.3% of blood component recipients). Furthermore, the most common intensity of red
blood cell use per transfusion day record and per patient is two units of red blood cells: the
findings relate to the ongoing debate regarding the commonly observed transfusion practice
of two-unit transfusions. There are mounting efforts to encourage unit-by-unit transfusions
with checks of haemoglobin levels after each unit, thereby conserving the blood supply and
reducing recipients' exposure to allogeneic blood (Palo et al, 2006a; Titlestad et al, 2001;
Mallett et al, 2000; Ma et al, 2005; Grey et al, 2006; Boralessa et al, 2000). The modal intensity
for platelet and cryoprecipitate use reported by this study is one unit per transfusion day
record and one unit per patient; for FFP the modal intensity is one unit per transfusion day
record and three units per patient. The approach to analysing the intensity of transfusion
adopted in this study is one way to address the issue of the time continuum encountered
when examining continuous data such as this. The approach adopted by other studies will
depend on the question being asked of the data, for example Titlestad et al (2001) approaches
this issue by reporting on blood component units used per patient per hospital admission.
Therefore, by considering various approaches, the intensity of transfusion could be
described per transfusion event, admission episode, continuous inpatient stay, or other time
period such as one year depending on the measure that is of interest.
In conclusion, the characteristics of the populations transfused with blood components
reported by this study provide evidence for the distributions of blood component use by age,
sex and intensity of transfusion that are comparable with previous published reports. In
particular, the findings support the awareness of older transfusion recipients as large users
of blood and demonstrate that the data can be used to estimate the marked effect of an
ageing population on the use of blood in Scotland for future years.
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11.2.2. Describing the use of blood components by clinical case group: surgery
The lack of a common set of conventions for reporting blood use by clinical reason for
transfusion has been identified as a key objective for studies of this sort (section 3.5 & 3.6).
For example, it means rather little to simply classifying transfusion events as "surgical", or
other broad, surgical case groups that contain multiple procedures and are classified by
incomparable groups such as surgical specialty or clinical directorate. Rather, clinical
groups based on internationally recognised clinical coding systems such as ICD-10 should
enable comparable classification and reporting of results across different studies.
The blood attribution rules devised for this study were employed to attribute blood use to
specific clinical case groups that represent the likely underlying reasons that can explain
why a patient was transfused. This study defined specific, individual red cell using
procedures or small clusters of very closely related procedures using the OPCS-4 coding
system. The procedures included were based on clinical knowledge of clinical and
transfusion practices, and on the surgical procedures commonly cited in maximum surgical
blood ordering schedules (MSBOS). Because those guidelines identify procedures that are
significant users of blood, being either commonly or heavily transfused, and that are
considered to be appropriate targets for reducing surgical red blood cell use, MSBOSs were a
useful reference for guiding the definition of notable red cell using procedures.
The red cell using procedures could otherwise have been defined experimentally using data-
driven approaches. However, instead of pursuing the data-driven approaches in the early
stages of this study it was decided to use the list of procedures as an initial attempt so that
progress could be made in the definition and validation of subsequent methods. Some
initial investigations into a data-driven approach have already been considered for future
work as it is acknowledged that changes could be made to potentially improve the accuracy
and relevance of the procedures studied, thereby affecting the overall reporting of blood use
by surgical case group (Section 11.4). The findings of this study are reported with this
understanding of potential limitations and with the acknowledgment that the number of red
blood cell units attributed to surgical case groups might be greater if additional, relevant red
cell using procedures were included.
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By using these specific blood attribution rules an inference is made about the reason for
transfusion. It is acknowledged that this inference cannot represent the only or absolute
reason for transfusion and different blood attribution rules would provide a different view
of the data. Indeed, in this study, where a transfusion day record can be attributed to both a
surgical procedure and a haematological diagnosis the overlap in blood use can be
quantified (Figure 9.3), demonstrating an acceptance of the potential for alternative plausible
explanations for defining transfusion events. Further, it is acknowledged that the methods
employed in this study were based on assumptions relevant to the current context of clinical
and transfusion practice, and as such, the results should be interpreted in this context alone.
The findings for blood use attributed to specific procedural case groups for this study are
discussed here in the context of the assumptions made for this study and in relation to
previous evidence for blood use by surgical case group.
Overall, 28.9% of the red blood cell units used in the present study could be attributed to the
specified surgical case groups, a lower proportion of total red blood cell use than is reported
for previous studies in which blood use was linked with "surgical" or "medical"
classifications. The proportion of red blood cell units attributed to "surgery" in previous
studies (reviewed in section 3.5) ranges from 70% in the earliest report to 33% in the most
recent report (Table 11.2). The variation is explained in part by the way in which the
definition of surgery varies depending on the source of clinical data (for example, by
department, from discharge letter, from blood request form, by survey) and by the clinical
classification systems used. If the definitions are considered to be comparable then the
findings are illustrative of a trend of decreasing blood use in surgery, and elective surgery in
particular, which echoes a general trend that is indicative of improvements in surgical and
anaesthetic techniques, the introduction of alterative blood conservation interventions, such
as intra-operative cell salvage, and changes in the education, attitudes and awareness of
clinicians (Wallis, Wells & Chapman, 2006; Karkouti et al, 2001; Lemos & Healy, 1996).
Further, the findings are perhaps evidence that these reports have acknowledged and
addressed the requirement to examine medical or diagnostic reasons for transfusion when
describing blood use by clinical case group.
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Cook, 1991 70:30 100% of attributed RBC units reported
Vamvakas, 1994 55:45 100% of attributed patients reported (NB. not units used)
Zimmerman, 1997 50:30 Remaining 20% of RBC units attributed to "other
specialties"
Mathoulin-Pelissier, 2000 47:53 100% of attributed patients reported (NB. not units used)
Titlestad, 2001 57:43 100% of attributed RBC units reported
Wells, 2002 41:52 Remaining 6%of RBC units attributed to Obstetrics &
Gynaecology and 1 % not attributed
Stanworth, 2002 51:36 Remaining 13% or RBC units attributed to "combined"
specialties
Wallis, 2006 33:62 Remaining 5% attributed to Obstetrics & Gynaecology
PhD study, 2007
(data for 2000)
23:67 Medical use is all units not attributed to surgical case
groups (including 12% to haematological conditions)
Notel: Cross-reference Table 3.4a: figures rounded up in Table 11.3 compared to Table 3.4a. Note2. Studies
referenced by first author and year of publication: data reported for previous study period. Note3. Reports
reviewed in section 3.5 only; additional reports compared to Table 3.4a to include reports for which this
information could be ascertained or deduced rather than specific studies of blood use by surgical/medical
classification.
Of the surgical case groups specified for this study the three that account for the largest
proportions of red blood cell use attributed to procedures are: primary coronary artery
bypass graft operations (21.2% of RBC units attributed to surgical case groups), primary total
hip replacements (10.3% of RBC units attributed to surgical case groups) and operations on
valves of the heart and adjacent structures (8.1% of RBC units attributed to surgical case
groups). The top three ranking procedures in terms of red blood cell units used per
operation performed are transplantation of liver (10.2 units), emergency replacement of
aneurysmal segment of aorta (8.1 units), and other operations on aorta (4.6 units). By
surgical specialty, the three highest users of red blood cell units for this study are
cardiovascular (41%), orthopaedic (34%) and gastrointestinal (13%) (Table 11.3).
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Table 11.3 Summary of reported top surgical case groups for red blood cell use
Study Surgical case groups(% of total RBC units used attributed to procedures)
Chiavetta, 1996 Digestive system (23)
Cardiovascular (18)
Muscoskeletal (17)
Titlestad, 2001 Cardiovascular/thoracic (50)
Urology (21)
Obstetrics & gynaecology (6)
Wells, 2002 Orthopaedics (14)
General surgery (10)
Cardiothoracic surgery (6)
Stanworth, 2002 General surgery & orthopaedics (50)
Cardiothoracics (16)
Obstetrics & gynaecology (10)
Wallis, 2006 Orthopaedics (19)







Notel: Cross-reference Table 3.4c: figures rounded up in Table 11.3 compared to
Table 3.4c; Table 3.4c classifications generalised whereas Table 11.3
classifications as described in original reports. Note2. Studies referenced by first
author and year of publication. Note3. Reports reviewed in section 3.5 only.
There is a large body of published evidence for blood use for a range of elective surgical
procedures, including recent large-scale studies that report for a wide range of surgical
procedures (section 3.3 and 3.4), and particularly for coronary artery bypass graft operations
and joint arthroplasty with respect to the proportions of patients transfused and the
proportions of units transfused per patient, the determinants of transfusion, patient
characteristics, and variation between hospitals and across procedure types (Surgenor et al,
1992; Surgenor et al, 1996; Goodnough, Johnston & Toy, 1991; Goodnough et al, 1989;
Chiavetta et al, 1996; Stanworth et al, 2002; Cobain et al, 2007; Hasley et al, 1995; Hutton et al,
2005; Sirchia et al, 1994; Wells et al, 2002). However, few published reports provide blood
use data for a range of individual, well-defined procedures: surgical blood use data is
commonly reported in other studies by surgical specialty or similar sub-category of surgical
classification. Surgical case groups of this type that account for a high use of red blood cell
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units are gastrointestinal, cardiothoracic/cardiovascular, and orthopaedic procedures (Table
11.3). In this respect the results of this study are comparable to published evidence,
although this could be anticipated since the inclusion of red cell using procedures was
influenced by knowledge of such previous results and similar clinical experiences of red
blood cell use. The variation between these studies in the classifications reported for
cardiovascular and cardiothoracic procedures specifically is noted. Further, the findings
compared in Table 11.3 are the percentages of red blood cells attributed to surgical case
groups. These cannot distinguish procedures that are frequently performed but have a
modest use of blood compared with procedures that have low incidence but are associated
individually with a high use of blood.
For joint arthroplasty specifically, the evidence suggests that there is wide variation within
and between hospitals for the measures of rates of transfusion as well as across procedure
types and patient groups (Wells et al, 2002; Maxwell et al, 2002; Hasley et al, 1995; Sirchia,
1994; Spencer et al, 2005; Lemos & Healy, 1996; Surgenor et al, 1991; Bierbaum et al, 1999;
Hutton et al, 2005; Boralessa et al, 2000 & 2001; Churchill et al, 1998). Although describing
inter-hospital variation was not a specific aim of this present study, overall the findings
agree that orthopaedic surgery and specifically total hip and knee replacement procedures
account for a large proportion of total red blood cell use for the study population, suggesting
that orthopaedic surgery might be an area worth targeting with developments in blood
conservation strategies. Strategies include, for example, reducing blood loss in joint
replacement surgery by the use of cement fixings and by specific surgical practices relating
to the timing of removal of tourniquets and the use of wound compression dressings (Lemos
& Healy, 1996); intra-operative cell salvage (section 11.4); and the increased use of
endoscopic, "key-hole", surgery reduces the requirement for blood (Lemos & Healy, 1996;
Huet et al, 1999; Carless et al, 2006).
Thus, the findings of the present study describe areas of high blood use, for both the total
number of units used and units used per operation performed. This application of the data
is supported by evidence for the role of national arthroplasty registers, such as in Sweden
and the UK, in identifying poor outcomes that are associated with surgery as well as for
benchmarking practice for the future (Burns & Bourne, 2006; Scottish Arthroplasty Project,
2007). For example, in Sweden the national arthroplasty project has demonstrated
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reductions in the number of different types of implant used as well as reductions in the
number of revision operations being performed (Burns & Bourne, 2006). With the overall
number of total hip and knee replacements, and subsequent revisions that are particularly
associated with increased costs and poorer outcomes, on the increase and with the trend
expected to worsen in the future due to the ageing population, at least in the UK, targeted
clinical and transfusion practice improvements in the area of joint replacement surgery are
recommended (Burns & Bourne, 2006; Scottish Arthroplasty Project, 2007). Thus, accurate
and timely evidence for trends in blood use, such as can be provided by the present study,
the epidemiology of related diseases, and population demographics should be monitored
and the information used to aid decisions about requirements for practice change in the way
blood is used or to inform resource planning.
Previous reports also cite obstetrics and gynaecology as a well-defined clinical case group to
which a reasonable amount of blood can be attributed. The SMR01 clinical data extracted for
the present study could not be linked with specific maternal or neonatal (SMR02 and SMR11)
hospital records and so obstetric and gynaecological blood use was not fully described for
this study. By examining the blood use for obstetric and gynaecology case groups for other
studies, it was noted that, as for other areas of surgery, the precise case group classifications
vary between studies: obstetrics and gynaecology has been classified as a specific surgical
specialty (6% and 10% of RBC units attributed to surgical case groups , Titlestad et al, 2001
and Stanworth et al, 2002, respectively), a specific medical specialty (1% and 7% of RBC units
attributed to medical case groups, Mathoulin-Pelissier, 2000 and Lim et al, 2004, respectively),
and also as a separate group that bridges surgical and medical specialties (4%, 5% and 6% of
all RBC units used per study, Zimmerman et al, 1997, Wallis, Wells & Chapman, 2006, and
Wells et al, 2002, respectively). Obstetric and gynaecological diseases and procedures,
classified by the CPHA6 List A Hospital Diagnosis Groups, were reported to account for
4.9% of all blood component units used and 6.7% of transfusion recipients by Friedman,
Burns and Schork (1979). Therefore, the findings of previous studies suggest that between
1% and 10% of used red blood cell units could be potentially attributed to obstetrics and
gynaecology if the appropriate record linkage was carried out to link SMR02 and SMR11
data schemes with the study dataset. Furthermore, the reports suggest that relevant,
6 CPHA: Commission on Professional and Hospital Activities (America)
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comparable case group definitions and approaches to describing blood use in the area of
obstetrics and gynaecology, and others, are needed for the future.
11.2.3. Describing the use of blood components by clinical case group: haematology
The haematological case groups reported for this study were the pre-malignant conditions
myelodysplastic syndromes or polycythaemia vera and the malignant conditions lymphoma,
myeloma and leukaemia, that were defined using ICD-10 codes. Overall, 12.1% of red blood
cell use in the study could be attributed to these haematological conditions. Previous studies
that included diagnostic analysis of red blood cell use report the percentage of red blood cell
units attributed to haematological case groups as 10.0% diseases of blood and blood-forming
organs combined with leukaemia, lymphoma and myeloma, 14.0% to leukaemia and
lymphoma combined with diseases of blood and blood-forming organs, 42.0% and 28.2% to
all neoplasms, and 15.5%, 36.3% and 30.0% to "haematology" (Chiavetta et al, 1996,
Zimmerman et al, 1997; Mathoulin-Pelissier et al, 2000 and Lim et al, 2004; Wells et al, 2002,
Stanworth et al, 2002, and Wallis, Well & Chapman, 2006, respectively) (Table 11.4). The
findings, and to an extent the classifications, for Chiavetta et al (1996), Zimmerman et al (1997)
and Wells et al (2002) are in good agreement with the findings of the present study.
Mathoulin-Pelissier et al (2000) and Lim et al (2004) report all neoplasms together: the case
group includes the ICD-10 codes included in the present study but also many additional
conditions and so the proportion of red blood cell units reported for the case group is not
high in comparison with the results reported for other studies (Table 11.4).
In general, the range of findings for blood use attributed to haematology reflects the
differences in the classification of case groups. Findings can only be compared where a full
description is available for how the case group was defined: for example definitions may be
by specific "haematology" category (either defined by medical specialty or by the
researchers), or may cover various clinical codes for specific haematological neoplasms
and/or diseases of the blood and blood-forming organs. In general, even where well-defined,
the classifications for haematological conditions are comparatively broad. A strength of the
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present study is that the haematological case groups are defined by specific, individual or
small groups of ICD-10 codes.





Notes on haematological case groups
Chiavetta, 1996 10.0 BDC IV, 280-289 + BDC 203-205
Zimmerman, 1997 14.0 BDC I, 200-208 + BDC IV, 280-289
Mathoulin-Pelissier, 2000 42.0 ICD-10 codes C00-D48
Wells, 2002 15.5 "Haematology" (survey form case group)
Stanworth, 2002 36.3* "Haematology" specialty or directorate
Lim, 2004 1.0 ICD-10 codes COO-D48
Wallis, 2006 30.0 "Haematology" (survey form case group)
PhD study, 2007
(data for 2000)
12.1 ICD-10 codes C81-85, C90, C91-95, D45&46
BDC: Broad diagnostic category * 44.2% if include all haematology, haematology & general medicine, and
haematology & oncology. Notel: Cross-reference Table 3.4b: figures vary by classification reported in tables;
Table 3.4b generalised whereas Table 11.4 classifications are as described in original reports. Note2: Studies
referenced by first author and year of publication. Note3: Reports reviewed in section 3.5 only
The present study investigated the extent to which attribution of blood component units to
individual haematological case groups (though not to "haematological conditions" in total)
was influenced by the resolution of intra- and inter-episode competition between
haematological conditions at the patient level. The findings demonstrated that there were
very few instances where more than one haematological condition could be attributed to a
patient during the study period and where it did occur then the conditions were clinically
related. These findings suggest that the haematological conditions in the study were
appropriately chosen and were representative of a well-defined group of transfusion
recipients, and that the haematological blood attribution rule was acceptable for identifying
relevant patients. In particular, the combinations of pre-malignant and malignant
haematological conditions identified in the study are interesting because they describe
typical clinical disease progression and related comorbidities that might be expected for
haematological patients. In the study, a large proportion of red blood cell units used were
attributed to the case group of pre-malignant conditions (myelodysplastic syndromes or
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polycythaemia vera). This is consistent with pre-malignant conditions being the diagnosis
that is likely to be made prior to a diagnosis of a malignant condition and in the present
study blood is attributed to the patient's first blood using haematological diagnosis. This
understanding of clinical disease progression and comorbidities was integral to defining
appropriate methods of attribution of blood to haematological case groups; similar
understanding will be required for the future development of additional diagnostic case
groups, such as for other chronic conditions where the broader clinical history of the patient
is also potentially relevant. This discussion, however, raises again the persistent question
concerning the actual reason for transfusion, that is, where one condition leads to another or
one condition necessitates surgery, what ultimately constitutes the underlying cause of
transfusion? This study largely addresses this issue using the practical approach of
describing blood use from the likely perspective of the clinicians and hospital transfusion
committees who will ultimately make use of reports on blood component use by clinical case
group.
Awareness of the use of blood for medical indications has grown as reductions in blood use
in surgical contexts are made due to improved surgical and anaesthetic techniques, the use
of intra-operative cell salvage and implementation of maximum surgical blood order
schedules, for example. Therefore, there is a need to monitor and optimise the use of blood
according to well-defined diagnostic case groups. A population based survey of red blood
cell use in 2000, in which the use of blood was divided between surgical and medical
indications at a ratio of 41:52, prompted a more detailed analysis of the use of red blood cells
for medical indications (Wells et al, 2002). The second survey four years later reported an
overall reduction in total red blood cell units used, and specifically, a reduction in surgical
use and an increase in use related to medical indications such as haematology, non-
haematological malignancies and gastrointestinal haemorrhage (Wallis, Wells & Chapman,
2006). The report also concludes that the average age of transfusion recipients increased
between the two studies and that the proportion of units used for medical indications
increased with advancing age (Wallis, Wells & Chapman, 2006).
The evidence suggests that not only is the amount of blood used for surgical procedures
decreasing but that the need for blood for patients with medical conditions is increasing.
This is likely to be in response to changes in incidence and patterns of disease, changes in
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treatment, and improved survival or some combination of these factors. Between 1994 and
2003 the incidence of cancer in the UK has remained fairly constant, with an overall 4%
decrease in males and a 3% increase in females (Cancer Research UK, online). Reporting and
registration changes have been described specifically for lymphomas: the decrease in
incidence of Hodgkin's lymphoma and increase in incidence of non-Hodgkin's lymphoma
reflects a change in classification for some cancers from Hodgkin's to non-Hodgkin's
lymphoma. Further, myelodysplastic syndromes are considered likely to be reported
inaccurately due to difficulties in diagnosing the condition and subsequent classification
(Aul et al, 1997). Although incidence rates overall are generally falling the incidence of
leukaemia, multiple myeloma and non-Hodgkin's lymphoma increases with age; similarly,
myelodysplastic syndromes are also associated with advancing age (Cancer Research UK,
online; Aul et al, 1997). Therefore, improved survival rates and an ageing population may be
expected to have a marked effect in terms of increasing the prevalence of cancers and hence
on the use of blood transfusion for supporting chemotherapy treatments as well as increased
use in cancer-related surgery (the excision of tumours, for example).
To facilitate analysis of haematological malignancies and cancers in general, a role for
specialist cancer registers has been suggested as a requirement for the future (Cartwright,
Gilman & Gurney, 1999). The clinical data used in the present study was linked to SMR06,
the ISD-held cancer register, but only a single indicator variable for patients' status in the
cancer register was provided: full linkage with SMR06 could provide specific oncology data
including information on the pathology and treatment of specific conditions. The cancer
register should be investigated to elucidate a role for this specific information in future
blood use analyses. Further, the International Classification of Disease classification system
has been criticised for inappropriate groupings of haematological diagnoses, particularly in
the way that different types of leukaemia diagnoses have been aggregated as well as for a
lack of detailed classification of pre-malignant haematological conditions. Problems such as
these, coupled with decisions regarding the appropriate underlying disease or condition that
necessitates transfusion are a challenge to the accurate and meaningful attribution of blood
to diagnostic case groups (Cartwright, Gilman & Gurney, 1999; Wells, 2002).
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Table 11.5 Summary of reported top diagnostic case groups for red blood cell use
Study Diagnostic case groups(% of total RBC units used attributed to diagnoses)
Friedman, 1979 Malignant neoplasm (19)
Non-malignant gastrointestinal disease (18)
Fracture/traumatic soft tissue injury (12)
Cook, 1991 Circulatory system (24)
Digestive system (17)
Neoplasms (16)
Chiavetta, 1996 Neoplasms (27)
Digestive system (18)
Circulatory system (16)
Zimmerman, 1997 Non-haematological neoplasms (27)
Circulatory system (23)
Leukaemia & lymphoma, and diseases
of blood & blood-forming organs (14)
Mathoulin-Pelissier, 2000 Neoplasms (42)
Injury & poisoning (16)
Digestive system (14)
Wells, 2002 Haematology (16)
Digestive system (11)
Stanworth, 2002 Haematology & general medicine (all groups) (70)
Renal medicine (11)
Radiology & oncology (8)
Lim, 2004 Neoplasms (28)
Injury & Poisoning (20)
Digestive system (13)






Notel: Cross-reference Table 3.4b: figures vary due to different classification reported in tables;
Table 3.4b generalised whereas Table 11.4 classifications are as described in original reports.
Note2: Studies referenced by first author and year of publication. Note3: Reports reviewed in
section 3.5 only
In addition to the haematological case groups defined for specific analysis of diagnostic
blood use in the present study, other diagnostic case groups have been reported for previous
studies, including neoplasms (all classifications, 16-42% of RBC units attributed to diagnostic
case groups), circulatory conditions (16-24% of RBC units attributed to diagnostic case
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groups) and disease of the digestive system (11-18% of RBC units attributed to diagnostic
case groups) (Table 11.5). The commonality of reported diagnostic case groups across
previous studies, and to an extent the consistency in findings for the attributed red blood ceil
use within these case groups, provides a comparable body of evidence and suggests areas
for which additional diagnostic case groups could be developed for further analysis of the
study dataset (section 11.4).
Also, although blood component use for haematological conditions in the present study, and
generally for medical use in previous studies, has focused on red blood cell transfusion,
there is evidence for the use of other blood component types for medical indications. For
example, malignant diseases alone have been reported as accounting for 57% of platelet use,
38% of which was attributed to leukaemia and lymphoma patients (Zimmerman et al, 1997).
Platelet transfusion is an essential intervention for leukaemia that enables treatment with
chemotherapy. Further, malignant, non-haematological neoplasms and diseases of the
digestive and circulatory systems have been reported as notable areas of use for fresh frozen
plasma (Mathoulin-Pelissier et al, 2000; Zimmerman et al, 1997). However, where the
effectiveness of fresh frozen plasma transfusion has been analysed by randomised control
trial the findings suggest that there is little evidence to support current practice guidelines of
FFP transfusion (Stanworth et al, 2004). Continued monitoring of blood component use,
patient outcome and appropriate trials of blood component therapy and alternative
interventions should be encouraged in order to monitor compliance with practice guidelines
for the effective use of all blood component types.
Overall, the findings of the present study, in which the proportion of red blood cell units
used for haematological conditions was quantified, provide evidence for another area of red
blood cell use that is supported by previous studies. As has been described previously, the
rule for the attribution of red blood cell units to haematological case groups could be applied
to other diagnostic case groups where patients' total transfusion data for a specified time
period is relevant to the condition. Taken together, evidence for the increasing use of blood
for medical or diagnostic conditions in contrast to decreasing blood use for surgical events,
the suggestions for improvements to reporting and classification of medical conditions, and
the reports of blood use for other medical or diagnostic conditions and blood component
types, suggest that blood component use attributed to medical or diagnostic case groups is
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an important area for future blood use analysis. Further, the findings are again evidence to
support the recommendation for common methods for classifying and reporting blood use.
11.2.4. Discussion of results for additional applications using study dataset
The final set of analyses carried out for this study addressed the objectives of identifying
additional, potential applications which became possible given the creation of the study
dataset. Topics of particular clinical interest that were explored include modelling analyses
to assess the impact of changes in transfusion practice, for example, the use of alternative
interventions, and the impact on the supply of blood and demand for blood due to changes
in future population demographics.
Concept of a best practice indicator and practice intervention for reducing allogeneic
transfusion requirements
A useful application of the study data was the investigation of the novel concept of a best
practice indicator for transfusion. A best practice transfusion indicator is a level of blood use
that is representative of low blood use for a specific procedure that is determined by
observing the transfusion practice of several surgical teams or across clinical institutions. It
should be the lowest observed value, a value in the lowest quartile of the observed
performance range, or a similar measure that is clinically effective and achievable.
Furthermore, the value of the best practice indicator depends on the assumption that the use
of lower rates of transfusion is not associated with any detriment to the patient and so an
appropriate measure of outcome is needed in order to assess detriment versus benefit. The
value of the best practice indicator will also have to be continually reassessed. In the event
that the best practice indicator is not the lowest value of observed practice, but another low
value that is not associated with detriment to patient outcome, the aim of reducing the
practice of high users may be in part countered by an increase in the practice of low users
where it is of clinical benefit to do so. The reality of achieving best practice targets for
transfusion is influenced by factors affecting individual institutions and should be supported
by the aims and actions of hospital transfusion committees. To estimate the potential impact
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of a change in transfusion practice to the use of a best practice indicator, best practice values
that were determined at a hospital level by observing practice variation, were modelled here
for total hip replacements and coronary artery bypass graft operations.
The range of red blood cell use reported for the study dataset for the number of units used
per procedure performed or per patient undergoing a procedure, by hospital, have been
described (section 10.3 and 10.4). Applying the lowest reported values for red blood cell use
for total hip replacements (0.6 red blood cell units per procedure performed) to the number
of procedures in the whole of Scotland in 2000 resulted in a saving of 3,589 red blood cell
units (53.8% of total red blood cell units used for total hip replacement procedures in whole
of Scotland in 2000) compared to normal practice as observed in the study dataset (Table
10.3). This indicates the potential for savings in red blood cell use for a surgical procedure
for which it has been predicted that red blood cell use will continue to increase in the future
if no blood conservation strategy or alternative intervention is employed. The introduction
of a best practice indicator, with appropriate education and support from hospital
transfusion committees, could be an effective way to encourage surgical teams to reduce
allogeneic transfusion.
The reported scale of savings in red blood cell use that could be achieved from another
blood conservation strategy, intra-operative cell salvage, is discussed next. Intra-operative
cell salvage (IOCS) is a mechanical process by which blood that is lost during surgery is
recycled and, after washing to remove plasma proteins, is returned to the patient. This
intervention can replace or reduce the need for allogeneic transfusion, and thus has the
potential to make marked savings in resources of allogeneic blood. Values for predicted red
blood cell savings were obtained from published evidence for IOCS in cardiac surgery and
were applied to data for coronary artery bypass graft (CABG) operations in this present
study to model the potential impact on blood use. CABG surgery was chosen because
procedures have a high requirement for blood and the use of IOCS has already been
demonstrated in this type of surgery (section 10.4) (Bell et al, 1992; McGill et al, 2002; Carless
et al, 2006). The findings of the modelling analysis in this study reported savings in red
blood cell use of between 1,300 and 3,046 red blood cell units; 15.6% and 36.6% of the total
red blood cell units used for all CABG procedures in Scotland in 2000 in comparison with no
intervention (Table 10.7).
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Furthermore, the estimated saving in red blood cell use in CABG surgery when a best
practice target of 1.4 red blood cell units per procedure performed (Aberdeen Royal
Infirmary) was applied was 24.4% of total red blood cell units used for CABG procedures
across Scotland in 2000 (Table 10.7). This potential saving falls within the range of savings
estimated for the use of IOCS in CABG surgery. Therefore, a change in practice behaviour
might be able to achieve savings in the same order as an expensive, technical intervention
which poses new risks. It is acknowledged that an intervention such as IOCS might be
employed in order to achieve best practice targets, though, where practice has been
improved all aspects of patient management and blood prescribing have been better
executed. Comparisons such as these are useful to informing practice decisions but these
should also be based on analysis of clinical effectiveness, cost effectiveness, the logistics of
implementation, resource issues, predicted long-term benefits and sustainability of practice.
The modelling analyses reported in the present study focused on intraoperative cell salvage
in coronary artery bypass graft procedures but there is also compelling evidence for its
efficacy when used in orthopaedic surgery such as joint arthroplasty. A systematic review of
cell salvage in adults undergoing surgery identified 23 studies relating to the use of IOCS in
CABG surgery and a further 23 relating to the use of IOCS in orthopaedic surgery:
reductions in allogeneic transfusion were reported for both settings, and in fact reductions in
allogeneic use were greater in orthopaedic cases than in the CABG settings. It was noted
that the quality of all studies reviewed was described as being poor or biased in favour of
cell salvage and so appropriately designed studies are recommended for the future (Carless
et al, 2006). Post-operative cell salvage, in which blood is collected from patients' wound
drains and is either filtered or washed prior to being re-infused, has also been shown to
reduce the need for allogeneic transfusion (Lemos & Healy, 1996). Controversy surrounds
the practice given concerns over contamination of the recycled blood but there is also
evidence that re-infusion of unwashed post-operative cell salvaged blood has immuno-
stimulatory effects which may be advantageous in fighting post-operative infection (UK
Blood Transfusion Service, online). Indeed, post-operative cell salvage is routinely
employed in mainly orthopaedic settings within the UK. This is noteworthy given the
modelling analysis in this study that described the effect of the ageing population on
increasing demand for blood for primary and revision total hip replacement procedures.
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Therefore, given the anticipated changes in demographics, the epidemiology of disease, and
changes in clinical and transfusion practice the efficacy of blood conservation interventions
should be examined for specific patient populations (for example, the elderly) and for
specific clinical case groups, diseases and surgical procedures, in order to identify areas
where allogeneic blood use can be reduced. As with all blood conservation strategies, as
indeed for allogeneic blood transfusion itself, the balance of risk versus benefit needs careful
consideration. The additional costs of IOCS may be considerable but if balanced by the
advantages of reduced infection and immuno-modulatory effects and reduced impact on the
supply of blood, the intervention could be of considerable benefit in a pressurised and
resource-constrained industry. IOCS in CABG and orthopaedic settings is neither related to
poorer early outcomes, such as hospital length of stay, post-operative bleeding and mortality,
nor to adverse reactions (Carless et al, 2006; Davies et al, 2006). Evidence for the effective use
of other blood conservation interventions in CABG and orthopaedic settings has been
reported: pre-operative autologous donation or normovolaemic haemodilution (though not
currently encouraged in the UK (DOH, Better Blood Transfusion Toolkit, online)),
transfusion protocols and restrictive thresholds, and the use of pharmacological agents
(aprotinin, tranexamic acid and erythropoietin for example) (Huet et al, 1999; McGill et al,
2002; Davies et al, 2006; Carless et al, 2006). However, there is a need for adequately
powered randomised controlled trials and comparative analysis of allogeneic transfusion
alternatives to describe the effectiveness and cost benefit of implementation, whilst
continuing to monitor the use of blood, such as can be done using this present study's data,
in order to identify and assess target areas for intervention with blood conservation
strategies (Davies et al, 2006).
Clinical effectiveness and best practise: a role for an appropriate evidence base of
transfusion efficacy in reducing inappropriate transfusions
The importance of adequate analysis of clinical effectiveness in transfusion practice is
exemplified by the analysis of fresh frozen plasma (FFP) use in relation to thrombotic
thrombocytopenia purpura (TTP) carried out using the present study dataset (section 10.5).
The findings demonstrate how effective monitoring and analysis of specific patient groups
in combination with appropriate evidence to inform transfusion practice can be used to
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reduce inappropriate transfusion and to conserve the supply of blood components of all
types.
The analysis was prompted by a review reporting the lack of evidence to demonstrate
clinical effectiveness of FFP transfusion in all conditions for which clinical guidelines
describe its use, that is, except in the case of TTP (Stanworth et al, 2004; Brunskill et al, 2007).
The analysis reported for the present study aimed to identify TTP patients and quantify FFP
use in comparison with the total number of FFP units used for all clinical indications in the
study in order to quantify the potential savings in FFP use in light of emerging evidence
about current transfusion practice and effectiveness. TTP patients were not well
characterised at the time (2000) and even now the condition is not defined by a specific ICD-
10 code. Therefore, patients of interest were defined by the two criteria of being linked to
the use of a high number of FFP units and having any diagnosis of purpura or other related
haemorrhagic conditions or thrombotic microangiopathy. By these criteria a small number
of patients (n=5) were identified who together were the recipients of 2,554 units of FFP,
representing 27.0% of the total number of FFP units used in the study (Table 10.13). The
conclusions are that the potential exists to make large savings in FFP units (potentially 73.0%
according to data in this study) if recent evidence for the clinical effectiveness of FFP
transfusion is observed and guidelines reconsidered; and that the study dataset can be used
to describe blood use for all blood component types and for specific groups of patients.
Donor exposure and vCJD
Donor exposure is a measure of the number of donors to whom blood recipients are exposed
though blood transfusion. The concept of donor exposure was investigated specifically to
identify patients who are transfused with many units of blood components and who are
therefore at increased risk of transfusion transmitted infections and errors of wrong blood
transfusion (section 10.5). The risks of transfusion transmitted infections are typically
expressed as the risk per donated unit of blood component rather than risk per unit used
and so the risk to the patient is underestimated for the transfusion of units of platelet and
cryoprecipitate, which are pooled from multiple donated units. The compound risk of
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infection for a patient who receives multiple transfusions is a concept that has not been fully
acknowledged by transfusion practitioners.
By describing donor exposure for patients in the present study the effect of the adjustments
made for calculating exposure for platelet (units used multiplied by five) and cryoprecipitate
(units used multiplied by six) use was elucidated (Tables 10.14 & 10.15). By not accounting
for these adjustments the number of patients with a donor exposure of 80 or more was
underestimated by a factor of four (4.2% of all patients, unadjusted, versus 16.8% of all
patients, adjusted). A donor exposure of 80 or more transfusions per patient throughout a
lifetime is the recent estimation of the threshold donor exposure after which a patient is
considered to be at particular risk of vCJD infection, though not necessarily disease
contraction (Dobra, personal communication). Since this estimate is likely to change with
new epidemiological data, donor exposure for all patients was reported for the present study.
For public health purposes there are important practical implications for the management of
patients who are considered to be at risk of vCJD and so it is important to have estimates of
the number of patients in the high risk category, however that might be defined.
Furthermore, the findings reported are for donor exposure in one year and there are
expected to be patients who have had transfusions prior to or subsequent to the study
period, therefore, the findings of this study are a minimum estimate for patients' total
lifetime exposure to blood. Given that the risk to the patient increases with each transfusion
to which the patient is exposed it is important to consider the overall transfusion-associated
risk for a patient for all blood component units received in a lifetime. Following death,
patients are evidently at no further risk of receiving a transfusion, but the latent phase of the
disease means that they may have been infected without being symptomatic at the time of
death. The findings of the present study report donor exposure for patients with and
without a record of date of death (up to 2004) to provide a first insight into donor exposure
in relation to survival for which specific future analyses are suggested. It is acknowledged
that because the study data contains at the most one year's transfusion data for the study
population and because up to date death record data was not sought, the findings are only
indicative of the potential to establish an individual's total exposure to blood, in relation to
infection risks and survival, where appropriate, that is, comprehensive, national data
covering a period of several years is available.
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It is well-documented that reductions in the use of blood should be made wherever possible
in order to reduce adverse events and reactions associated with transfusion, and this is
especially true for those who are heavily transfused (McClelland, 2007; SEHD, 1999a &
1999b; JPAC, 2007). Prior to the emergence of vCJD, there was confidence that blood
transfusion was highly safe in terms of transfusion transmissible infection, far safer than
ever before. The emergence of vCJD and evidence for the potential risk of vCJD
transmission through blood transfusion has become one of the main concerns surrounding
transfusion practice and particularly the transfusion of multiple units per patient (SEHD,
1999b; Llewellyn et al, 2004). Under new UK regulations introduced to control the spread of
vCJD, surviving transfusion recipients are subsequently excluded from donating blood
(JPAC, 2007; SEHD, 1999b). Other regulations introduced thus far in the UK relate to the use
of, and subsequent cleaning or disposal of, surgical instruments as surgical instruments have
been implicated in the transmission of vCJD from infected patients undergoing surgery,
regardless of the transfusion risk or donor status of these patients. CJD contracted through
accidental transfer during a medical intervention such as via surgical instruments, organ and
tissue transplants and indeed blood transfusion is termed iatrogenic CJD. CJD is extremely
resistant to chemical and physical decontamination processes meaning that it could not be
guaranteed that sterilisation processes would render surgical instruments free of CJD (RCSE,
2001; JPAC, 2007; NICE, 2006).
In 1999 the government recommended the introduction of single-use instruments for high
risk procedures involving the central nervous system and eye (particularly tonsillectomy
and adenoidectomy but excluding operations involving cerebrospinal fluid except spinal
surgery where the outer layer of the meninges is breached) and in 2001 announced a £200
million upgrade of decontamination facilities to improve sterilisation processes for surgical
instruments (SEHD, 1999b). However, by the end of 2001 single-use instruments were
withdrawn due to concerns that the quality of instruments was reduced and was affecting
their safe and effective use in surgery (RCSE, 2001; NICE, 2006). Current precautions
recommend comprehensive cleaning and sterilisation procedures on all surgical and
diagnostic instruments, the quarantine of instruments used on suspected cases of vCJD
pending confirmation of a diagnosis, and the incineration of instruments used on confirmed
cases of vCJD. Crucially, early notification of suspected cases is required in order to
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facilitate the tracing and recall of blood donations made by individuals who are
subsequently found to be infected with vCJD (SEHD, 1999b; NICE, 2006).
The risk of infection through surgery is aggravated by the fact that a patient undergoing
surgery will not necessarily be known to be a vCJD infected individual as no specific,
reliable test is available to date, although a claim to a notable advance has recently been
made in the form of a new test that could be used to routinely test blood donations for vCJD
by 2009 (Moss, 2007). Meanwhile, the nature and frequency of surgical procedures of all
patients, but particularly of patients who have a high level of donor exposure, should be
investigated to examine potential routes of transmission; that is, specific procedures with
high risk of infection or high levels of transfusion, to identify individuals who may be at risk.
Data such as the study dataset can be used for this purpose: indeed the study dataset has
already been used to provide preliminary data on the subject of multiply-transfused patients
in the context of concerns over vCJD transmission via blood. Interest in this important area
of research is unlikely to diminish as the emergence of vCJD is one of the largest influencing
factors on blood donation, transfusion risks and transfusion practice currently contributing
to the drive towards safe and effective use of blood components, and although the present
study was limited to data for the year 2000 and to a subset of Scottish hospitals, the methods
of analysis could be applied to similar national data for a longer time period in the future .
Impact of the ageing demographic of the UK population on red blood cell use
The UK has an ageing population: people are living longer and younger age groups are
diminishing. Because changing demographics are expected to have a marked impact on
clinical and transfusion practice, the effect on the use of red blood cell transfusion was
modelled up to the year 2031 (section 10.6). The findings demonstrated that red blood cell
use is expected to increase at a rate higher than the rate of population growth due to the
expansion of older age groups, typically over 60 years of age (and particularly for males)
who have a higher rate of transfusion than other age groups (Figure 10.5). Indeed, the total
population in 2031 is projected to be the same as in the year 2000 but red blood cell use is
estimated to increase by 37.8% in that time. The effect was exemplified by total hip
replacement procedures that are commonly performed for patients over 60 years of age. The
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change in red blood cell use for primary and revision hip replacements was modelled for the
whole of Scotland for the year 2031 based on observed rates of transfusion and at a best
practice figure described for the study population but not accounting for any changes in the
epidemiology of disease, changes in treatment options or developments in prostheses, for
example; the latter of which could provide more successful options for long-term primary
fixtures thus reducing the need for revision operations and related requirements for blood.
The findings indicate that the estimated number of red blood cell units used for total hip
replacements in 2000 was 8.4% of the total red blood cell use for Scotland and was predicted
to increase to 11.5% of the total red blood cell use for Scotland in 2031 (section 10.4, Table
10.7). Thus, the findings show that the dataset can be employed to predict the effect of
demographic change (in the form of an ageing population) on the use of blood in general
and specifically for procedures that are common to old age.
There are likely to be numerous opportunities in which the study data and the application of
the methods employed in this study can be utilised in the future, further to the applications
explored in Chapter 10 and discussed here in section 11.2. Analyses of transfusion recipient
survival, donor exposure, practice variation, infection risks and further analysis of the
clinical use of blood for epidemiological, research, quality assurance and planning purposes
will be highly valued in the context of continuing efforts to make blood transfusion as safe
and effective as possible.
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11.3. Study data and methods
The data extracted for the STEP feasibility project, and subsequently used in this PhD study,
came from two routine datasets: an inpatient clinical data scheme (linked SMR01/06/GRO,
ISD), and a blood bank record system (MAK-Progesa, SNBTS). To evaluate the implications
of using these data sources in the development of the present study, the specific strengths
and weaknesses of the data, the merits of using routine data in medical research and issues
concerning the population represented by the study data are discussed here.
Further, a review of comprehensive, descriptive studies of red blood cell use by clinical case
group raised particular methodological issues central to appropriate analysis of the clinical
use of blood, highlighting the developments needed in research methods to ensure studies
are conducted appropriately and effectively in the future. These factors, namely definition
of study population, coding of clinical data and classification of case groups, and the
methods used to link blood use to clinical case groups, were considered in the approaches
employed for this study.
11.3.1. Strengths of study data and methodology
The transfusion data used in the study was extracted from SNBTS blood banks that utilise
the Progesa blood bank computer system. Because the records were obtained from a
common, routine reporting system records from different hospitals could easily be combined
to form a single source of transfusion data in preparation for further processing.
Transfusion records underwent compaction by 24-hour period (using date of transfusion) to
create transfusion day records, in order to facilitate later stages of record linkage using date
variables. The process was carried out by SNBTS staff as it required specialist knowledge of
and access rights to the SNBTS blood bank computer system.
The study included all available transfusion day records of used blood component units for
the study population for the year 2000. Even though restricted to one year, the available
transfusion data provided a comprehensive resource of information for all blood component
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units used in the year for patients included in the study. This meant that the data could be
viewed at a patient level rather than being restricted to single transfusion events per patient
such as in the study by Mathoulin-Pelissier et al (2000). The value of this is illustrated by the
case group of haematological conditions for whom all transfusion events within the study
period were attributed to the haematological diagnosis making it possible to consider the
patient's total transfusion requirements for that period. For certain other patient groups not
yet defined the most meaningful study period may be from point of first diagnosis to death:
however, a compromise between availability of data and feasibility of analysis must be made.
Clinical (SMR01-CD) data was extracted from a routine database of SMR01 records held by
ISD, linked to cancer (SMR06) and death (GRO) records, for all patients whose identities
could be linked to a patient identity in the source data of transfusion day records of blood
component unit assignments. SMR01 is a data scheme for inpatient and day case records
that contain patient demographic and clinical data and data pertaining to individual
consultant episodes of hospital care submitted to ISD by hospitals. Issues regarding the
large amount of clinical data and the consequences for defining methods are discussed
presently (section 11.2.2). First, SMR01 records are generated from information largely
drawn from discharge letters and patient case notes by hospital coding staff. The
conventions of clinical coding are governed by comprehensive guidelines developed by ISD:
these include guidelines on how to resolve queries by encouraging coding staff to consult
with the clinicians responsible for the episode of care and subsequent discharge letter. The
data contained in SMR01 records undergoes routine quality assurance checks that are
carried out by ISD to validate the accuracy of coding practices. Quality assurance checks
indicate that SMR01 data variables consistently show a high rate of accuracy for the coding
of clinical data by comparing coding information submitted by hospitals with original
hospital clinical records, though the level of accuracy have on occasion been below the target
level required (ISD, 2004). Further, the completeness of SMR01 records at a given point in
time is affected by the promptness of submission of records by hospitals to ISD and could
pose a potential cause of data loss. However, in 2004, when data for the year 2000 was
extracted for the STEP feasibility study the submission of SMR01 records by relevant
hospitals for the study period was complete. The date of death variable was current at the
date of data extraction and no subsequent update on the date of death variable was sought
during this study as survival analyses were not planned in the present study.
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As well as the file of all SMR01-CD records that could be linked to patient identities in the
source data of transfusion day records, a file of all SMR01-CD records for the whole of
Scotland for the year 2000 was available. This file provided a source from which relevant
denominator data could be obtained: for example, number of operations performed, number
of patients who underwent specific operations, number of episodes containing specific
diagnoses, and number of patients with those specific diagnoses regardless of patients'
transfusion status.
Following extraction, transfusion and clinical source data underwent linkage processes at
ISD. The first process utilised probability matching of patient identifier variables: by
comparing patient identifying information to decide whether or not records relate to the
same person a unique number could be attached to records on an individual patient basis.
The process of exact matching previously used by ISD for this process missed many true
matches due to errors in recording but probability matching employs a highly validated
computer algorithm that allows for imperfections in the recording of data (Kendrick &
Clarke, 1993; Kendrick, 1997). The variables examined include surname (and its phonetic
code to overcome differences in spelling), first initial (and full forename and second initial
where available) sex, postcode, date of death (if available), and year, month and day of birth.
Other patient identifiers such as hospital case reference number, CHI/UPI7 number and NHS
number are used where available. The assignment of a unique patient identifier to all
records was critical to selecting SMR01-CD records for patients with transfusion day records
and to the linkage of SMR01-CD and transfusion day records to form the study dataset.
Unique patient identifiers also allow for additional record linkage in the future such as to
new or additional SMR data schemes or updated GRO death record information.
The sources of routine transfusion and clinical data and the processes of validation and
quality assurance of clinical data have been examined and described to evaluate the data
used in this study. The data was obtained from datasets that are routinely collected and
routinely undergo validation and quality assurance checks. By utilising routine datasets not
only is the quality of the data monitored but important savings are made in the time and
resources, and indeed funding, that would otherwise be required for data collection. Further,
7 CHI: Community Health Index number, the national unique number for any health communication related to a
patient. UPI: Universal/unique patient identifier
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because the data exists in established computer registers there is added benefit in that data
input is eliminated and automated linkage and computational processes can be utilised. The
role for routine, computerised data sources and automated processing in blood use analyses
have been described previously (Titlestad et al, 2001 & 2002; Syrjala et al, 2001; Zimmerman
et al, 19997 & 1998; Lim et al, 2004; Stanworth et al, 2002).
11.3.2. Weaknesses of study data and methodology
Potential weaknesses of the available data including problems with data variables, the study
population and study period, and missing data are discussed next. First, in transfusion day
records there was no variable based on direct observation and recording of the number of
units infused into, or used by, the patient. The variables for blood component unit
measurement contained in extracted transfusion day records were the number of units
assigned (that is, reserved and compatibility labelled for a specific patient) and the number
of units deassigned (that is, returned to blood bank). Therefore a new variable, termed
"used", was computed and consequently, all results relating to blood use are subject to the
assumption that the number of units used is equal to the number of units assigned minus
units deassigned. The assumption could overestimate blood use in cases where blood
component units were assumed to be transfused but were in fact otherwise discarded
without record. However, previous validation of this assumption indicates that the estimate
is appropriate (Palmer, personal communication);
The study population was defined as all patients with a transfusion day record in an SNBTS
blood bank Progesa system and all extracted transfusion day records were retained in the
study if they could be linked to SMR01-CD records. However, some of the transfusion day
records in the study data carried hospital codes for hospitals that were not expected to be
included in the study because they do not utilise the SNBTS/Progesa blood bank system. In
the main these represent instances where SNBTS/Progesa blood banks assigned blood
component units directly to patients in other hospitals that do not use the same blood bank
system, for example, for whom there has been a special request for specially typed units of
red blood cells for a patient with red cell antibodies that make it difficult to find compatible
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donor red blood cell units. In addition, some instances of unexpected hospital codes may
represent patient transfers whereby blood component units were assigned in one location
and were transferred with the patient to a different location where the patient was
subsequently transfused. The number of units accounted for by these instances is small and
has minimal effect on the attribution of transfusion events to clinical case groups.
However, this issue does affect the selection of an appropriate denominator population. The
hospital code included in the dataset is the hospital at which the transfusion was given and
so for patients whose transfusion day record was generated as a result of a special request or
patient transfer a non-SNBTS/Progesa blood bank hospital is reported. Selecting a
denominator population based on the hospital codes contained in SMR01-CD records in the
study dataset would include all SMR01-CD records for the year 2000 for those hospitals for
which a special request for blood or patient transfer had occurred, whereas the majority of
these hospitals' transfusion data is not included in the study. Therefore, by overestimating
the size of the denominator population, blood component use per episode of care, patient, or
operation would be underestimated. Thus, the issue was addressed by selecting a
denominator population for all hospitals in the transfusion day records source data
excluding those hospitals for which blood was not supplied by an SNBTS/Progesa blood
bank other than for special requests or patient transfers. That is, the hospitals selected
represent only hospitals for which all blood banking (and so patient specific blood
component assignments) is performed by an SNBTS/Progesa blood bank. Therefore, the
denominator data selected for the study underestimates the total number of procedures and
diagnoses for the study population because it excludes some clinical data relevant to the
study dataset (that is, the data for patients transfused at non-SNBTS/Progesa hospitals).
However, only a small number of transfusion and clinical records with such excluded
hospital codes appear in the study dataset.
The data shows that the red cell using surgical procedures defined in the study tend to be
associated with a single inpatient episode and any further, related clinical care tends to be at
the same hospital as that at which the procedure was performed. Therefore, for analyses of
blood attributed to surgical case groups the denominator population was largely
appropriate. However, for haematological conditions, patients may be diagnosed and
receive treatment at several different hospitals over a protracted period of time. The
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distribution of patients between the haematological diagnoses varies between the
denominator data and the study data because of cases where the patient was initially
diagnosed and treated (transfused) for a haematological condition and where the patient
was subsequently treated (transfused) for that or a related haematological condition at a
different location, and depending on the progression of disease of those conditions if any
was reported. The issue of selecting a representative denominator population would have
been avoided had the transfusion day records that carried a non-SNBTS/Progesa blood bank
hospital code been removed from the study dataset at the start of the study and is a
reminder of the benefit in studying a whole population's use of blood.
Another potential weakness in the scope of the study was the study period. Firstly, the data
was for the year 2000 which, at the time of the present study, means that the data is seven
years out of date. It is acknowledged that changes in clinical and transfusion practices that
could affect the rules for blood attribution and subsequent interpretation of the findings for
blood use by clinical case group are likely to have occurred during this time. This is an issue
integral to the study being a pilot study and one that has been addressed by the subsequent
creation of the Scottish Transfusion Epidemiology Database (STED) (section 11.5) which
provides up to date blood use data for Scotland. Further, the one-year period provided a
cross-sectional observation of patients' clinical events and would be expected to include a
case mix of a range of stages and severity of disease and surgical complexities. Any fixed
time frame that defines a window of available data means that information at the very start
and very end of the period cannot be properly assessed unless specific, additional records
are sought, because interpretation may be dependent on transfusion or clinical data in
previous or subsequent records not included in the study. This is not a problem of the data
per se, rather is an issue of the methodological approach adopted. The so called "edge
effect" has less impact on analysis and interpretation of available data the longer that the
continuous time frame of study is. In the review of published evidence of comprehensive,
descriptive studies of clinical blood use, the study period ranged from two weeks to six
years, with the most common length of study being one year (section 3.4). Again, as has
been previously acknowledged, a compromise has to be made between comprehensive data
collection and feasibility of collection and analysis.
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A further potential weakness of the available clinical data is that it does not include
information for outpatients and so the study dataset can not be used to report on blood use
by clinical reason for outpatient transfusions. Outpatient data is recorded in a separate data
scheme designated SMROO that was not available for linkage to SMR01 records when the
study data was extracted. The study data also lacks maternal, neonatal, and birth data
because SMR02 (maternal) and SMR11 (neonatal, now Scottish Birth Record) data schemes
could not be linked at the time the study data was extracted. Transfusion events that could
have been linked with one of these other data schemes could have been missed out of the
study dataset if the patient did not also have an SMR01 record in the study year.
Transfusion day records in the study dataset that could have been linked with one of these
other data schemes and were linked to patient identities with SMR01 records may have been
more appropriately described by the non-SMROl data either in place of or in addition to the
link with clinical indications identified within the SMR01 records.
In summary, potential weaknesses of the source data include the lack of a variable for
transfused units, the inclusion of some specific, non-SNBTS/Progesa blood bank transfusion
day records and the subsequent impact on defining a denominator population, the scope of
the study period, and the lack of record linkage to additional Scottish Morbidity Record data
schemes. Notably, a weakness of the source data is that in neither SMR01-CD records nor
transfusion day records is the clinical reason for transfusion specifically recorded; this issue
is central to the requirement for the definition of blood attribution rules and clinical case
groups, which are discussed next (section 11.3.3). Whilst acknowledging the limitations
posed by these issues, the source data of transfusion day records and SMR01-CD records
was considered to have been appropriately selected and to have provided useful and
validated data for the study. Further, subsequent methods were devised with consideration
for potential approaches to address these limitations.
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11.3.3. Study dataset development: Records not included in study
As has been described and discussed elsewhere, the study dataset was created by linking
patient identities in the source data, that is, transfusion day records of unit assignments and
SMR01-CD records, and selecting for transfusion day records of units used (section 5.2).
Some transfusion day records of unit assignments could not be linked to a patient identity
with an SMR01-CD record in the year 2000, a subset of which are transfusion day records of
units used. Transfusion day records that cannot be linked to SMR01-CD records are likely to
occur because the hospital activity of the transfused patient was recorded in an alternative
SMR data scheme, for example, maternal (SMR02), neonatal (SMR11) and outpatient (SMR00)
records that were not available for study at the time the data was extracted for the STEP
feasibility study. 5.7% of the total number of transfusion day records of units assigned in the
source data was not included in the study dataset because they could not be linked with
SMR01-CD records for the year 2000. The implication is that 3.6% of red blood cell units
used could not be described by clinical case group and the reasons for maternal, neonatal or
outpatient transfusions could not be elucidated. Record linkage with these data schemes is
recommended for future analyses of this sort.
Further, the study dataset was limited to transfusion day records of units used and so
SMR01-CD records for patients for whom blood was assigned but who were not
subsequently transfused were not included in the study dataset. However, these records are
available for future analysis, for making estimate of total blood supply requirements, for
example.
The small number of transfusion day records of units used that cannot be linked to SMR01-
CD records and the fact that reasonable explanations can be provided for this indicate that
low levels of data loss were encountered between data extraction and record linkage,
thereby providing what can reasonably be considered to be a comprehensive study dataset
for the relevant study population and period.
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11.3.4. Methodological challenges relating to dataset development and the attribution
of blood to appropriate clinical case groups
The strengths and weaknesses of the source data were discussed previously (section 11.3.2)
and are referred to here in the context of the methodology that was devised and employed to
create and analyse the study dataset. Basic characteristics of transfused patients and blood
component use were described directly from the transfusion data in the study dataset.
Further to this, a principal objective of the study was to identify a means of classifying and
quantifying blood component use by clinical case group. The fundamental issue with this
aim was that the clinical indication or reason that can explain the patient's requirement for a
blood transfusion was not recorded in the available data; indeed it is rarely explicitly
recorded in transfusion records or patients' case notes not just in Scotland but in other
countries in which this kind of analysis has been attempted (Sirchia et al, 1994).
Consequently, a major part of this study was to devise methods that could be used to
attribute used blood component units to an appropriate reason for transfusion thus enabling
blood use by clinical case group to be described. The issues encountered and the
consequences for the methods employed in this study are discussed here.
Two notable challenges were the multiplicity of clinical and transfusion records per patient
during the study period and how to utilise the large amount of clinical data contained in the
SMR01-CD records; these are discussed next in the context of defining the blood attribution
rules.
The first issue with the existence of multiple transfusion and SMR01-CD records for many
patients was concerned with the handling and management of the data. In order that all
potential relationships between clinical data and blood component use could be examined,
every SMR01-CD record had to be linked in some way to every transfusion day record on a
patient by patient basis. To facilitate this, the file of SMR01-CD records was restructured so
that all records for each patient were compacted into a single, complex record representing
the patient's available SMR01-CD history for the year 2000. Restructuring transfusion day
records in this way resulted in the multiplication of blood units which, in the initial trials,
caused difficulties in enumerating actual units attributed to clinical case group. The
resolution of this problem by restructuring SMR01-CD records and not transfusion day
records was a marked advance in terms of the mechanics of data handling. Consequently,
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the study dataset allowed for all possible relationships between transfusion day records and
SMR01-CD records to be examined in a format that would facilitate subsequent flexibility of
analyses of blood use.
In order that an inference could be made as to which clinical code within SMR01-CD records
was the relevant clinical data to which blood use should be attributed, blood attribution
rules were devised. The first task undertaken to relate blood use to clinical case groups was
to define date rules that linked transfusion day records with SMR01-CD with temporal
relevance. The date rule developed to link transfusion day records with a specific SMR01
episode of surgical intervention defined a relationship between the date of blood component
assignment and dates in the clinical record pertaining to the episode of clinical care (date of
admission and date of discharge). A wider window of attribution was considered for
haematological diagnoses: all transfusion day records for the year 2000 of patients with any
instance of a relevant diagnosis were attributed to haematological case groups. The date
rules were defined using clinical judgement about the likely temporal relationship between
blood assignment and use in the context of current transfusion and clinical practices in
Scotland. The date rules employed in future studies of this sort should consider relevant
practices to ensure that appropriate attribution of transfusion day records to SMR01-CD
records is made. Changes to the date rules may require additional clinical experience to be
incorporated, as well as adjustments to account for the effects of changes in transfusion
practice and clinical practice over time.
The second requirement of the blood attribution rules was to link transfusion day records
with clinical case groups identifiable within appropriately linked SMR01-CD records. The
conventions used to code clinical data in SMR01 records (as defined by ISD) were examined
to gain an understanding of the availability and construction of the data coded in the
procedural (OPCS-4) and diagnostic (ICD-10) variables. An inference had to be made about
the clinical event or condition that should be considered as the likely reason for transfusion:
clinical case groups could be coded in any of the four procedure variables and six diagnostic
variables (intra-episode competition, Figure 5.4a). Where the surgical date rule linked more
than one SMR01-CD containing a red cell using procedure to a transfusion day record or
where a haematological patient had more than one SMR01-CD containing a haematological
diagnosis in the year a further decision had to be made to define the relevant case group that
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represented the overall likely reason for transfusion (inter-episode competition, Figure 5.4b).
The issue of multiple clinical variables giving rise to intra- and inter-episode competition
was one of the largest factors affecting the definition of clinical case groups and how blood
use was attributed to clinical case groups. Because the clinical coding conventions guide the
coding of clinical data by importance or priority, the issues of competition were resolved by
accepting the first red cell using procedure or haematological condition occurring
chronologically, and within SMR01-CD records, as the case group to which blood use was
attributed. The impact of this on the findings of blood use by clinical case group depends on
the likelihood of major surgical events or chronic conditions being recorded together; the
specific findings for this study are described next.
The combinations of clinical case groups for instances of competition were reported
alongside the overall results for surgical and haematological red blood cell in order to give a
more complete picture of the clinical reasons that can be related to blood use (Chapters 8 and
9). All instances of competition for the attribution of blood in this study are between two red
cell using procedures or between two haematological diagnoses. Overall there were few
instances when using the surgical blood attribution rule that red blood cell use could be
attributed to more than one of the defined surgical procedures (and in no case more than
two): 26.0% of transfusion day records were linked to one SMR01-CD record containing a
red cell using procedure; 0.2% could be linked to two SMR01-CD records containing a red
cell using procedure. 73.8% of transfusion day records of red blood cell use (71.1% RBC
units used) could not be linked by the surgical blood attribution rule to any SMR01-CD
records. In some instances the two competing red cell using procedures were the same, that
is, a red cell using procedure was recorded in both of the two SMR01-CD records that
satisfied the temporal relationship for the surgical blood attribution rule. In some instances
the two competing red cell using procedures were related by specialty of anatomical site.
The competition was therefore potentially illusionary and could be considered as resolvable
in these cases. In only a small number of instances were the two competing procedures
different and not related in an obvious way, and therefore considered to be irresolvable.
Because of the small scale of the problem it had minimal impact on the findings.
Furthermore, the cases of competing haematological conditions reflect clinically relevant
changes in diagnosis likely due to clinical progression and presentation of disease. The
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initial condition may evolve to another condition and complications due to the primary
condition are common in these diseases, therefore, competing reasons for transfusion are not
unexpected for haematological patients. Because pre-malignant conditions were included as
a haematological case group the assumption that relates blood use to the first haematological
case group within and between competing SMR01-CD records may cause the amount of
blood attributed to pre-malignant conditions to be overestimated: the pre-malignant
condition is more likely to be diagnosed first and so blood is attributed to that rather than
any subsequent diagnosis of haematological malignancy. This issue supports the underlying
issue regarding what constitutes the most likely reason for transfusion and highlights again
that the rules developed for this study make inferences about the appropriate attribution of
blood use to clinical case groups as well as being based on decisions about the definition of
haematological case groups considered to be appropriate for inclusion in this study.
Concerns regarding the poor or inaccurate classification of haematological malignancies in
clinical practice and research were raised in section 11.2.3 (Cartwright, Gilman, & Gurney,
1999).
Had competing case groups, particularly competing red cell using procedures, been
frequently identified, adjustments to the ways in which clinical data was summarised and
patients were classified would have been necessary. Because only a few instances of
irresolvable competition were identified, because the assumption reflects the inherent order
of priority or importance that is conventionally given to clinical data at the point at which
SMR01 records are coded, and because it can be argued to be logical, clinically, to relate
blood use to the first relevant case group, the proposed assumption was accepted as being
appropriate for this study. This is an example of how investigation of clinical coding played
an integral part in the validation of the methods that were employed for the attribution of
blood to clinical case group in this study.
Finally, the clinical case groups employed in this study are representative of the data coded
in a single clinical variable: the detail of clinical data across other variables is disregarded
and the decisions made in each case affect subsequent analyses. However, the clinical data
had to be summarised by some method and this step was considered to be appropriate and
useful for facilitating further analysis although it is acknowledged that alternative
approaches and definitions could be used in other studies of this sort. The full clinical data
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was retained in the study dataset and could be referred to if there was a data query or
particular interest regarding a particular clinical combination of procedures and/or
diagnoses, and meaning that alternative case groups could be included should that be a
requirement of future analyses.
In conclusion, the availability of multiple transfusion and clinical records and the large
amount of clinical data for many patients in the study dataset meant that methods had to be
devised to address intra-episode competition (when ascribing clinical case groups to SMR01-
CD records) and inter-episode competition (when multiple SMR01-CD records could be
linked to a transfusion day record) so that blood could be attributed to appropriate clinical
case groups. A sound understanding of the data as well as clinical input was required in
order to define appropriate blood attribution rules but it is acknowledged that the methods
were based on a number of assumptions, specifically relating to the list of red cell using
procedures, the date rules and the resolution of competition. Due to the variation of the
clinical nature of the inpatient study population, and the lack of a recorded clinical
indication for transfusion, it is acknowledged that an inference was made to define the
reason for transfusion and that the study was unable to determine absolutely the reason for
transfusion. All rules, methods and assumptions were made in with a sound understanding
of the nature and structure of the clinical data in SMR01-CD records in combination with
clinical advice, and an awareness of the limitations of the approach. However, potential
areas for future developments of the methodology exist and are discussed in section 11.5.
11.3.5. Study population: representation of blood component use in Scotland
In order to quantify how much blood a population such as Scotland needs, it is desirable to
collect data that represents the complete picture of transfusion activity for the whole
population for the specified time period. However, the data utilised in the study had been
collected for the STEP feasibility study and was limited to one year's transfusion data from
SNBTS/Progesa blood banks. The data from this common and routinely employed reporting
system was readily accessible by Scottish National Blood Transfusion Service staff.
However, as has been described, the SNBTS/Progesa blood bank system was not used by all
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blood banks in Scotland in the year 2000 and hence the extracted transfusion data represents
only a proportion of the hospitals that were supplied with blood by SNBTS in the year 2000.
The study population could not be calculated as a proportion of patients in the population
because data was not available to quantify the population served by individual hospitals.
The population of each health board area was available but not all hospitals in a health
board area were included in the study data. Similarly, it was considered inappropriate to
describe the study population in terms of the proportion of transfusion day records because
an appropriate denominator could not be identified or quantified; nor in terms of SMR01-CD
records because they do not represent a measure of transfusion practice and further, due to
variations in hospital type, specialties provided and patient case mix make an appropriate
denominator difficult to quantify.
Because of these reasons the proportion of the Scottish population represented by the
transfusion data was calculated in terms of the proportion of red blood cell units supplied by
SNBTS during the study year. Red blood cell supply data for the year 2000 for the blood
banks included in the study and the total supplied to the whole of Scotland was available
from SNBTS records: records of total issues by depot, total issues per period and summaries
of units assumed to have been transfused by institution were available for individual
hospitals. However, the data was difficult to interpret and understanding was only made
possible due to the work carried out for the development of Surgical Blood Use reports for
the Better Blood Transfusion Programme (Stewart, personal communication). Using this
data it was possible to estimate that the study population represented 38% of the Scottish
supply of red blood cell units in the year 2000. However, this estimation makes an
assumption about transfusion practice in Scotland similar to the issue of variation in clinical
practice described above; that is, the estimate relies on the assumption that that the use of
red blood cells was the same for the included in and excluded subgroups of the population.
Subsequent analysis using the Scottish Transfusion Epidemiology Database, in which data
for almost all of Scotland is included, suggests that red cell use per head of population is
higher in the west of the country (section 11.4).
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11.3.6. Future opportunities with new and additional data
It was acknowledged from the start of the study that due to the partial nature of the blood
bank data then available this pilot study would be able to make estimates only of blood use
for the whole population based on the assumption of uniform use. The limitations of the
study data provide scope for developments for future analyses of clinical blood use. For
example, because the data was for one year it is difficult to describe the clinical use of blood
in the broader context of patients' lives. Also, because the available source of transfusion
data restricted the study population to a proportion of the Scottish population, it was not
possible to explore the question of a whole population's use of, or need for blood. The
availability of transfusion and clinical data that represents the whole population for a
specified study period would mean that movements of blood between institutions such as
by special blood type requests, or movements of blood and patients such as by patient
transfer between clinical facilities would not affect the population included in the study data
and that the denominator population could be easily defined. Further, the data would
represent the entire case mix of patients for the whole country and would eliminate the need
to make assumptions about the transfusion and clinical practice of a proportion of the
country as was done in this study. Indeed, preliminary evidence indicates that blood use
does vary in Scotland depending on the provision of medical services, health status and
deprivation (Stewart, personal communication).
In conclusion, the dataset created in the present study provided a suitable resource for this
pilot study but further development of the project would benefit from the availability of
clinical and transfusion data that relates to the whole population, can be linked with data for
additional years, and is recent data that reflects current transfusion and clinical practices.
The Scottish Transfusion Epidemiology Database was created subsequent to the methods of
dataset creation in the present study and is a potential resource of comprehensive and
continuous, national data (section 11.4).
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11.4. Better Blood Transfusion Programme reporting system
The present study represents an essential phase of research that created a study dataset and
devised methods with which to link transfusion and clinical events in order to describe
blood use by clinical case group. In this way, the present study has directly contributed to
the creation of the Scottish Transfusion Epidemiology Database (STED). The Better Blood
Transfusion Programme (BBTP) has undertaken to collect data similar to the present study's
dataset for the whole of Scotland on a continuous, routine and automated basis. The
methods employed in this present study are now being applied to the Scottish Transfusion
Epidemiology Database and the results for blood use attributed to procedural case groups
are being packaged as standard Surgical Blood Use reports.
The format and content of Surgical Blood Use reports were developed by BBTP in
collaboration with clinical consultation and have been rolled out across Scotland for all
providers of blood use data. Initially coverage was low but extensive work was carried out
to encourage participation and to facilitate data sharing in order that all institutions in
Scotland that use blood are included, although to date coverage is still not 100% complete.
Institutions are required to submit blood use data on an annual basis; a secure, web-enabled
data transfer facility is available for this. The data is held in a data warehouse (the Better
Blood Universe) at ISD and feeds a web-based, end-user reporting system in hospitals.
Table 11.4 Variables in data warehouse used in surgical blood use reporting
(Appendix A.3: excerpt from example Surgical Blood Use report)
Variables reported for surgical blood use
Number of patients
Number of patients at risk of transfusion (blood component assigned)
Number of patients transfused (blood component used)
Number of procedures
Number of procedures transfused t
Blood components used per patient (and patient transfused)
Blood components used per procedure (and procedure transfused)
'Recorded as confirmed transfused via the "Bag and tag" traceability
system (not available for PhD data). f Cannot be quantified
automatically for PhD study where patients have more than one blood
using procedure.
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Surgical Blood Use reports are available at a clinician, hospital, regional and national level,
and organisational and temporal comparative data can be provided (Appendix A.3) (Stewart,
personal communication). The data is linked with inpatient and day case (SMR01), cancer
(SMR06) and death (GRO) records and can be linked with maternal (SMR02), neonatal
(SMR11), outpatient (SMROO) and Ward Watcher clinical records if, or indeed when, future
developments facilitate such record linkage
Ongoing development of STED and available blood use reports has also preliminarily
addressed diagnostic blood use, like the haematological conditions described for this study,
and considers additional patient case groups that have as yet not been fully described or
incorporated into blood use reports. The data warehouse and user requirements are
continually updated in response to project developments.
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11.5. Alternative approaches and future work
The study aimed to describe the clinical use of blood: this aim was achieved to the extent
that 29% of red blood cell units were attributed to surgical case groups and 12% of red blood
cell units were attributed to haematological case groups specifically developed for this study.
Therefore 59% of red blood cell use has not been attributed to an underlying clinical reason
that can explain the use of blood as defined in this present study (Figure 11.1). It has been
acknowledged here that the nature of the procedural and haematological rules developed
for the study mean that the reason for transfusion is inferred from the clinical data in
available SMR01-CD records and that alternative relationships could potentially be inferred
if those rules were altered. A quality of the study dataset is that alternative or additional
blood attribution rules of a similar format to those devised for the present study could be
applied to report on blood use by clinical case group in the future.
Figure 11.1 Classification of blood component use by specified clinical case groups
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Thus there are two areas that could be targeted for future development. One, improvements
could be made to the existing blood attribution rules to reflect changes in clinical and
transfusion practice. Two, clinical case groups could be defined in addition to the red cell
using procedure and haematological case groups defined in the present study in order to
describe the clinical reason for the use of red blood cell units so far not attributed in this
study. Factors such as the type of surgeries performed, new diseases and combinations of
procedures or clinical conditions should be taken into account in the future. Suggested
developments in these areas are discussed next.
11.5.1. Alternative approaches to blood attribution rules
The two aspects to the rules developed for the attribution of blood to clinical case groups are
the date relationships between transfusion event and relevant period of clinical care and the
clinical case groups defined as likely users of blood.
The surgical blood attribution rule referred to instances where it was considered sensible to
view the data from a procedural perspective for which a small timeframe of association was
used to link transfusion events to major elective procedures that were likely to require a red
blood cell transfusion: for example, coronary artery bypass graft operations and hip
replacement procedures. The haematological blood attribution rule referred to instances
where it was considered useful to view the data from a diagnostic perspective for chronic
haematological conditions that are likely to require multiple transfusions over a protracted
timeframe (a year in the case of this study). The date rules were defined for the context of
current transfusion and clinical practices using clinical input but could be adapted to reflect
changes in treatment protocols and prescribing practices in the future. Changes could affect
the temporal relationship between blood assignment and the relevant period of clinical care
during which blood components may potentially be used, or might affect the approach
employed to resolve instances of competition between case groups. Iterative, data-driven
approaches to defining timeframes within which a specified proportion of blood
assignments are made for different clinical case groups could be utilised but whatever
approach is adopted, the date rules developed should always have clinical relevance to the
practices of prescribing and treatment with transfusion.
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The red cell using procedures and haematological diagnoses included in the study were
experientially defined but there is scope to employ a data-driven approach. By exploring the
frequency with which procedures or diagnoses are coded in the primary procedural or
diagnostic variables in SMR01-CD records and can be linked (by whatever temporal rule is
employed) with transfusion events, additional or alternative red cell using procedures or
diagnoses that are frequently coded clinical events that can be linked to transfusion events
might be identified. However, as with alternative definitions for date rules, the methods
employed to define relevant clinical case groups cannot be purely data-driven and will
always require an element of clinical input to eliminate procedures and diagnoses that,
while identified by data-driven approaches, have no clinical relevance for inclusion.
Therefore, changes to the date rules to reflect changes in transfusion practise and changes to
the clinical case groups that define the likely reasons for transfusion should be considered
and explored in order that the most full and accurate description of the use of blood by
clinical case group is made in the future. Additional clinical case groups and alternative
perspectives for defining the clinical reason for transfusion are described next (section 11.5.2).
11.5.2. Additional approaches to describing blood use for transfusion events not
already attributed to clinical case groups
There are numerous opportunities to revise or add to the clinical case groups that could be
related to transfusion events in future analyses. Methods to identify additional red cell
using procedures and diagnostic conditions were discussed briefly in the previous section
(11.5.1). Specifically, other chronic medical conditions for which frequent blood transfusions
are the usual method of treatment could be added as the use of blood for medical conditions
is frequently reported as being on the increase. Some of the diagnostic areas that might be
considered can be identified from previous reports and include oncology and
gastroenterology (Table 11.5). Where medical conditions have potential to be common
comorbidities of conditions already described by the haematological case groups or by new
diagnostic case groups, separate case groups should be defined that allow for the analysis of
any overlap in blood that can be attributed to more than one diagnostic case group, or
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indeed to both diagnostic and procedural case groups. Competition within and between the
red cell using procedures and haematological conditions defined for this study has been
explored; further competition between the specifically defined red cell using procedures in
this study and other surgical procedures not yet classified by case group in this study might
also occur and require investigation.
In general, the 15,475 transfusion events (58.9% of total in study dataset) that are thus far not
attributed to a clinical case group in the present study represent patients with multiple
inpatient admissions (average SMR01-CD records per patient 4.45, SD 3.98) and complex
clinical histories that encompass both surgical events and multiple comorbidities. In many
cases the relationship between clinical information is not easily revealed, is not amenable to
automated analysis and requires case-by-case clinical judgement. Furthermore, as for the
whole study dataset, many of the patients are elderly (mode ageband 70-79 years, 59.1% of
patients "not attributed" aged over 65 years). The combinations of procedures and
diagnoses for these so called complex patients might in the future be viewed in various ways:
as specific combinations of related procedures and diagnoses, or as particular cohorts of
patients of interest from a public health perspective. The various approaches that could be
explored to identify additional, appropriate case are described here.
The approach of defining case groups using specific combinations of related procedures and
diagnoses is perhaps best described by an example: gastroenterology has been identified as
an area of significant blood use but the underlying need for transfusion is not easily
distinguished (Wallis, Wells & Chapman, 2006; Friedman, Burns & Schork, 1979; Cook &
Epps, 1991; Chiavetta et al, 1996; Mathoulin-Pelissier et al, 2000; Lim et al, 2004). Some
gastrointestinal procedures are already included in the red cell using procedure case groups
identified for this study (open operations on oesophagus, excision of colon, excision of
rectum) but other related diagnoses (for example, malignant neoplasm of gastrointestinal
tract, peptic ulcer, oesophageal varices, Crohn's disease, ulcerative colitis and
gastrointestinal haemorrhage) are also likely to be important in identifying gastrointestinal
patients at risk of transfusion. Specifically, gastrointestinal endoscopy may prove to be an
important marker for identifying blood users. Although the endoscopy in itself cannot be
described as the reason for transfusion it is very common for bleeding patients to have an
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endoscopy both to identify the source of bleeding and to arrest the bleeding. It also follows
that gastrointestinal bleeding often necessitates transfusion.
Endoscopies are included in a list of supplementary procedures that were defined during
the study but have as yet not been utilised in analyses (Table 11.6). Supplementary
procedures were defined in the course of this study in an attempt to identify procedures that,
while not primary clinical reasons that necessitate transfusion, instead represent procedures
that may prove to be useful markers for indicating potential blood using clinical case groups.
The frequency of supplementary procedure codes in SMR01-CD records, and the diagnoses
and procedures with which they are coded in combination could provide useful information
for the development of gastrointestinal and other complex clinical case groups. The use of
supplementary procedures may be limited by under-reporting of these procedures due to
the convention for clinical coding in SMR01-CD that states that diagnostic procedures
should be coded only after therapeutic procedures (ISD, online). Endoscopy use can be both
diagnostic and therapeutic: it is not clear exactly how this is defined by coders, but where
ambiguity is encountered guidelines require coders to seek clarification from the clinician
responsible for the episode of care.
Table 11.6 OPCS-4 fields that contain procedure codes classified as "supplementary"
Number of times coded in variable:
Supplementary Procedure
OP1 OP2 OP3 OP4
Endoscopic operations on kidney 5 0 0 0 100.0%
Chemotherapy 5,431 278 103 41 92.8%
Endoscopic operations on prostate 77 7 4 0 87.5%
Endoscopy of upper gastrointestinal tract 2,494 487 141 35 79.0%
Endoscopic operations on bladder 472 100 28 14 76.9%
Endoscopic operations on oesophagus 183 62 25 6 66.3%
Blood transfusion 3,929 1,385 508 198 65.3%
Endoscopic operations on colon 919 388 90 29 64.4%
Compensation for renal failure 428 203 40 17 62.2%
Endoscopy of lower respiratory tract 119 26 53 11 56.9%
Other operations on unspecified organ 2,199 1,404 778 439 45.6%
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The supplementary procedures investigation identified a total of 6,020 instances of coding
for "blood transfusions" in the SMR01-CD records included in the study dataset. Blood
transfusion (OPCS-4 X32-X33) includes transfusion of red blood cells and platelets, neonatal
exchanges and other and unspecified blood transfusions. The infusion of plasma,
coagulation factors and serum (OPCS-4 X34) was not included. As the study dataset
represents 11,994 patients who can be linked to 26,269 transfusion day records of units used
(25,315 of which are transfusion day records of red blood cell or platelet use), it is evident
that blood transfusion was under-reported in SMR01-CD records available for study in 2000.
The complexities of gastrointestinal medicine illustrate the requirement to identify common
combinations of related procedures, diagnoses and appropriate supplementary procedures
in order to define appropriate clinical case groups. The following approach is more general
in that it could be used to identify cohorts of patients, such as could be easily defined by
medical specialty or other cohorts of interest from a public health perspective. SMR01-CD
records can be viewed at a patient level, rather than on a record by record basis, as
exemplified by the haematological conditions described in this study. This approach would
be useful where individual SMR01-CD records do not contain information that could be
identified as a likely reason for blood use, but where aggregating information from multiple
SMR01-CD records provides an overall picture of the patient's medical conditions and
clinical needs. This approach could also be used to address the argument as to which
specific aspect of clinical data should be linked to the transfusion. That is, it may render
unnecessary the decision as to whether the blood transfusion was due to a procedure or the
initial underlying condition that made that procedure necessary. Examples might include
cohorts of patients with alcoholic liver disease, colorectal cancer, chronic renal disease, and
diseases of old age. These general, patient based approaches may be useful in
epidemiological research, high-level reporting contexts but might be less useful to individual
clinicians, particularly surgeons, and in specific resource planning contexts.
Finally clinicians with an interest in a particular area of medicine or transfusion practice are
also able to describe potential procedure- or diagnosis-specific case groups. Clinicians'
specialist knowledge can be used to define specific case groups to identify patients to whom
the clinician can relate, thus improving the relevance of and aiding the interpretation of
blood use reports. In the early stages of this present study clinical input and an awareness of
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clinical requirements was gained from opportunities such as this, especially for oncology
and gastroenterology. This approach could be utilised further, either to inform the
definition of clinical case groups in general, or to develop specialist case groups if required
in the future.
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11.6. Conclusion
The aim of this study was to explore the feasibility of analysing the clinical use of blood for
Scottish hospitals by means of linking records of transfusion and clinical data. The creation
of the study dataset has demonstrated that record linkage of routine data is feasible. By
defining specific clinical case groups and by devising novel rules for the attribution of
transfusion events to clinical case groups, automated analysis of routine data to describe
blood component use has been demonstrated. The study reports unique findings for blood
component use for Scotland, and specifically by novel clinical case groups. Furthermore, it
has been demonstrated that the study data can be used in additional applications to answer
a range of other questions about the clinical use of blood.
The limitations of this study in terms of the study population being a subset of Scottish
hospitals and the study period being some years past, can be resolved by applying the
study's methods to more recent, routine and national data. This study has contributed
directly to the recent development of the Scottish Transfusion Epidemiology Database
(STED), in which, to date, the representation of red blood cell use for the whole of Scotland
is almost complete, and data is available for a continuous period of time from 2002.
Given the complexities of some clinical cases and the necessary judgements as to the actual
reason for blood component use, further work is warranted in order to facilitate
comprehensive analyses of blood use by clinical case group in the future. One, there is a
requirement to define additional, appropriate clinical case groups for the classification of
transfusion events, considering the often complex relationships coded within clinical data,
using definitions that are internationally recognised and comparable, and considering
changes in the epidemiology of disease. Two, there is a requirement to revise the blood
attribution rules, taking into consideration future changes in transfusion practice. Further
developments with regards to clinical case groups and blood attribution rules should be
devised and validated for STED data rather than for the present study dataset.
Transfusion practice faces mounting pressures on the balance of supply versus demand and
therefore it is valuable that the study dataset can be utilised to explore and quantify the use
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of blood components in response to potential changes in factors affecting transfusion
practice. In this study a novel concept of best practice transfusion targets and the use of an
alternative intervention, intra-operative cell salvage, were shown to result in encouraging
savings in orthopaedics and cardiac surgery, areas of high red blood cell use blood. In
particular, current concerns regarding vCJD infection affecting the supply of blood, and the
predicted marked effect of the ageing Scottish population on the future demand for blood,
alert to the need to consider the development and implementation of blood conservation
strategies.
The appropriate use of blood is paramount: initial blood loss must be minimised to reduce
the need for allogeneic transfusion, the decision to transfuse should be made considering the
balance of benefit versus risk, and a safe and effective replacement for blood should be
readily available when required. Thus, there is a need for an appropriate evidence base for
the efficacy of blood conservation strategies, such as specific transfusion protocols and
alternative interventions, in parallel with an ongoing requirement for monitoring the use of
blood, particularly by clinical reason for transfusion and using appropriate and comparable
methods, in order to facilitate the safe and effective use of blood in an ever more resource-










Number of Study Denominator
TDRs dataset8 data8
Hospitals included in study dataset and denominator data
Edinburgh Royal Infirmary (old) 67,673 7,025
Y Y
Aberdeen Royal Infirmary 77,609 6,444 Y Y
Ninewells Hospital 63,249 5,901 Y Y
Raigmore Hospital 35,565 2,311 Y Y
RHSC (Edinburgh) 13,610 1,074 Y Y
Woodend General Hospital 7,246 1,012 Y Y
Princess Margaret Rose Hospital 3,590 448 Y Y
Liberton Hospital 898 146 Y Y
Royal Victoria Hospital (Dundee) 1,037 141 Y Y
Royal Aberdeen Children's Hospital 8,028 129 Y Y
Roodlands General Hospital 2,386 83 Y Y
Kings Cross Hospital 2,454 81 Y Y
Chalmers Hospital (Edinburgh) 483 76 Y Y
Dr Gray's Hospital 13,447 55 Y Y
City Hospital 4,529 44 Y Y
Astley Ainslie Hospital 826 23 Y Y
Hospitals included in study dataset
St John's Hospital At Howden
33,842 91 Y N
Perth Royal Infirmary 21,637 88 Y N
Western General Hospital (Edinburgh) 59,068 67 Y N
Aberdeen Maternity Hospital 70 44 Y N
Portree Hospital 388 33 Y N
Mackinnon Memorial Hospital 1,168 31 Y N
Tor-Na-Dee Hospital 1,067 31 Y N
Roxburghe House, Tor-Na-Dee Hospital 416 30 Y N
Town and County Hospital Nairn 361 22 Y N
Ross Memorial Hospital 466 21 Y N
Fraserburgh Hospital 677 20 Y N
Belford Hospital 3,616 19 Y Y
Stracathro Hospital 8,522 17 Y N
Lawson Memorial Hospital 1,181 15 Y N








Number of Study Denominator
TDRs dataset data







Caithness General Hospital, Wick







Insch & District War Memorial Hospital
Seafield Hospital
Edington Cottage Hospital
692 12 Y N
816 9 Y N
297 6 Y N
294 6 Y N
379 3 Y N
95 2 Y N
4,606 1 Y N
1,541 1 Y N
729 1 Y N
422 1 Y N
371 1 Y N
304 1 Y N
232 1 Y N
218 1 Y N
208 1 Y N
179 1 Y N
39 1 Y N
Hospitals for which transfusion day records and SMR01/cancer/death records were available but
excluded from dataset because not study area
Victoria Hospital (Kirkcaldy) 36,784
321 N N
Queen Margaret Hospital 26,873 101 N N
Borders General Hospital 20,188 7 N N
Gilbert Bain Hospital 3,372 5 N N
Balfour Hospital, Kirkwall 2,308 5 N N
Western Isles Hospital 4,665 2 N N
Cameron Hospital 96 2 N N
Hospitals not included in study dataset because no year 2000 SMR01/cancer/death records were
available
Simpson Memorial Maternity Pavilion
0 83 N N
Park House Psychiatric Day Hospital 0 54 N N
Glenview Unit, Inverness 0 30 N N
Ashludie Day Hospital 0 13 N N
Kings Cross Hospital, Dundee 0 9 N N
Pluscarden Clinic, Dr Gray's Hospital 0 8 N N
City Hospital, Aberdeen 0 8 N N
Crieff Cottage Hospital 0 4 N N
Aberdeen Royal Infirmary 0 3 N N
Dudhope House, Dundee 0 1 N N
Dundee Royal Infirmary 0 1 N N
Royal Edinburgh Hospital 0 1 N N
Park House Psychiatric Day Hospital 0 1 N N
Edenhall Hospital, Musselburgh 0 1 N N
Eastern General Hospital 0 1 N N
Ladysbridge Hospital 0 1 N N
St Vincent's Hospital 0 1 N N
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Hospital SMR01-CD Number of Study Denominator
. TDRs dataset data
records
Hospitals not included in study dataset because no year 2000 SMR01/cancer/death records were
available (continued)
RHSC (Drumchapel) 0 1 N N
Hospital Cancer Registrations 0 1 N N
unknown 0 17 N N
Hospitals outwith study area for which no transfusion day records were available
Western Infirmary/Gartnavel General
78,389 0 N N
Glasgow Royal Infirmary 56,359 0 N N
Monklands Hospital 42,124 0 N N
Crosshouse Hospital 40,430 0 N N
Southern General Hospital 39,577 0 N N
Victoria Infirmary (Glasgow) 38,502 0 N N
Stobhill Hospital 38,024 0 N N
The Ayr Hospital 37,795 0 N N
Royal Alexandra Hospital 36,539 0 N N
Law Hospital 34,476 0 N N
Dumfries & Galloway Royal Infirmary 29,368 0 N N
Stirling Royal Infirmary 28,235 0 N N
Falkirk and District Royal Infirmary 24,617 0 N N
Hairmyres Hospital 24,610 0 N N
Inverclyde Royal Hospital 21,105 0 N N
RHSC (Yorkhill) 20,205 0 N N
Vale of Leven District General Hospital 13,476 0 N N
Canniesbum Hospital 9,701 0 N N
Stonehouse Hospital 7,002 0 N N
Lorn & Islands DG Hospital 4,697 0 N N
Glasgow Dental Hospital and School 3,788 0 N N
Garrick Hospital 3,339 0 N N
Forth Park Hospital, Kirkcaldy 2,633 0 N N
Edinburgh Dental Hospital 2,534 0 N N
Ayrshire Central and Maternity Hospital 1,843 0 N N
Dunoon & District General Hospital 1,774 0 N N
Victoria Infirmary Geriatric Unit (Glasgow) 1,394 0 N N
Campbeltown Hospital 1,271 0 N N
St Andrews Memorial Hospital 1,018 0 N N
Lightbum Hospital 1,009 0 N N
Biggart Hospital 956 0 N N
Daliburgh Hospital 721 0 N N
Isle of Arran War Memorial Hospital 707 0 N N
Victoria Hospital, Rothesay 613 0 N N
Davidson Cottage Hospital 580 0 N N
Mid Argyll Hospital 550 0 N N
Ravenscraig Hospital 411 0 N N
Kelso Hospital 378 0 N N
Park House Psychiatric Day Hospital 369 0 N N
Crieff Community Hospital 361 0 N N






Number of Study Denominator
TDRs dataset data
Hospitals outwith study area for which no transfusion day records were available (continued)
Forfar Infirmary 325 0 N N
Hay Lodge Hospital 316 0 N N
Brechin Infirmary 304 0 N N
Kincardine Community Hospital 304 0 N N
Bellefield Hospital 299 0 N N
Cowglen Hospital 289 0 N N
Islay Hospital 289 0 N N
Lockhart Hospital 279 0 N N
Leanchoil Hospital 274 0 N N
Blairgowrie Cottage Hospital 268 0 N N
Moffat Hospital 253 0 N N
Lady Margaret Hospital 242 0 N N
Kello Hospital 232 0 N N
Ballochmyle Hospital 229 0 N N
Kirkcudbright Hospital 222 0 N N
Aboyne Hospital 217 0 N N
Coathill Hospital 213 0 N N
Mental Health Day Service, Stevenston 207 0 N N
Whytemans Brae Hospital, Kirkcaldy 201 0 N N
St Margaret's Hospital 197 0 N N
Knoll Hospital 188 0 N N
Irvine Memorial Hospital 187 0 N N
Coldstream Cottage Hospital 159 0 N N
Lady Home Hospital 153 0 N N
Newton Stewart Hospital 152 0 N N
Victoria Cottage Hospital, Kilsyth 149 0 N N
Castle Douglas Hospital 145 0 N N
Belhaven Hospital, Dunbar 145 0 N N
Adamson Hospital 143 0 N N
Glen O'dee Hospital 142 0 N N
Udston Hospital, Hamilton 142 0 N N
Glenrothes Hospital 141 0 N N
Fleming Cottage Hospital 139 0 N N
Maidencraig House 137 0 N N
Pluscarden Clinic, Dr Gray's Hospital 136 0 N N
Migdale Hospital 130 0 N N
Aberfeldy Cottage Hospital 128 0 N N
Witchbum Hospital 128 0 N N
Randolph Wemyss Memorial Hospital 127 0 N N
St Brendan's Hospital 123 0 N N
Victoria Infirmary (Helensburgh) 118 0 N N
Kincardine O Neil War Memorial Hospital 110 0 N N
Montrose Royal Infirmary 95 0 N N
Sister Margaret Cottage Hospital 94 0 N N
Loanhead Hospital 77 0 N N
Beatson Oncology Centre 73 0 N N






Number of Study Denominator
TDRs dataset data
Hospitals outwith study area for which no transfusion day records were available (continued)
Lochmaddy Hospital 67 0 N N
Gesto Hospital, Isle of Skye 62 0 N N
Netherlea Hospital 52 0 N N
Dumbarton Joint Hospital 49 0 N N
Victoria Hospital Annexe 39 0 N N
Knowepark Hospital 39 0 N N
Ross House, Inverness 37 0 N N
Campbell Hospital 31 0 N N
Sanderson Hospital 31 0 N N
Mental Health Day Service, Stevenston 31 0 N N
Merchiston Hospital 28 0 N N
Shawmill Day Hospital 23 0 N N
Eastbank Hospital, Kirkwall 18 0 N N
Strath lea 11 0 N N
Glenrothes Hospital 10 0 N N
Wester Moffat Hospital 6 0 N N
Hyperbaric Centre (Aberdeen) 2 0 N N
Thornhill Hospital 1 0 N N




Table A.2 SPSS programming syntax for study dataset creation and analyses
Development step Notes
Sort Transfusion day record file (all linked records)
a. Calculate blood component units used
COMPUTE Redused = red_iss - red_rtn
SELECT IF Redused>0
b. Calculate age bands
COMPUTE Agebands
IF (age < 10) ageband = 0
IF (age >= 10 and age <20) ageband = 1
Repeat for pit, ffp, cry
Repeat for pit, ffp, cry
Repeat for age bands
2-10 (age=100+)
Sort SMR01/cancer/death file (all linked records)
a. Recode procedure and diagnosis variables
STRING OP1 (A8)
COMPUTE OP1 = SUBSTR (op1a, 1, 3)
STRING diag13 (A8).
COMPUTE diag13 = SUBSTR (diagl, 1, 3)
b. Define blood using procedure, supplementary procedure, and
blood using diagnostic groups
i. Blood using procedures
IF (op1="A01" OR op1-"A02" OR op1="A03" OR op1="A04" OR
op1="A05" OR op1="A06" OR op1="A07" OR op1="A08" OR op1="A09"
OR op1="A10") bidpre 1 = 1
IF (op1="A12" OR op1="A13" OR op1="A14" OR op1="A15" OR
op1="A16" OR op1="A17" OR op1="A18" OR op1="A19" OR op1="A20"
OR op1="A21" OR op1="A22") bldprcl = 2
IF (op1="A44" OR op1="A45" OR op1="A46" OR op1="A47" OR
op1="A48" OR op1="A49" OR op1="A50" OR op1="A51" OR op1="A52"
OR op1="A53" OR op1="A54" OR op1="A55" OR op1="A56" OR
op1="A57") bldprcl = 3
IF (op1="B08" OR op1="B09" OR op1="B10" OR op1="B11" OR
op1="B12" OR op1="B13" OR op1="B14" OR op1="B15" OR op1="B16")
bldprcl = 4
Repeat for OP2, 3, 4
Repeat for diag2, 3, 4,
5, 6
Repeat for OP2, 3, 4
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IF (op1~"B27" OR op1="B28" OR op1="B29" OR op1="B30" OR
op1="B31" OR op1="B32" OR op1="B33" OR op1="B34" OR op1="B35"
OR op1="B36" OR op1="B37") bldprcl = 5
IF (op1="E19" OR op1="E20" OR op1="E21" OR op1="E22" OR
op1="E23" OR op1="E24" OR op1="E25" OR op1="E26" OR op1="E27")
bldprcl = 6
IF (op1="E29" OR op1="E30" OR op1="E31" OR op1="E32" OR
op1="E33" OR op1="E34" OR op1="E35" OR op1="E36" OR op1="E37"
OR op1="E38") bldprcl = 7
IF (op1="E41") bldprcl = 8
IF (op1="E42") bldprcl = 9
IF (op1="E14" OR op1="E15" or op1="E16" or op1="E17") bldprcl = 10
IF (op1="E52") bldprcl = 11
IF (op1="E53") bldprcl = 12
IF (op1="E54") bldprcl = 13
IF (op1="E55") bldprcl = 14
IF (op1="E57") bldprcl = 15
IF (op1="E59") bldprcl = 16
IF (op1="E61") bldprcl = 17
IF (op1="F34" or op1="F35" or op1="F36" or op1="F37" orop1="F38" or
op1="F39" or op1="F40") bldprcl = 18
IF (op1="G01"OR op1="G02" OR op1="G03" OR op1="G04" OR
op1="G05" OR op1="G06" OR op1="G07" OR op1="G08" OR op1="G09
OR op1="G10" OR op1="G11" OR op1="G12" OR op1="G13") bldprcl =
19
IF (op1="G21" OR op1="G22" OR op1="G23" OR op1="G24" OR
op1="G25") bldprcl = 20
IF (op1="G27" OR op1="G28" OR op1="G29" OR op1="G30" OR
op1="G31" OR op1="G32" OR op1="G33" OR op1="G34" OR op1="G35
OR op1="G36" OR op1="G37" OR op1="G38" OR op1="G39" OR
op1="G40" OR op1="G41") bldprcl =21
IF (op1="G49" OR op1="G50" OR op1="G51" OR op1="G52" OR
op1="G53" OR op1="G54" OR op1="G55" OR op1="G56" OR
op1="G57") bldprcl = 22
IF (op1="G58" OR op1="G59" OR op1="G60" OR op1="G61" OR
op1="G62" OR op1="G63" OR op1="G64" OR op1="G65" OR op1="G66
OR op1="G67") bldprcl = 23
IF (op1="G69" OR op1="G70" OR op1="G71" OR op1="G72" OR
op1="G73" OR op1="G74" OR op1="G75" OR op1="G76" OR op1="G77
OR op1="G78" OR op1="G79" OR op1="G80" OR op1="G81" OR
op1="G82") bldprcl = 24
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IF (op1="H04" OR op1="H05" OR op1="H06" OR op1="H07" OR
op1="H08" OR op1="H09" OR op1="H10" OR op1="H11") bldprcl = 25
IF (op1="H33") bldprcl = 26
IF (op1="J01") bldprcl = 27
IF (op1="J02") bldprcl = 28
IF (op1="J03" OR op1="J04" OR op1="J05" OR op1="J06"
OR op1="J07" OR op1="J08" OR op1="J09" OR op1="J10" OR
op1—"J11" OR op1="J12" OR op1="J13" OR op1="J14" OR op1="J15"
OR op1-"J16") bldprcl = 29
IF (op1="J18" OR op1="J19" OR op1="J20" OR op1="J21"
OR op1="J22" OR op1="J23") bldprcl = 30
IF (op1="J27" OR op1="J28" OR op1="J29" OR op1="J30"
OR op1="J31" OR op1="J32" OR op1="J33" OR op1="J34" OR
op1="J35" OR op1="J36" OR op1="J37") bldprcl = 31
IF (op1="J54" OR op1="J55" OR op1="J56" OR op1="J57"
OR op1="J58" OR op1="J59" OR op1="J60" OR op1="J61" OR
op1="J62" OR op1="J63" OR op1="J64" OR op1="J65") bldprcl = 32
IF (op1="J69" OR op1="J70") bldprcl = 33
IF (op1="K01" OR op1-"K02") bldprcl = 34
IF (op1="K25" OR op1="K26" OR op1="K27" OR op1="K28" OR
op1-"K29" OR op1="K30" OR op1="K31" OR op1="K32" OR op1="K33"
OR op1="K34" OR op1="K35" OR op1="K36" OR op1="K37" OR
op1="K38") bldprcl = 35
IF (op1="K40" OR op1="K41" OR op1="K42" OR op1="K43" OR
op1-"K44" OR op1="K45" OR op1="K46" OR op1="K47" OR op1="K48")
AND (op1a ne"K442" OR op1a ne"K456" OR
op1a ne"K465") bldprcl = 36
IF (op1a="K442" OR op1a="K456" OR op1a="K465")
bldprcl = 37
IF (op1="L01" OR op1="L02" OR op1="L03" OR op1="L04"
OR op1="L05" OR op1="L06" OR op1="L07" OR op1="L08" OR
op1="L09" OR op1="L10" OR op1="L11" OR op1="L12") bldprcl = 38
IF (op1="L13") bldprcl = 39
IF (op1=-"L18" OR op1="L20") bldprcl = 40
IF (op1="L16" OR op1="L19" OR op1="L21" OR op1="L22"
OR op1="L23" OR op1-"L24" OR op1="L25") bldprcl = 41
IF (op1="L26") bldprcl = 42
IF (op1="L29" OR op1="L30" OR op1="L31" OR op1="L32"
OR op1="L33" OR op1="L34" OR op1="L35" OR op1="L36" OR
op1-"L37" OR op1="L38" OR op1="L39") bldprcl = 43
IF (op1="L41" OR op1="L42" OR op1="L43") bldprcl = 44
IF (op1="L45" OR op1="L46") bldprcl = 45
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IF (op1-"L77") bidpre 1 = 46
IF (op1-"L91") bldprcl = 47
IF (op1="M01") bldprcl = 48
IF (op1="M02" OR op1="M03" OR op1="M04" OR op1="M05" OR
op1="M06" OR op1-"M07" OR op1="M08") bldprcl = 49
IF (op1a="M34" OR op1="M35") bldprcl = 50
IF (op1="M36" OR op1="M37" OR op1="M38" OR op1="M39"
OR op1="M40" OR op1="M41") bldprcl = 51
IF (op1="M51" OR op1="M52" OR op1="M53" OR op1="M54"
OR op1="M55" OR op1="M56" OR op1="M57" OR op1="M58") bldprcl
52
IF (op1="M61" OR op1="M62" OR op1="M63" OR op1="M64") bldprcl
53
IF (op1="Q07" OR op1="Q08") bldprcl = 54
IF (op1="T85") bldprcl = 55
IF (op1="V14") bldprcl = 56
IF (op1="W10" OR op1="W11" OR op1="W12" OR op1="W13" OR
op1="W14" OR op1="W15" OR op1="W16" OR op1="W17" OR
op1="W18" OR op1="W19" OR op1="W20" OR op1="W21" OR
op1="W22" OR op1="W23") bldprcl = 57
IF (op1="W24" OR op1="W25" OR op1="W26") bldprcl = 58
IF (op1="W36") bldprcl = 59
IF (op1="W37" OR op1="W38" OR op1="W39") AND (op1a ne"W373"
OR op1a ne"W383" OR op1a ne"W393") bldprcl = 60
IF (op1a="W373" OR op1a="W383" OR op1a="W393") bldprcl = 61
IF (op1="W40" OR op1="W41" OR op1="W42") AND (op1a ne"W403"
OR op1a ne"W413" OR op1a ne"W423") bldprcl = 62
IF (op1a="W403" OR op1a="W413" OR op1a="W423") bldprcl = 63
IF (op1="W46" OR op1="W47") bldprcl = 64
ii. Supplementary procedures
IF (op1="E49") suppl = 1
IF (op1="G14" OR op1="G15" OR op1="G16" OR op1="G17"
OR op1="G18" OR op1="G19") suppl = 2
IF (op1="G43" OR op1="G44" OR op1="G45") suppl = 3
IF (op1="H20" OR op1="H21" OR op1="H22" OR op1="H23"
OR op1="H24" OR op1="H25" OR op1="H26" OR opWH27"
OR op1="H28") suppl = 4
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IF (op1="M09" OR op1="M10" OR op1="M11" OR op1="M12") suppl = 5
IF (op1="M42" OR op1="M43" OR op1="M44" OR op1="M45") suppl = 6
IF (op1="M65" OR op1="M66" OR op1="M67") suppl = 7
IF (op1="X32" OR op1="X33") suppl = 8
IF (op1="X35" OR op1='X37" OR op1="X38") suppl = 9
IF (op1="X40" OR op1="X41" OR op1="X42") suppl = 10
IF (op1='X55") suppl = 11
iii. Blood using diagnoses
IF (diag13="C81" or diag13="C82" or diag13="C83" or diag13="C84" or
diag13="C85") bldiagl = 22
IF (diag13="C90") bldiagl = 23
IF (diag13="C91" or diag13="C92" or diag13="C93" or diag13="C94" or
diag13="C95") bldiagl = 24
IF (diag13="C96") bldiagl = 25
IF (diag13="D45" or diag13="D46") bldiagl = 26
iv. Value labels for case groups
VALUE LABELS bldprcl bldprc2 bldprc3 bldprc4 bldproc
1 'Brain'
2 'Ventricle'
3 'Spinal cord and contents of spinal canal'




8 'Open placement ofprosthesis in trachea'
9 'Exteriorisation of trachea'
10 'Sinus'
11 'Other operations on bronchus'
12 'Transplant of lung'
13 'Excision of lung'
14 'Open extirpation of lesion of lung'
15 'Other open ops on lung'
16 'Other ops on lung'
17 'Open ops on mediastinum'
18 'Tonsil and mouth'
19 'Open oos on oesophagus'
20 'Other ops on oesoph'




25 Excision of colon'
26 'Excision of rectum'
27 'Transplant of liver'
28 'Partial excision of liver'
29 'Other ops on lived
30 'Gall bladder1
31 'Open ops on bile duct'
32 'Open ops on pancreas'









K44, K31, K50, K70,






35 'Valves and adjacent structures'
36 'Open bypass graft operations (minus revisions)'
37 'Open bypass graft operations revisions'
38 'Open operations on GV and PA'
39 'Transluminal ops on PA'
40 'Emergency replace aneurysm aorta'
41 'Other ops on aorta'
42 'Transluminal ops on aorta'
43 'Carotid cerebral and subclavian'
44 'Reconstruction of renal artery'
45 'Open ops on visceral branches of aorta'
46 'Connection vena cava or branch of VC'
47 'Other vein related operations'
48 'Transplantation of kidney'
49 'Other open ops on kidney'
50 'Excision of bladder'
51 'Other open ops on bladder'
52 'Ops on female bladder'
53 'Open ops on prostate'
54 'Hysterectomy'
55 'Block dissection of lymph nodes'
56 'Excision ofmandible'
57 'Open reduction fracture'
58 'Closed reduction fracture'
59 'Diagnostic puncture of bone'
60 'Total hip replacement (minus revisions)'
61 'Total hip replacement revisions'
62 'Total knee replacement (minus revisions)'
63 'Total knee replacement revisions'
64 'Replace head of femur'
VALUE LABELS suppl supp2 supp3 supp4
1 'Endoscopy of lower respiratory tract'
2 'Endoscopic ops on oesoph'
3 'Endoscopy of upper Gl tract'
4 'Endoscopic ops on colon'
5 'Endoscopic ops on kidney'
6 'Endoscopic ops on bladder1
7 'Endoscopic ops on prostate'
8 'Blood transfusion'
9 'Chemotherapy'
10 'Compensation for renal failure'
11 'Other ops on unspecified organ'
VALUE LABELS bldiagl bldiag2 bldiag3 bldiag4 bldiag5 bldiag6
1 'Mai neo of Oesophagus'
2 'Mai neo ofStomach'
3 'Mai neo of Small Intestine'
4 'Mai neo of Colon'
5 'Mai neo ofRectosigmoid'
6 'Mai neo of Rectum'
7 'Mai neo ofAnal Canal'
8 'Mai neo ofLarynx'
9 'Mai neo of Other Biliary'
10 'Mai neo ofPancreas'
11 'Mai neo of Other Digestive'
12 'Mai neo of Gallbladder'
13 'Mai neo of Trachea'
14 'Mai neo ofBronchus'
15 'Mai neo of Cervix'
16 'Mai neo of Uterus'
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17 'Mai neo of Ovary'
18 'Mai neo of Prostate'
19 'Mai neo of Testis'
20 'Mai neo ofMeninges'




25 'Other & Unsoec haematopoietic & related tissues'






32 'Gastrointestinal haemorrhage Unspec'
33 'Acute renal failure'
34 'Chronic renal failure'
35 'Peptic ulcer'
36 'Alcoholic liver disease'
37 'Toxic liver disease'
38 'Fibrosis/Cirrhosis of liver1
39 'Diaphragmatic hernia'
40 'Other diseases of stomach & duodenum'
41 'Nutritional anaemias'
42 'Haemolytic anaemias'
43 'Aplastic and other anaemias'
44 'Coagulation defects, purpura and other haemorrhagic conditions'
45 'Other diseases of blood and blood forming organs'
46 'Certain disorders involving the immune mechanism'
RECODE (SYSMIS=0)
Define Group A procedures
Repeat for bldprc3, 2, 1
IF (bldprc4=1 or bldprc4=4 or bldprc4=8 or bldprc4=13 or bldprc4=14 or [NB. Reverse order]
bldprc4=16 or bldprc4=19 or bldprc4=25 or bldprc4=26 or bldprc4=27 or
bldprc4=28 or bldprc4=34 or bldprc4=35 or bldprc4=36 or bldprc4=37 or
bldprc4=40 or bldprc4=41 or bldprc4=44 or bldprc4=48 or bldprc4=49 or
bldprc4=53 or bldprc4=54 or bldprc4=57 or bldprc4=58 or bldprc4=60 or
btdprc4=61 or bldprc4=62 or bldprc4=63 or bldprc4=64) bldproc = bldprc4
Define Group B diagnoses
IF (bldiag1=22 or bldiag1=23 or bldiag1=24 or bldiag1=26) haemdiag1 =
bldiagl
RECODE haemdiagl (SYSMIS=0)
IF (bldiag2=22 or btdiag2-23 or bldiag2=24 or bldiag2=26) and
(haemdiagl-0) haemdiagl = bldiag2
IF (bldiag3=22 or bldiag3=23 or bldiag3=24 or bldiag3=26) and
(haemdiagl=0) haemdiagl = bldiag3
IF (bldiag4-22 or bldiag4=23 or bldiag4=24 or bldiag4=26) and





IF (bldiag5=22 or bldiag5 =23 or bldiag5=24 or bldiag5=26) and
(haemdiag1=0) haemdlagl = bldiag5
IF (bldiag6=22 or bldiag6=23 or bldiag6=24 or bldiag6=26) and











Merge Transfusion day records and restructured
SMR01/cancer/death records
GET Transfusion day records file
MATCH FILES by ISD_NO to SMR01/cancer/death records
SAVE AS Study database
Date attribution




records i.e. to da123
COMPUTE tlda = SUM (da1, 2,3 ... 123)
Group A. Surgical patients: number of red blood cell units used
(rctp) and red cell using procedure (rcup)
IF (da1=1 and (bldproc.1>0)) rctpl = redused Repeat for all
SMR01 /cancer/death
IF (da1=1 and (bldproc.1>0)) rcupl = bldproc.1 records i.e. to
bldproc.123
RECODE (SYSMIS=0)
COMPUTE tlrctp = SUM (rctpl, 2, 3 ... 123)
Number of red cell using procedures (nrcup)
COMPUTE nrcup = tlrctp /redused
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Main red cell using procedure (procedure)
IF (rcup1>0) procedure = rcupl
RECODE procedure (SYSMIS=0)
IF (procedure=0 and rcup2>0) procedure = rcup2
Group B. Haematological patients: diagnosis (haemdiag)
AGGREGATE SMR01/caner/death records by ISD_NO and return 1ST
maindiag (rename "HAEMDIAG").
MATCH back to Merged STEP Database
Repeat for all
SMR01/cancer/death
records i.e. to rcupl23
Appendix 3.
Appendix 3.
Table A.3 Excerpt from STED regional Surgical Blood Use report (2002/3-2005/6)
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